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1
I N T RO D U C T I O N
Many phenomena in the real world are a consequence of the interaction between en-
tities of identical or different kind, whether at subatomic, atomic, molecular, cellular
level, or at the level of people and populations of people. From a computing science
point of view, quite naturally network models come to mind as a means to describe
the interaction between such entities. Since the interaction between entities may have
a stochastic nature, network models often have a probabilistic semantics.
The question that motivated the research described in this thesis was how we can
make probabilistic networks practically useful for the detection of interactions between
diseases – our entities here –, where some of these interactions might be novel, whereas
others were already known. As people can have multiple diseases at the same time, net-
work models can be useful to obtain insight into the interaction between these diseases,
and the new probabilistic network methods in this thesis are therefore applied to the
field of medicine, exploiting large datasets coming from primary care.
Discovering disease network models involves applying machine-learning methods
to available data. The chosen setting of the research underlying this thesis, namely to
exploit available large clinical datasets not especially gathered for research purposes,
had major implications for the methods we had to develop. The idea of exploiting facts
for understanding nature as it is, has been the basis of the empirical sciences at least
since Galileo Galilei [59]. The importance of observations was also acknowledged by
one of the most important scientists in the life sciences in the history of mankind:
My mind seems to have become a kind of machine for grinding general
laws out of large collections of facts – Charles Darwin
Nowadays many machine-learning techniques are available to distil models out of
data. Many of these are also applicable to medicine, which led to the development of,
e.g., probabilistic models that deal with the uncertainty related to diagnosis, prognosis,
or the evaluation of therapy [116].
1.1 I N T E R AC T I O N S I N N AT U R E
Since ancient history, humans have tried to understand how one thing affects another.
Sometimes the interaction between different entities are nowadays well understood and
have been empirically verified. For example, the ideal gas law describes how the state
of the amount of gas is determined by its pressure, volume, and temperature. Keeping
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one of these variables constant, one obtains an isobaric, isochoric, or isothermal pro-
cess, respectively. In these processes the interaction between the remaining variables
is either directly or inversely proportional. For example, in an isobaric process, the in-
teraction between volume and temperature is directly proportional, meaning that if the
volume rises, the temperature also rises. Altogether, the interactions between pressure,
volume, and temperature can be captured in one elegant mathematical model, which
was first stated by Clapeyron in 1834. Recently, it was shown that the dynamics can
also be modelled using a probabilistic network model [34].
As long as we can keep the amount of gas isolated from the outside world – a so-
called closed system – the ideal gas law is a deterministic model. This would also
imply that we cannot measure properties of the system, as then it would inevitably lose
its closedness. Thus, open systems with unknown hidden factors are the norm, and
we cannot predict exactly what will happen if we change one of the variables. At this
point, probabilistic models come into sight. From domain knowledge we can build a
probabilistic network model that can make predictions with a certain probability, and
by using scientific evidence and observations we can make the model and its predic-
tiveness more accurate [93].
Many interactions also have a temporal dimension, i.e., the effect can only be mea-
sured after a certain amount of time or it has a dynamic nature. It is in the people’s
nature trying to use the observations of today to predict what will happen in the fu-
ture. Typical examples, and probably the most frequently used prediction models in
the world, are those used for weather forecasting. Weather forecasts make use of cur-
rent observations and experiences from the past, so the predictions are never entirely
certain. Short term predictions are easier to make and more accurate, requiring fewer
variables than predictions for the long term. The relevance of climate change for the lat-
ter type of predictions implies that many more variables with many more interactions
between them need to be considered.
Probabilistic networks, e.g., Bayesian networks, have recently been used in this field
of environmental modelling, providing a natural way to facilitate missing data, domain
knowledge, and causal learning [202]. Their usefulness in making predictions about
one of the major concerns in our world, the Arctic sea-ice loss and its interaction with
greenhouse gas mitigation, has recently been demonstrated, including its influence on
the polar bear population [4]. The loss of sea-ice extent in square miles is much more
prominent in the summer and depends loosely on last year’s extent and to a larger
degree on the Arctic weather conditions, which in turn depends on the greenhouse
effect. Figure 1.1 shows a very simplified ‘plausible’ model of the effect of human
activities on the Arctic sea-ice extent and polar bear population.
Thus, there is growing evidence that probabilistic graphical models are practically
useful in capturing interactions: they make it possible to connect all the domain vari-
ables involved in an intuitive network structure – with a temporal dimension if nec-
essary – thereby allowing the researcher to investigate their interactions, qualitatively
and quantitatively. Here in this thesis we apply them to the epidemiology of multiple
chronic diseases that occur within one patient simultaneously, i.e., multimorbidity, to
investigate the interactions between these diseases.
Probabilistic networks have been used in medicine before, but mainly from a single-
disease perspective; networks containing multiple diseases were built for diagnostic
2
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Last year ice extent
This year ice extent
Arctic weather conditions
Human activitiesGreenhouse gases
Polar bear population
Figure 1.1: Simplified graphical model of the Arctic sea-ice extent and polar bear population. An
edge between two entities means that the outcome of one influences the outcome of
the other.
purposes [120]. So far, probabilistic models have not been used as a means to better
understand the interaction among multiple chronic diseases. In particular, their usage
with large medical observational datasets coming from multiple sources has not been
explored.
1.2 C O R R E L AT I O N A N D C AU S A L I T Y
“Correlation does not imply causation” is a phrase used in science and statistics to em-
phasise that a correlation between two variables does not necessarily imply that one
causes the other. Many large datasets are observational and therefore not suitable for
existing techniques that try to establish causality. Probabilistic graphical models, and
in particular temporal models, can shed more light on cause and effect relationships
in such datasets. Just recently, novel approaches using probabilistic graphical mod-
els were introduced to detect new causal relations – with a certain probability – from
the combination of observations, even when coming from multiple different experi-
ments [29].
However, to claim true causality remains a difficult task in medicine. For example, in
the metabolic syndrome, lipid disorders, diabetes mellitus, and hypertension go side by
side, and there are many hypotheses about the causal cascade of pathophysiologies. As
another example, in case of a violent traumatic brain accident, one can still debate about
the root cause. A psychiatrist might argue that we should not blame the perpetrator –
who hit the patient’s head – but that his or her behaviour is caused by a traumatic youth
or a genetic predisposition. Darwin would argue that it is all part of the Evolution, and
the true determinist originates everything back to the Big Bang.
David Hume – a Scottish philosopher in the 18th century – took an even more
sceptical position: he argued that knowledge about causality is based on experience,
and experience is similarly based on the assumption that the future models the past,
which in turn can only be based on experience, which leads to a circular logic. In
conclusion, he asserted that causality is not based on actual reasoning, and that only
correlation can actually be perceived. This emphasises that we should be cautious with
conclusions drawn from clinical research that tries to address certain ground truth.
From a practical point of view it might sometimes be wise to accept a certain level
of uncertainty about the true cause and just try to deal with the consequences. Both ap-
proaches are present in the history of medicine. For some conditions, there is a strong
3
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focus on both determining the cause and finding ways to eliminate it; e.g., in cancer
research both types of research are common. In other cases, the condition is accepted
but its symptoms are treated using other physiological processes; e.g., use of diuretics
for treating essential hypertension. The same distinction can be detected in psychia-
try. Cognitive behavioural therapy tries to provide ways to cope with the psychiatric
problems. On the other hand, there is a lot of research going on that tries to link psy-
chiatric phenotypes, in particular developmental disorders, e.g., autism and attention
deficit hyperactive disorders (ADHD), with biological substrates and genotypes.
If we can analyse how pathophysiological processes can be influenced – where elim-
ination is (yet) not possible – this can help us to find ways for treating multiple diseases.
If a condition A is (patho)physiologically linked to condition B, treating condition A
also affects condition B. Secondly, if we can analyse the statistical influences over time
between multiple diseases, this can help us to shed more light on causality. If a condi-
tion A is associated with a condition B later in time – under certain conditions known
as Granger causality – this might imply direct causality. If indeed, we find such pat-
terns in temporal observational data, the justification of a clinical study would gain
more support.
1.3 C L I N I C A L S T U D I E S
Nowadays, many patient data is present in so-called electronic health records, which
exist in information systems of hospitals, general practices, insurance companies, and
so on. From a scientific point of view the nature of patient data present in electronic
health records resembles to the one of observational studies. Because of the size of
such datasets, its analysis may be taken as belonging to the ‘Big Data’ problem. Al-
though their usage for treatment comparisons is not recommended due to treatment
selection bias [23], they may be very useful in other research studies, e.g., in the areas
of epidemiology, prognosis, diagnosis, quality improvement, and healthcare planning.
But even for these purposes, it is often not clear how inference should be performed
and in which way the right conclusions should be drawn [37].
The patient’s health status with respect to multiple chronic diseases is a complex
process. Both diagnosis and therapy become more biased each time a new disease
emerges within the patient. The identification of all the interactions that play a role in
this process can only be accomplished by using large sets of patient data. However,
most of the clinical research is typically carried out by using randomised controlled
trials (RCTs). Randomised experiments first appeared in psychology, where they were
introduced by Charles Sanders Peirce in 1885 [152], and the first published RCT ap-
peared in 1948 [130]. A brief history of the RCTs can be found in [131].
RCTs are designed to focus on one or two outcome variables using a relatively small
patient dataset. They often exclude patients with comorbidity and polypharmacy, which
makes them more or less unsuitable to investigate multiple diseases at the same time.
On the other hand, when using observational studies, one should take notice of the bias
introduced by possible non-random selection criteria. For example, several prominent
medical researchers issued the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement, in which they called for observational studies to
4
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conform to twenty-two criteria that would make their conclusions easier to understand
and generalise [49].
Since there are hardly any randomised clinical trials that cover a large set of chronic
diseases, the focus of this thesis is on patient data retrieved from large observational
studies, e.g., from general practices. Recent explorations of patient data from primary
care registries to quantify associations between chronic disorders, have shown these to
be valuable for obtaining a broad picture of chronic diseases [11, 77, 225].
1.4 C O M O R B I D I T Y A N D M U LT I M O R B I D I T Y
The term comorbidity was introduced in 1970 by Feinstein [50]. He defined comor-
bidity as the occurrence of other medical conditions additional to an index disease.
Before the term multimorbidity was coined, there were already several indices that
measured the impact of co-existing diseases on the outcome of a disease variable re-
lated to the primary disease of interest. A user’s guide to select such comorbidity in-
dices for clinical research was presented by Hall in 2006 [71]. He discussed the four
most commonly used general comorbidity indices: the cumulative illness rating scale
(CIRS) [113], the Kaplan-Feinstein classification (KFC) [91], the Charlson comorbid-
ity index (CCI) [27], and the index of co-existent disease (ICED) [30]. Other popular
measures are the chronic disease score (CDS), the adjusted clinical groups (ACG) sys-
tem, and the Duke severity illness checklist (DUSOI); all three are discussed in [85].
More recently, the term multimorbidity has been introduced in chronic disease epi-
demiology to refer to any co-occurrence of two but often more than two medical con-
ditions within a person [206]. The introduction of this term indicates a shift of interest
from a given index condition to the individuals who have multiple disorders. Figure 1.2
shows that in the last five years the usage of the term multimorbidity in scientific re-
search has grown exponentionally. However, in a substantial part of this research, mul-
timorbidity is used as an explaining variable in a regression model of a primary disease
of interest. In these cases the term comorbidity would be a more appropriate one to use.
The same holds for the identified reviews in PubMed with the term multimorbidity
in the Title or Abstract. Only a limited amount of them have a focus on multimorbidity
without a perspective from a single disease or intervention; they are listed in Table 1.1.
In particular, in the last three years there have been a tremendous effort to systemati-
cally review the multimorbidity related research papers. The European General Prac-
tice Research Network reports eleven main themes in multimorbidity research: chronic
disease, acute disease, biopsychosocial factors and somatic risk factors, coping strate-
gies of the patient, burden of the disease, healthcare consumption, disability, quality of
life, frailty, social network, and health outcome.
A systematic review on multimorbidity indices, i.e., indices that address the severity
of the patient’s disease status with respect to the presence of multiple diseases, can be
found in the work of Diederichs et al. [39]. They concluded that the literature further
emphasises the heterogeneity of existing multimorbidity indices. However, one impor-
tant similarity is that the focus is on diseases with a high prevalence and a severe impact
on affected individuals.
Currently, multimorbidity research still has a strong focus on disease counts, pair-
wise associations and clustering methods. Recently, disease networks were proposed
5
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Title of article Year Journal
Comorbidity or multimorbidity; what’s in a name? A review
of the literature [206]
1996 Eur J General Practice
Problems in determining occurrence rates of multimorbid-
ity [208]
2001 J Clin Epidemiol
Multimorbidity is common to family practice: is it commonly
researched? [52]
2005 Can Fam Physician
Defining comorbidity: implications for understanding health
and health services [204]
2009 Ann Fam Med
The measurement of multiple chronic diseases – a systematic
review on existing multimorbidity indices [39]
2011 J Gerontol A Biol Sic Med Sci
Aging with multimorbidity: a systematic review of the litera-
ture [125]
2011 Ageing Res Rev
Measures of multimorbidity and morbidity burden for use in
primary care and community settings: a systematic review
and guide [85]
2012 Ann Fam Med
A systematic review of prevalence studies on multimorbidity:
toward a more uniform methodology [54]
2012 Ann Fam Med
Multimorbidity in primary care: a systematic review of
prospective cohort studies [55]
2012 Br J Gen Pract
Managing patients with multimorbidity: systematic review of
interventions in primary care and community settings [192]
2012 BMJ
Multimorbidity in Older Adults [178] 2013 Epid Rev
The European General Practice Research Network Presents
a Comprehensive Definition of Multimorbidity in Family
Medicine and Long Term Care, Following a Systematic Re-
view of Relevant Literature [166]
2013 JAMDA
Table 1.1: Systematic reviews of multimorbidity.
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Figure 1.2: Multimorbidity as search term in PubMed and Google Scholar.
as a method for modelling disease progression of multiple diseases and have found
their way in both somatic diseases [10] and psychiatric diseases [33]. However, the
interactions in such disease networks are still defined based on pairwise associations
rather than on conditionally independence, something which is provided in probabilis-
tic graphical models. A key advantage of using a probabilistic network for the repre-
sentation of uncertain knowledge is that they offer an easily understandable graphical
statistical model of how disease variables interact with each other. In our research we
adopted them as the main technique for modelling multimorbidity.
1.5 O U T L I N E O F T H I S T H E S I S
With the ageing of the population in western countries comes the fact that many of the
elderly are nowadays faced with the presence of multiple chronic diseases at the same
time. Traditionally, diagnostic processes often try to find one disease that explains all
the symptoms presented by the patient. Applying therapy to multiple diseases often
involves mostly adding up what is recommended by the separate guidelines on individ-
ual diseases. In the future, an integrated approach would be more desirable to meet the
individual needs of a patient that is faced with multiple diseases [69].
This goal has still a long way to go, and here we take a step forwards by determin-
ing how interactions between multiple chronic diseases should preferably be analysed
from a epidemiological point of view. Starting from the statistics that currently exist in
multimorbidity research, for example, total disease counts or pairwise associations, we
move to graphical models in which diseases and their related measurements are put in a
disease network where the connections (edges) represent their statistical dependences.
By doing this, we ensure that every patient variable – and thus each disease already
present – still matters, when zooming into the model for a particular disease. In short,
7
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we try to bridge the gap that exists between current statistical methods and the demands
resulting from an integral approach when facing a patient with multimorbidity.
In Chapter 2 we review the basic concepts of probabilistic graphical models (PGMs)
as used in this thesis, i.e., Bayesian networks, qualitative probabilistic networks, and
chain graphs. Besides that, we also summarise the basic properties of the more tradi-
tional techniques used, i.e., regression analysis and principal component analysis, and
show that they can be seen as special cases of PGMs.
In Chapter 3 we first provide background information about clinical guidelines and
the patient data used in this thesis, followed by a short review of the current state of
the art of methodologies used in current multimorbidity research. These methodologies
can be divided into five main themes:
1. Total disease counts of chronic diseases.
2. Pairwise associations between chronic diseases.
3. Clustering of chronic diseases.
4. Effects of chronic diseases.
5. Disease networks.
We will evaluate and illustrate some of the techniques used in other research by ap-
plying them to a large patient dataset extracted from multiple general practices in the
Netherlands. In this way, we avoid comparing apples and oranges when using all the
multimorbidity research results obtained from the literature. Moreover, it can be shown
that a certain caution should be taken when applying these techniques to a large obser-
vational dataset that includes multiple diagnosis.
In Chapter 4, we go back to the formal definitions of multimorbidity and show how
probabilistic networks can be used to model most of the concepts used in multimorbid-
ity. We summarise existing classifications and terminologies used in definitions related
to multimorbidity and point out their similarities and differences. It turns out that many
of the used terminologies are similar from a probabilistic point of view. We show that a
limited number of probabilistic network templates can be used to formalise most of the
existing terminologies used in multimorbidity research. This work was also presented
in [102].
in Chapter 5 we introduce a statistical measure, called critical factors, that best ex-
plains the co-occurrence of two diseases when the complete set of disease variables is
arranged in a Bayesian network. Learning the structure of such a network is a complex
task, and we show that the outcome is fairly sensitive to the sample size and extreme
prevalences. Having determined which structure learning technique is empirically the
most useful in large sets of patient data, we learned the critical factors between pair-
wise combinations of malignant tumours. These critical factors can roughly be divided
into patient characteristics, lifestyle related conditions, and pre-malignant pathophysi-
ology. Furthermore, the resulting networks also reveal the (known) pathways of metas-
tasis. This work was partially presented in [103].
In Chapter 6, we explore the fact that certain biases can be introduced when data is
extracted from multiple patient datasets. The data we used was extracted from multi-
ple general practices. It is known that some of these practices have a higher (or lower)
8
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prevalence of certain chronic diseases because of population differences induced by the
practice related variables, e.g., urbanity, region, and average age. This requires a mul-
tilevel analysis, e.g., multilevel regression, that takes into account this bias. Given the
perceived higher usefulness of Bayesian networks for the analysis of multiple diseases,
we introduced a new concept, called multilevel Bayesian networks (MBNs), that incor-
porates multilevel analysis into Bayesian network. The concept is illustrated with an
generated dataset and with real-life patient data from over a hundred general practices
in the Netherlands. This work appeared in [105].
In Chapter 7 we extend the MBN with a temporal dimension. The resulting frame-
work is used to evaluate the associations between cardiovascular diseases and their
progression over a period of five years. We used three major chronic health conditions:
obesity, hypertension, and lipid disorders, and we analysed their effect on six (groups
of) cardiovascular (related) diseases, i.e., diabetes mellitus, ischaemic heart disease,
heart failure, stroke, retinopathy, and nephropathy. The same model is also used to
evaluate the progression of total disease count over time. This work appeared in [106].
The idea of qualitative influences, as introduced in Chapter 2, is further studied in
Chapter 8, where we explore the consequences of the fact that a one-way causal direc-
tion between two associated diseases cannot always be determined. Many physiologi-
cal processes are maintained in a kind of equilibrium state, and pathophysiology can
be seen as a disturbance of such equilibria. Previously, it was shown that chain graphs
– which is a hybrid graph containing both directed and undirected edges – can model
such equilibria [107, 34]. Using the existing properties of chain graphs and qualitative
reasoning we introduced qualitative chain graphs (QCG) and explored its usefulness in
the medical domain. This work is under revision in [104].
Finally, in Chapter 9, our results are discussed and put in a general context. We also
provide recommendations for future research in the area of multimorbidity. The hu-
man body is a very complex system; it constantly tries to maintain homoeostasis and it
has many physiological and behavioural adaptations to cope with chronic disturbances.
Integrating more and more of these concepts into one model – the road to a patient
oriented clinical guideline – makes inference of such a model a hard task. Moreover,
numbers that explain some of the more rare conditions might be overwhelmed by those
concerning more common chronic conditions. The hybrid solution of Chapter 8, which
incorporates both expert knowledge and empirical knowledge into one model in a qual-
itative manner, provides a possible way to integrate knowledge from different sources.
Complex, statistically improbable things are by their nature more difficult
to explain than simple, statistically probable things – Richard Dawkins
9
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P RO BA B I L I S T I C G R A P H I C A L M O D E L S
A B S T R AC T
In this chapter, we summarise the basic statistical concepts that are required to under-
stand the remaining chapters. Particular details of a topic that are only dealt with in one
specific chapter are discussed in that chapter itself. Probabilistic graphical models, e.g.,
Bayesian networks and chain graphs, are used to model the statistical dependences and
independences that exist between observed variables. There are several techniques to
learn both the structure and the parameters of such models, which will be described
here. The qualitative abstraction of a Bayesian network is often referred to as a qual-
itative probabilistic network. In such a network we speak of influences and synergies
rather than the quantitative differences in probabilities. Finally, commonly used statis-
tical techniques, for example, regression and latent class analysis, can be viewed upon
as special cases of probabilistic graphical models, and will also be discussed briefly.
2.1 P RO B A B I L I T Y T H E O RY
We start with a brief summary of notation and some basic concepts. Random variables
are denoted by upper case characters, e.g., X; a value is indicated by lower case char-
acters or numbers, e.g., x. The expression X = x, with the equality predicate ‘=’, is
a logical expression that is either true or false. Other logical operators and predicates
can also be used within expressions, depending on the nature of the random variable of
concern. Often we will write x rather than X = x to indicate that a variable X has value
x. A random variable X can have one of the values from its domain, i.e., its values are
mutually exclusive. In contract to variables, for random variables values are real num-
bers with associated properties, such as that they are totally ordered. Often, however,
we will not make a distinction between variables and random variables.
In case variables are binary with values true and false, its values are denoted by x and
x respectively. If the value of a variable is known, this is referred to as an observation,
an instantiation, or as evidence.
A random variable X is always assumed to be a set of variables, being a singleton
set when we are dealing with a single variable. We assume there is a multivariate, or
joint, probability distribution over the set of random variables X, denoted by P(X). The
joint probability distribution of two sets X and Y is denoted by P(X, Y). When the
actual value of a random variable does not matter, we will often also write P(X) rather
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than P(X = x) for a probability. We assume the reader is familiar with Kolmogorov’s
axioms of probability theory.
We make a distinction between discrete and continuous random variables. For the
discrete case, the probability distribution can be defined by a probability mass function
fX : R → [0, 1] and it holds that P(X = x) = fX(x). An associated distribution
function FX is defined in terms of the probability mass function fX as follows: FX(x) =∑x
−∞ fX(x). For the continuous case, a probability distribution is defined indirectly
by a probability density function fX : R → [0, 1], such that the associated distribution
function is defined as FX(x) =
∫x
−∞ fX(u)du. From the basic axioms of probability
theory, it follows then for both discrete and continuous random variables that: FX(x) =
P(X 6 x).
We now turn to some useful properties of joint probability distributions.
Definition 1 (conditioning). Let P be a joint probability distribution of a set of vari-
ables X. A conditional probability distribution P(X | Y) is defined as:
P(X, Y)/P(Y)
for positive P(Y). The corresponding conditional density or mass functions are denoted
by fX|Y .
Proposition 1 (chain rule). Let P be a joint probability distribution of a set of variables
X = {X1, . . . ,Xi, . . . ,Xn}. It holds that:
P(X1, . . . ,Xn) = P(Xn | X1, . . . ,Xn−1) · · ·P(X2 | X1)P(X1)
Definition 2 (marginalisation). Let P be a joint probability distribution of a set of
variables X. The marginal distribution of Y ⊆ X for discrete variables is defined as:
P(Y) =
∑
Z=X\Y
P(Y,Z)
Similarly, for continuous variables the marginal density function of Y is defined as:
fY(y) =
∫
z:Z=X\Y
fY,Z(y, z)dz
with fY,Z the joint probability density function.
Definition 3 (independence). Two sets of variablesX and Y are said to be conditionally
independent given a third set of variables Z, denoted as X ⊥ P Y | Z, if
P(X | Y,Z) = P(X | Z)
for any value of Y. If, in contrast, these variables are conditionally dependent, this is
denoted by X 6⊥ P Y | Z.
Theorem 1 (Bayes’ rule). Let P be a joint probability distribution of a set of variables
X. Let Y,Z ∈ X then:
P(Y | Z) =
P(Z | Y)P(Y)
P(Z)
where P(Z) > 0.
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The odds is defined as the ratio of the probability that a particular event will happen
to the probability that the event will not happen:
odds(X = 1) =
P(X = 1)
P(X = 0)
= p/(1− p)
for a binary variable X with P(X = 1) = p.
In case the sequence of random variables X = {X1, . . . ,Xn} is a time series and they
adhere to the Markov property, i.e., given the present state Xi, the future state Xi+1,
and the past states X1, . . . ,Xi−1 are independent, we speak of a Markov chain. More
formally,
P(Xi+1 | X1, . . . ,Xi) = P(Xi+1 | Xi)
Note that the possible values of Xi should form a countable set S, also called the state
space of the Markov chain. Very often, Markov chains are described using a directed
graph, where the edges represent the transitions between states. Such transitions occur
with a certain probability, and the parameters of the probability distributions are often
attached as labels to the edges.
2.2 B AY E S I A N N E T W O R K S
2.2.1 Definition
Formally, a Bayesian network, BN for short, is a tuple B = (G,X,P), with G = (V ,E)
a directed acyclic graph (DAG), X = {Xv | v ∈ V} a set of random variables indexed
by the set of vertices V , E a set of directed edges (also called arcs) between vertices in
V , and P a joint probability distribution of the random variables in X. P is a Bayesian
network with respect to the graph G if P can be written as a product of the probability
of each random variable, conditional on their parent variables:
P(x1, . . . , xn) =
∏
v∈V
P(xv | xpa(v)) (1)
where pa(v) is the set of parents of v (i.e. those vertices pointing directly to v via
a single arc). Likewise we have children of v, and together with the parents they are
called the neighbours of a vertex, denoted by ne(v). As a convenience, we will often
write v if we mean the random variable Xv that is associated to v. In Bayesian networks,
the arcs between variables model dependences between variables which give rise to
probabilistic conditional independence relationships. The graph G is an independency
map (I-map), which means that the independences implied by G also hold in P, i.e.:
X ⊥G Y | Z =⇒ X ⊥ P Y | Z (2)
where X ⊥ G Y | Z can be read off the graph G using the well-known criterion of
d-separation [149].
The graph where all arcs are replaced by undirected edges is called the skeleton of
a Bayesian network. The Markov blanket (MB) of a vertex v is the set of vertices such
that v is d-separated of all other vertices given the set of vertices in the Markov blanket.
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central obesity (O) P(o) = 0.04
diabetes mellitus (D)
P(d | o) = 0.18
P(d | o) = 0.08
lipid disorder (L)
P(l | o,d) = 0.10
P(l | o,d) = 0.08
P(l | o,d) = 0.06
P(l | o,d) = 0.02
hypertension (H)
P(h | o,d) = 0.20
P(h | o,d) = 0.15
P(h | o,d) = 0.10
P(h | o,d) = 0.05
stroke (S)
P(s | l,h) = 0.10 P(s | l,h) = 0.05
P(s | l,h) = 0.06 P(s | l,h) = 0.02
Figure 2.1: Example of a Bayesian network.
In a BN, the Markov blanket of a vertex is the set of parents, children, and parents of
children.
Figure 2.1 shows an example of a Bayesian network. In this network, for example,
it holds that S ⊥ O | L,H. Furthermore, the Markov blanket of H, for example, is
{O,D,L,S}, where the variables O,D are a parent, S is a child, and L is a parent of a
child.
2.2.2 Parameter learning
Suppose we have a set of independent and identically distributed observations x =
(x1, . . . , xn) and a statistical model f(x; θ) with parameters θ = (θ1, . . . , θk), that
explains the observations. For an independent and identically distributed sample, the
joint probability density function is:
f(x; θ) = f(x1; θ)f(x2; θ) . . . f(xn; θ) =
n∏
i=1
f(xi; θ) (3)
with x varying freely and θ a fixed parameter. Now we look at this function from a
different perspective by considering the observed values x as fixed parameters and θ as
a variable. This results into the likelihood:
L(θ) =
n∏
i=1
f(xi; θ) (4)
Very often the log-likelihood is used, which turns the product sign into a summation:
logL(θ) =
n∑
i=1
log f(xi; θ) (5)
Let L(θ̂) be the maximised value of the likelihood function of the model, i.e., L(θ̂) =
argmaxθ L(θ). This defines a maximum likelihood estimator (MLE) of θ. Since the
function log is monotonically increasing, the MLE estimate is the same regardless of
whether we maximise Equation 4 or Equation 5.
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For example, suppose X is a single binary variable with P(X = 1) = θ and P(X =
0) = 1− θ. Then f(x; θ) = θx(1− θ)1−x, and the log-likelihood is defined as:
logL(θ) = n1 log θ+n0 log(1− θ)
with n1 the number of observations where X = 1, n0 the number of observations
where X = 0, and n1 + n0 = n. The MLE then becomes: θ̂ = n1/(n1 + n0) =
n1/n. In case X is a multi-valued discrete random variable with P(X = i) = θi and
i ∈ {i1, . . . , ik}, it is easy to prove that θ̂i = ni/n, with ni the number of observations
where X = i.
In case of a Bayesian network the likelihood can be decomposed according to the
decomposition in Equation 1:
L(θ) =
∏
v∈V
n∏
i=1
fv|pa(v)(xv,i; θ) =
∏
v∈V
Lv(θv) (6)
with pa(v) the parents of Xv. For discrete variables the likelihood can be further de-
composed resulting in θ̂v|pa(v) = nv|pa(v)/npa(v).
2.2.3 Comparing models
In case of competing models, there are several criteria to select the most desirable
model. The most well-known approaches are Akaike’s information criterion (AIC) [2],
which is based on the Kullback-Leibler (K-L) information loss [99], and the Bayesian
information criterion (BIC) [183], which is based on Bayesian factors.
Definition 4 (K-L information). Let g denotes the full reality or truth (g has no pa-
rameters), and let h be an approximating model with a probability distribution. The
K-L information, denoted as I(g,h), is the information lost when a model h is used to
approximate g:
I(g,h) =
∫
g(x)log
(
g(x)
h(x | θ)
)
dx (7)
Since g does not depend on the data nor on the model, this can be rewritten as:
I(g,h) = C− Eg
[
log(h(x | θ))
]
(8)
Replacing θ with the MLE θ̂, this becomes:
I(g,h) = C− EOEg
[
log(h(x | θ̂))
]
(9)
with O the set of observations. Akaike showed that the latter part can be estimated
by the maximised log-likelihood value with a bias equal to the number of estimated
parameters k in the model, i.e.,:
C− EOEg
[
log(h(x | θ̂))
]
= log(L(θ̂)) − k (10)
For historical reasons the right part is multiplied by -2, and this became Akaike’s infor-
mation criterion for model selection.
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Definition 5 (AIC).
AIC = −2log(L(θ̂)) + 2k (11)
The model with the lowest AIC value is seen as the best model that approximates the
truth. A few years after Akaike published his results, Schwarz proposed an alternative
metric that puts a larger penalty on the number of parameters in the model:
Definition 6 (BIC).
BIC = −2log(L(θ̂)) + log(n)k (12)
Nowadays, there are still debates on which one to choose, and of both metrics there
are a number of variants [22].
2.2.4 Structure learning
In case one is not sure about the dependences and independences within the network
structure G of a BN we can apply structure learning. Given a dataset D with N ob-
servations, i.e., D = (D1, . . . ,DN) with Di an instantiation of all the variables in
V , Bayesian network structure learning is the problem of learning a network structure
G from D. This can be done using various methods, which are basically divided into
constraint-based methods, score-based (or search-and-score-based) methods, and hy-
brid methods.
The constraint-based methods make use of statistical independence tests to directly
test whether variables are independent from each other. The score-based methods em-
ploy a measure that scores a network structureG given the dataD, and use this measure
to carry out a a heuristic search through the space of DAGs, and sometimes the space
of equivalence classes of DAGs. As the number of possible graphs grows more than ex-
ponentionally with the number of variables, one uses mostly a greedy search algorithm
to obtain the graph that minimises the score. The hybrid methods combine ideas from
constraint-based and score-based methods.
In this thesis, we applied the following algorithms that were implemented in the bn-
learn R package [185]: (i) the grow-shrink (GS) algorithm [126], (ii) the tabu search
(TABU) algorithm [126], and (iii) the max-min hill-climbing (MMHC) algorithm [200].
We will describe them briefly here for the discrete case, following the definitions
in [200, 115, 185, 126].
The GS algorithm is a constraint-based structure learning algorithm. It uses the
Markov blanket information of vertices to determine the structure. The Markov blan-
kets are determined by a grow and a shrink phase as follows:
1. MB(v)← ∅
2. Growing phase: while ∃w ∈ V − {v} such that w 6⊥ v |MB(v),
do: MB(v)←MB(v)∪ {w}.
3. Shrinking phase: while ∃w ∈MB(v) such that w ⊥ v |MB(v) − {w},
do: MB(v)←MB(v) − {w}.
The network structure is then determined as follows:
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1. Determine the direct neighbours of all the vertices: ∀v ∈ V ,w ∈MB(v) : ∀S ⊆
T : v 6⊥ w | S → w ∈ ne(v), where T is the smallest of the sets MB(v) − {w}
and MB(w) − {v}.
2. Determine which direct neighbours are a parent: ∀v ∈ V ,w ∈ ne(v) : ∃u ∈
ne(v) −ne(w) − v, such that ∀S ⊆ T : w 6⊥ u | S∪ {v}→ w ∈ pa(v), where
T is the smallest of the sets MB(v) − {u,w} and MB(u) − {v,w}.
3. Remove those cycles by identifying the minimal set of edges that need to be
reversed for all cycles to disappear.
4. Propagate remaining directions: ∀v ∈ V ,w ∈ ne(v) such that w → v /∈ G and
v→ w /∈ G, do: if there exists a directed path from v to w, orient v→ w.
Tabu search is a score-based structure learning algorithm. In these algorithms, a scor-
ing function is used to measure the goodness of fit of a learned structure. The score
approximates the probability of the structure given the data and represents a trade-off
between how well the network fits the data and how complex the network is. Assuming
that the scoring function is decomposable, the score for a Bayesian network structure
G can be calculated as the sum of scores for individual variables:
Score(G | D) =
∑
v∈V
Score(v | pa(v),D) (13)
The learning problem is then to find G∗ such that G∗ = argmaxG Score(G | D).
Usually, the scoring functions are in the form of a penalised log-likelihood function.
If we take the MLE θ̂ for the parameters θ given the graph G, it holds that:
P(D | G) = P(D | G, θ̂) (14)
where:
logP(D | G, θ̂) =
∑
v∈V
N∑
i=1
logP(vi | pa(vi)) (15)
with vi and pa(vi) instantiations in data point Di. Note that Equation 15 is similar to
the log of Equation 6, except that here P(D | G, θ̂) is a function of G, rather than θ.
Then, the penalised LL is defined as:
LLpen(G,D) = logP(D | G) −
∑
v∈V
Penalty(v,G,D) (16)
It is easy to see that this penalised LL is decomposable as in Equation 13. In this thesis,
three different penalties are used:
1. PenaltyAIC(v,G,D) = pv,
2. PenaltyBIC(v,G,D) = pv · 12 logN
3. PenaltyBDE(v,G,D) =
∑
j∈pa(v)
Kv∑
k=1
log P(Dijk|Dij)
P(Dijk|Dij,α)
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central obesity (O)
diabetes mellitus (D)
lipid disorder (L) hypertension (H)
stroke (S)
+
−
+ + +
++
+ +
Figure 2.2: Example of a qualitative probabilistic network.
with pv the number of parameters for v, Kv the number of possible values for v, Dijk
the number of times vi = k and pa(vi) = j inD. The parameter α is a hyperparameter,
called the equivalent sample size, to make scores equal for networks within the same
equivalence class [74]. The penalties 1 and 2 are equivalent to those used in Definition 5
(AIC) and 6 (BIC).
Because the number of possible structures is more than exponential in the number of
variables [171], TABU employs a local search method to limit the search. The MMHC
Bayesian network learning algorithm is a hybrid algorithm. The algorithm first identi-
fies the parents and children set of each variable, then performs a greedy hill-climbing
search in the space of Bayesian networks. The search begins with an empty graph. The
edge addition, deletion, or direction reversal that leads to the largest increase in score
is taken and the search continues in a similar fashion recursively. The same scores as
used in TABU can be used for this step in the MMHC algorithm.
2.3 Q UA L I TAT I V E P RO B A B I L I S T I C N E T W O R K S
Qualitative probabilistic networks (QPNs) were introduced by Wellman [221], as a
qualitative abstraction of Bayesian networks. Conditional probability distributions are
replaced by qualitative knowledge in the form of signs, which describe the relationships
among variables by the concepts of probabilistic influences and synergies.
A qualitative influence expresses how the value of one variable influences the proba-
bility of observing values of another variable. In addition to influences, a qualitative
probabilistic network includes synergies modelling interactions between influences.
An additive synergy expresses how the interaction between two variables influences
the probability of observing the values of a third variable. Product synergies are used
to provide intercausal reasoning, i.e., they express how upon observation of a common
child of two vertices, observing the value of one parent vertex influences the probability
of observing a value of the other parent.
Consider the qualitative network in Figure 2.2, which is the same network as in
Figure 2.1, but now with qualitative signs instead of probability distributions. The plus
signs along the edges represent positive influences. For example, there is a positive
influence of hypertension on stroke, meaning that if hypertension is present there is a
higher probability of stroke, no matter the value of lipid disorder. The plus sign above
the dashed line represents a positive synergy between hypertension and lipid disorder
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on stroke, meaning that there is an interaction between hypertension and lipid disorder,
making stroke more likely. On the other hand, once it is known that stroke is present,
the probability of one condition (either hypertension or lipid disorder) decreases in the
presence of the other – it is so-called ‘explained away’ – which is represented by the
minus sign above the dotted line.
More formally, we say that A has a positive qualitative influence on B if
P(b | a,Z) > P(b | a,Z) (17)
with Z the set of variables pa(B) \ {A}. A negative influence, and a zero influence, are
defined analogously, by replacing > with 6 and = respectively. If none of this holds,
the influence is called ambiguous.
Secondly, we say there is a positive additive synergy of A1 and A2 on B if
P (b | a1,a2,Z) + P (b | a1,a2,Z) > P (b | a1,a2,Z) + P (b | a1,a2,Z) (18)
with Z the set consisting of the variables pa(B) \ {A1,A2}.
Finally, we say there is a positive product synergy of A1 and A2 with regard to the
value b of variable B if
P (b | a1,a2,Z) · P (b | a1,a2,Z) > P (b | a1,a2,Z) · P (b | a1,a2,Z) (19)
Negative, zero, and ambiguous additive and product synergies are defined analogously.
Both influences and synergies adhere to a set of convenient properties, such as sym-
metry [221], which will be further discussed in Chapter 8.
2.4 C H A I N G R A P H S
In a Bayesian network each edge is directed, which implies that for each individual
vertex a probability distribution can be defined that depends only on the vertex’s par-
ents. In chain graphs, however, some of the edges are undirected, which implies that
probability distributions are defined over cliques of vertices rather than for the indi-
vidual vertices. In the abstraction where the cliques of vertices are replaced by single,
composite vertices, the resulting network resembles again a Bayesian network, in fact
a polytree-shaped BN. This property is captured by the outer factorisation of the defi-
nition of the joint probability distribution, which follows later.
To illustrate the concept of a chain graph, Figure 2.3 shows a possible chain graph
over the variables used in Figure 2.1, along with its Bayesian network abstraction. In
the chain graph the edges between diabetes mellitus, lipid disorder and hypertension
are undirected. The probability distribution of these variables together with obesity is
defined by the potentials ϕODHL, which puts ratios on the probabilities within this
clique of vertices. The probability of stroke is conditioned by diabetes mellitus, lipid
disorder, and hypertension only. In the Bayesian network abstraction, the latter diseases
are represented by a single vertex.
More formally, associated to a chain graph G = (V ,E) is a joint probability distri-
bution P over the set of vertices V that is faithful to the chain graph G, i.e., it contains
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central obesity (O)
diabetes m. (D)
lipid disorder (L) hypertension (H)
stroke (S)
ϕODHL
P(s | d,h, l), . . . ,P(s | d,h, l)
P(o) = 0.04 central obesity (O)
disease cluster (LDH)
stroke (S)
Figure 2.3: Example of a chain graph (on the left) and its Bayesian abstraction – representing the
outer factorisation of the joint probability distribution – on the right.
all the independences implied by the graph. Such distributions can be factorised by an
outer factorisation of the cliques in C:
P(V) =
∏
C∈C
P(C | pa(C)) (20)
with the set of vertices V =
⋃
C∈C C, and where each P(C | pa(C)) is defined by a
clique-wise factorisation:
P(C | pa(C)) = Z−1(pa(C))
∏
M∈MC
ϕM(M) (21)
given that MC are the complete (fully connected) subsets in the closure graph of C,
i.e., the subgraph GC∪pa(C) where each arc is replaced by a line and each pair of
vertices of pa(C) is also connected by a line, also referred to as moralization. The
functions ϕ are non-negative real functions, called potentials; they generalise joint
probability distributions in the sense that they do not need to be normalised. Finally,
the normalising factor Z is defined as:
Z(pa(C)) =
∑
C
∏
M∈MC
ϕM(M) (22)
If a chain graph only contains directed edges, then it is a Bayesian networks, as then
each chain component consists of a single vertex, so only the outer factorisation applies.
Chain graphs that only contain undirected edges are called Markov networks. More
details on chain graphs are provided in Chapter 8.
2.5 S P E C I A L C A S E S O F P RO B A B I L I S T I C G R A P H I C A L N E T W O R K S
2.5.1 Regression equations
In a Bayesian network in which there are solely edges from the explanatory variables
to the outcome variable, i.e., P(O,E1, . . . ,En) = P(O | E1, . . . ,En)
∏n
i=1 P(Ei),
with O the outcome variable and Ei the explanatory variables, the conditional proba-
bility distribution P(O | E1, . . . ,En) can be estimated using a regression model. For
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obesity (O)
diabetes mellitus (D) lipid disorder (L)
hypertension (H)stroke (S)
Figure 2.4: Example of regression modelled as a Bayesian network .
example, in Figure 2.4 the outcome variable stroke can be explained by regression of
the variables obesity, diabetes mellitus, lipid disorder, and hypertension.
In general it is assumed that the outcome variableO is linear dependent with weights
β on the set of explanations e through a link function g, i.e., g(E[O|e]) = βT e. This
is the so-called generalised linear model (GLM). For example, in the standard linear
regression model, the link function is defined as g(x) = x, and the regression model
becomes:
P(O | e) ∼ Normal(µ,σ) (23a)
µ = βT e (23b)
With e = (1, e1, . . . , ei, . . . , en)T and β = (β0,β1, . . . ,βn). In case of binary out-
come variables, the logistic regression model is often used. In this case, the link func-
tion g is given by the logit function, i.e., g(x) = logit x = x1−x , and the model
becomes:
P(O | e) ∼ Bernoulli(p) (24a)
logit p = βT e (24b)
In case the outcome variable is a count variable, e.g., the total disease count, the Poisson
or negative binomial regression models are often used. Their link function is given by
the log function, i.e., g(x) = log x, and the model becomes:
P(O | e) ∼ Poisson(λ) or Negbin(λ, τ) (25a)
log λ = βT e (25b)
Regression models can be extended to deal with data that is hierarchically organised.
This will be further discussed in Chapter 6.
2.5.2 Naive Bayes
Graphically, the naive Bayes model is the reverse model compared to the regression
model. The edges now point to the explanations, see e.g., Figure 2.5, and the Bayesian
network decomposition becomes:
P(O,E1, . . . ,En) = P(O)
n∏
i=1
P(Ei | O) (26a)
Just like in regression analysis, the computation of the parameters in the naive Bayes
model is tractable and its predictive power is comparable to logistic regression. It was
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obesity (O)
diabetes mellitus (D) lipid disorder (L)
hypertension (H)stroke (S)
Figure 2.5: Example of a naive Bayes model.
shown that naive Bayes reaches its asymptotic error very quickly with regards to the
number of training examples. Thus, if training data is scarce, one can expect naive
Bayes to outperform logistic regression, but as the number of training examples grows,
logistic regression will outperform naive Bayes and achieve a lower asymptotic error
rate [137].
2.5.3 Latent variable models
In certain modelling techniques it is assumed that the observed association between
observed variables is caused by a set of latent (hidden) variables [12]. Given a set of
specific values for such variables, the observed variables are then independent, e.g.,
see Figure 2.6. The joint probability distribution of the set of observed variables O =
{O1, . . . ,On} and the set of latent variables L can be factorised as follows:
P(O,L) = P(L)
n∏
i=1
P(Oi | L) (27)
In case of factor analysis the (conditional) distribution of both the observed and
latent variables are considered to be Gaussian:
P(Oi | L) ∼ Normal(αi +βiL,σ) (28a)
P(L) ∼ Normal(0, 1) (28b)
In a latent class analysis (LCA) the associations between observations are also clari-
fied by means of hidden (latent) variables. But here the latent variables are considered
to be discrete.
P(Oi | L) ∼ Fi(L) (29a)
P(L) ∼ Categorical(φ) (29b)
Theoretically, the conditional distribution Fi can follow any distribution, but in most
parameter estimators it is considered to be either Gaussian, Poisson, or categorical.
In factor analysis, one can distinguish between an explanatory factor analysis (EFA)
and a confirmatory factor analysis (CFA). In an EFA, the researcher’s a priori assump-
tion is that any observed variable may be associated with any latent variable. There is
no prior theory and one uses factor loadings to intuit the structure of the data. A CFA
tries to determine if the number of latent variables and the loadings of observed vari-
ables on them, is conform to what is expected on the basis of a pre-established theory.
The researcher’s a priori assumption is that each latent variable is associated with a
specified subset of observed variables. In a CFA, a number of analyses can be used to
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Latent variable (Li) Latent variable (Lj)
obesity (O)
diabetes mellitus (D) lipid disorder (L) hypertension (H)
stroke (S)
Figure 2.6: Example of a model with latent variables.
determine if the model has a good fit, whereas in an EFA one tries to find the optimal
number of latent variables that best explains the set of observations [12].
The number of latent classes in LCA can be obtained by comparing fit indices of so-
lutions with varying numbers of classes. Typical fit indices for LCA are the likelihood
ratio χ2 statistic, the Akaike Information Criterion (AIC) and the Bayesian informa-
tion criterion (BIC). Additionally, the Lo-Mendell-Rubin adjusted likelihood ratio test
can be used to determine the number of latent classes in the model [143]. It allows one
to compare the model with k classes to the model with k − 1 classes. Based on the
p-value of the significance test one can choose to reject the model with k classes and
turn back to the model with k− 1 classes.
The intuition behind the difference in determining the parameters of an LCA model
is that factor analysis is concerned with clustering variables, whereas LCA is more
concerned with clustering cases, i.e., the latent taxonomic structure. Therefore, LCA
is more analogously closer to cluster analysis, e.g., item response theory (IRT) and
grade-of-membership (GOM) analysis [123].
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M U LT I M O R B I D I T Y I N G E N E R A L P R AC T I C E
A B S T R AC T
There are many diseases that put a chronic burden on the patient’s quality of life, es-
pecially when they co-occur in one patient. Collections of large observational patient
datasets are frequently used to examine the epidemiology of multiple chronic diseases
occurring at the same time. The resulting multimorbidity figures can be divided into
five main themes: total disease counts, pairwise associations, clusters of diseases, tem-
poral effects of multimorbidity, and disease networks. Here we discuss their properties
and illustrate them using a large patient dataset, which was obtained from multiple
general practices in the Netherlands. Except for childhood and ages above eighty, total
disease counts were proportional with age on a logarithmic scale. Pairwise combina-
tions of diseases often show a higher prevalence than expected, especially at higher
ages. The more complex figures obtained with cluster analysis and disease networks
show that diabetes mellitus, lipid disorders, hypertension, and musculoskeletal disor-
ders, are responsible for many of the observed associations between other chronic dis-
eases. Using a Bayesian network, which takes into account these confounding effects,
the resulting network of the most commonly observed chronic diseases is less dense
and more comprehensive than the one obtained by taking all the significant pairwise
associations.
3.1 I N T RO D U C T I O N
Epidemiological research indicates that more than two third of the elderly have two
or more chronic diseases at the same time; this problem, one of the most challenging
of modern medicine, is referred to as the problem of comorbidity or multimorbidity.
Its focus has been increasing lately, and, as pointed out in Chapter 1, a large number
of multimorbidity indices are available these days. In this chapter, we provide more
background information about several aspects of multimorbidity in primary care. First,
we describe how and when diseases are considered to be a chronic disease. Next, we
provide the necessary information about the patient data that was used for analysis
throughout this thesis. This patient data was collected from multiple general practices
in the Netherlands.
In the sections thereafter, we review the most popular techniques that are currently
used to analyse multimorbidity in general practice. These techniques are illustrated by
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the same patient data used further in this thesis. Finally, we briefly discuss the pros
and cons of these techniques and demonstrate a first preliminary use of a probabilistic
graphical network concerning multimorbidity in general practice.
3.2 T H E D E F I N I T I O N O F C H RO N I C D I S E A S E S
In the definition of multimorbidity, a disease is seen as a ‘chronic disease’ if it is irre-
versible without any expectation of complete recovery and with a relatively long period
of illness or recurrence of illness. Patients with chronic diseases distinguish themselves
by a prolonged need of healthcare. This definition is further detailed by O’Halloran et
al. [144]. The complete list (last accessed on October 26, 2012) of chronic diseases
made by O’Halloran, based on the international classification of primary care (ICPC)
codes, can be found at:
• http://sydney.edu.au/medicine/fmrc/classifications/
DefiningChronicConditions.pdf
Based on these criteria, a definition based on the ICPC codes was provided in 2008 for
the Netherlands [79], which divided chronic diseases into 29 disease groups. This list
(last accessed on October 26, 2012) can be found at:
• http://www.nationaalkompas.nl/gezondheid-en-ziekte/
ziekten-en-aandoeningen/chronische-ziekten-en-multimorbiditeit/
selectie-van-chronische-ziekten/
This led to a final set of chronic diseases used for analysis in this thesis, which is listed
in Table 3.1. The chronic diseases are organised in thirteen groups, following the main
morphology of the human body. For the detailed specification of the subgroups, e.g.,
’not otherwise specified’ (NOS) or ’other’, we refer to [144].
3.3 C H RO N I C D I S E A S E S A N D C L I N I C A L G U I D E L I N E S
Clinical guidelines provide recommendations to physicians and patients, mostly about
the management of one disease; the recommendations are based as much as possible
on scientific evidence. The diagnostic process of a disease is supported by indicating
relevant symptoms, risk factors, signs obtained by physical examination and laboratory
investigations to decrease the uncertainty in the diagnosis. Treatments are supported
by providing advice through a stepwise approach with regular control of the patient’s
symptoms and signs, until a proper balance in the patient’s condition is achieved.
In case of the elderly, the physician often deals with multimorbidity, and then sev-
eral guidelines need to be consulted. As medical knowledge in clinical guidelines is
organised around single disorders, this knowledge may not be fully applicable to pa-
tients with multiple disorders [17], offering no guarantees that elderly patients receive
appropriate treatment. Eventually this can lead to conflicts, e.g., treatment of one dis-
ease can reduce the efficacy of a treatment of another disease or worsen its outcome.
It has been noted that guidelines should be adapted to account for multimorbidity [69],
and multimorbidity has not only implications for healthcare, but also for research and
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ICPC chapter Chronic disease
A – General/Infections tuberculosis, malignant neoplasm, congenital anomaly NOS, weakness or tired-
ness syndromes: chronic fatigue syndrome, myalgic encephalomyelitis, post viral
fatigue syndrome;
B – Haematology Hodgkin and non-Hodgkin lymphoma, leukaemia, malignant neoplasm NOS, be-
nign neoplasm, hereditary haemolytic anaemia, vitamin B12 and folate deficiency
anaemia, anaemia NOS, purpura and coagulation defects, HIV, AIDS;
D – Gastroenterology viral hepatitis, malignant neoplasm: stomach, colon, rectum, pancreas, other lo-
cations; congenital anomaly, duodenal ulcer, peptic ulcer, diverticular disease, ir-
ritable bowel syndrome, chronic enteritis, ulcerative colitis, liver disease NOS,
cholecystitis, cholelithiasis, other: e.g., pancreatitis, gluten and lactose intolerance,
stenosis;
F - Ophthalmology retinopathy, macular degeneration, cataract, glaucoma, blindness, neoplasm;
H - Otolaryngology vertiginous syndrome, presbyacusis, deafness, neoplasm;
K - Cardiovascular rheumatic fever, neoplasm, congenital anomaly, ischaemic heart disease with and
without angina pectoris, acute myocardial infarction, heart failure, atrial fibril-
lation/flutter, paroxysmal tachycardia, cardiac arrhythmia NOS , heart murmur
NOS, pulmonary heart disease, heart valve disease NOS, heart disease NOS, hy-
pertension uncomplicated/complicate, postural hypotension, transient cerebral is-
chaemia, stroke, cerebrovascular accident, cerebrovascular disease, atherosclero-
sis, peripheral vascular disease, pulmonary embolism, phlebitis, thrombophlebitis,
varicose veins of leg;
L - Musculoskeletal malignant neoplasm, congenital anomaly, neck syndrome, back syndrome with
and without radiating pain, acquired spine deformity, rheumatoid and seroposi-
tive arthritis, osteoarthritis: hip, knee, other locations; shoulder syndrome, tennis
elbow, osteoporosis, other: e.g., osteitis, polymyositis, dystrophy;
N - Neurology neurologic infection, malignant neoplasm, benign neoplasm, congenital anomaly,
multiple sclerosis, parkinsonism, epilepsy, migraine, cluster headache, trigeminal
neuralgia, carpal tunnel syndrome, peripheral neuritis and neuropathy, other: e.g.,
encephalopathy, palsy, paraplegia;
P - Psychiatry chronic alcohol abuse, dementia, schizophrenia, affective psychosis, organic psy-
chosis, anxiety disorder, somatisation disorder, depressive disorder, neurasthenia,
compulsive disorder, personality disorder, hyperkinetic disorder, post-traumatic
stress disorder, mental retardation, anorexia nervosa, anorexia bulimia, psychosis
NOS;
R - Pulmonology malignant neoplasm: bronchus, lung, other locations; hypertrophy tonsils, ade-
noids, chronic obstructive pulmonary disease, asthma, other: e.g., asbestosis, fi-
brosis;
S - Dermatology malignant neoplasm, seborrhoeic dermatitis, dermatitis and atopic eczema, psori-
asis, acne, other: e.g., rosacea, lupus, lichen sclerosis;
T - Endocrinology malignant neoplasm thyroid, neoplasm other, congenital anomaly, goitre, obesity,
overweight, hyperthyroidism, hypothyroidism, diabetes: insulin and non-insulin
dependent; gout, lipid disorder, other: e.g., Cushing, Addison, cystic fibrosis,
haemochromatosis;
U - Urology malignant neoplasm: kidney, bladder, other; glomerulonephritis, nephrosis, other:
chronic renal failure or insufficiency, urethral stenosis;
Table 3.1: Chronic diseases (NOS=not otherwise specified).
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medical education [11]. Eventually, there is a need for an electronic guideline that can
be easily adapted to each patient [16, 84].
With the continuous advancement in healthcare due to scientific research, clinical
guidelines are constantly adjusted by incorporating the newest scientific evidence. For
example, for a long while, hypertension guidelines focused on blood pressure as the
only or main parameter determining the need and the type of treatment. Modern guide-
lines on hypertension now emphasise that the diagnosis and management of hyperten-
sion should be based on the quantification of total cardiovascular risk. Therefore, it
also establishes connections with other chronic diseases. For example, the presence of
obesity, diabetes, or lipid disorders, worsen the prognosis of hypertension and common
consequences of hypertension are cerebral vascular disease, heart disease, renal disease
and retinopathy.
There are many ways in which computing science can play a role in improving
clinical guidelines. In related research, clinical guidelines, as computer-program-like
textual documents, were formalised and verified mathematically using temporal log-
ics [82]. In this thesis, the emphasis is on using probabilistic methods to capture the
uncertain relationships between diseases, based on data, and to reasoning about the
presence and evolution of diseases by means of probabilistic reasoning methods.
3.4 DATA C O L L E C T I O N I N G E N E R A L P R AC T I C E
The patient data used for analysis were obtained from the register of the Netherlands
Information Network of General Practice (LINH). It started in 1996 as a register of
referrals of general practitioners to medical specialists. Nowadays, twice a year, infor-
mation about contacts and diagnoses, prescriptions, referrals and – since 2007 – lab
and physiological measurements are extracted from the practice information systems.
All Dutch inhabitants are obligatory registered with a general practice, and the LINH
database contains information of routinely recorded data from about all patients of ap-
proximately 90 general practices. Only practices with a proper registration were used
in the analysis.
The first Dutch General Practitioners Information Systems, GPIS for short, date
from the 1980’s. These systems allow for making and recording appointments with
patients, on the one hand, and recording all other patient-related and care-related in-
formation a doctor is supposed to collect, on the other hand. There are around eight
different vendors of GPIS in the Netherlands, some of whom have their origin in the
pharmacy IT. The names of these different GPIS are: Medicom, Promedico, MicroHIS,
OmniHis, Mira, Webhis Zorgdossier, HetHis and TetraHis, ordered from Medicom,
which has the largest market share, to TetraHis having the smallest. LINH is a repre-
sentative network with respect to the population, type of practice and type of GPIS.
The first five of the above mentioned GPIS are supported by the LINH database. For
each GPIS, software was developed to extract coded data from the systems.
The Dutch college of General Practitioners (NHG) develops the so-called GPIS ref-
erential model. Every GPIS should support all features and entities described in this
model. For this purpose, the ICT companies developing the GPIS are subscribed to
receive annual updates of this model. Despite the fact that every type of GPIS has its
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own design and, therefore, database structure, LINH pre-processes the extracted data
in such a way that it fits the uniform LINH data model.
Before data are stored in the LINH database, several validity checks are performed.
First, it is checked whether a received file contains data and to which practice the data
belongs. In addition, the number of registered weeks is checked to see whether data
is missing, and the order of variables listed is checked, as variables could be swapped,
for example because of an update of the system to a new release at the general prac-
tice. Also, the average number of records per patient are calculated and compared to
developed standards.
In the LINH relational database model, data are patient-centred and, thus, a record
can always be related to a patient, and to a specific date of the event that took place
in a specific GP practice. For example, laboratory measurements or prescriptions for a
patient have an attached date. Every module (prescription, referral, consult, etcetera) is
represented in a table and has a unique identifier. Every patient has a unique identifier,
the client id. Every time new data is extracted, the data are linked to the same patients
who are already known to the database before adding all these data incrementally to
the database. The client table stores all patient information, such as to which practice
the patient belongs. The practice table has been excluded from the model; it contains
information on the location, and thus the degree of urbanisation, the number of GPs,
and the GPIS the practice uses. When data are stored in the MS SQL database, type-
checking is performed on the data.
As a last step, quality checks on the data registered by the GP are performed to,
for example, calculate the number of ICPC codes recorded, ATC coded prescriptions,
etcetera. These checks are done on the basis of criteria developed by the LINH research
team. Only good quality data are used for LINH research. Every GP practice receives
feedback on the delivered dataset.
The dataset used in this thesis is a subset from the LINH dataset, consisting of con-
sultations, measurements, referrals, and prescriptions until December 2011. Figure 3.1
shows the relational data-model of this particular dataset, showing that the data is hier-
archically organised by one-to-many relationships.
Having obtained the data, we noticed that laboratory results and medication were
not always consistent with the diagnoses present in the LINH database. For example,
insulin was sometimes prescribed to patient who were not diagnosed with diabetes mel-
litus according to the data. To compensate for such missing or incorrect information,
we used lab results and medication to infer the diagnosis of obesity, hypertension, lipid
disorders, and diabetes mellitus, in conjunction to the ICPC codes.
Corrections were made by using the following rules adopted from the Dutch guide-
line on cardiovascular risk management [223], which are in line with the European
guidelines on cardiovascular risk management in clinical practice [156]. For obesity: a
body mass index over 30 kg/m2; for hypertension: a high blood pressure (systolic >
140 mm Hg or diastolic > 90 mm Hg) within at least two recurring measurements; for
lipid disorders: an abnormal blood lipid profile (low density lipoprotein > 3 mmol/l,
high density lipoprotein < 1 mmol/l, or triglycerides > 2 mmol/l); and for diabetes
mellitus: a fasting glucose > 6 mmol/l, or a prescription of either insulin or oral blood
glucose lowering medication.
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Figure 3.1: High level model of the patient data retrieved from general practices in the Nether-
lands.
3.5 D I S E A S E C O U N T S O F C H RO N I C D I S E A S E S
The easiest way to measure multimorbidity is to count the number of diseases per pa-
tient, and determine the average number of diseases by age, see e.g., [224, 53, 201].
In this way, Van den Akker et al. [207] already determined prevalences and indices
of multimorbidity (defined as two or more co-occurring diseases) for the Dutch pop-
ulation in the nineties of the last century. Overall, the ratio of the observed and the
expected number of diseases had a U-shaped distribution when plotted for age. The
differences between the observed and expected number of diseases were strongly sta-
tistically significant (p < 0.0001) for both sexes and all ages.
When modelling count data, i.e., a discrete variable taking values 0, 1, 2, ...,K, with
lower values more likely, Poisson regression is often the first choice. Alternatively, one
can use the geometric or negative binomial distribution. Real-life data frequently dis-
play overdispersion and excess zeros. The former regression methods are then extended
with an additional parameter leading to zero-inflated Poisson, geometric, or negative
binomial regression. Most of the research on multimorbidity starts with modelling dis-
ease counts using one of these techniques, see e.g., [157, 6, 193, 48].
Using the lme4 package in the statistical software package R 1, we applied the count
models, as described above, to the LINH patient dataset. Table 3.2 shows the resulting
Akaike information criterion (AIC) and Bayesian information criterion (BIC), for all
patients and a specific patient group, i.e., diabetics. The negative binomial zero-inflated
models show the best fit, and Figure 3.2 shows the observed disease counts by age and
gender on a logarithmic scale, along with the estimations derived by a negative bino-
mial zero-inflated regression model. One can see that between 20 and 80 years the total
disease count can be fitted very well by this model. On a logarithmic scale, the average
1 R is a free software environment for statistical computing (see http://www.r-project.org/).
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(b) Diabetics
Figure 3.2: Total disease counts in general practice in the Netherlands; shown are the average
number of chronic diseases by age on a logarithmic scale. The black line represents
the average observed disease count for the whole population, red represents females,
and blue males. Dashed lines represents estimation by negative binomial zero-inflated
regression using the 20-80 year interval. The estimation for all patients is plotted in the
results obtained for diabetics (b), to show that their counts are systematically higher.
31
M U LT I M O R B I D I T Y I N G E N E R A L P R AC T I C E
All Patients Diabetics
Model AIC BIC AIC BIC
Poisson 955959 955990 84790 84813
Poisson zero-inflated 853709 853750 82495 82526
Negative binomial 827401 827443 78486 78509
Negative binomial zero-inflated 823500 823553 78406 78445
Geometric 827936 827967 82483 82498
Geometric binomial zero-inflated 826898 826940 82487 82518
Table 3.2: Comparison of count models.
disease count has a steady pace: from approximately 1 at 40 years to approximately 5
at 80 years. However, for children the observed disease count is much higher than ex-
pected by this model, which is in line with observations of Van den Akker et al. [207].
For the elderly above 80 years, the observed counts are lower than expected. This is
partly due to the fact that the dataset is in some sense censored, i.e., patients over 80
years in the population observed here are ’survivors’. For diabetics the starting age at
which the model starts to explain the data better is approximately 40 years. Note that,
the absolute values of the disease counts depend on the total number of diseases used
in the analysis.
To detect possible interactions between diseases that affect the total disease counts
we need to model the observed counts more precisely. Assume that a chronic disease
D is modelled by the Markov chain of Figure 3.3, and we assume that pt = peCt (for
C = 0 we obtain the time-homogeneous model). Then, the expectation of D at time
T = t is given by:
E[D | T = t] = 1− pte(Ct(t−1)/2) (30)
Furthermore, suppose that the ages of the observed patients are uniformly distributed
over the interval [0,M], withM being the maximal possible age, i.e., by defining T as a
uniform distribution over the interval [0,M], then it can be shown that the expectation
of D over the whole population is equal to:
E[D |M = m] = 1−
1
m
m∑
t=1
pte(Ct(t−1)/2) (31)
In case of time-homogeneity, i.e., C = 0, the summation in Equation 31 corresponds to
the geometric series, whose sum equals (1− pm)/(1− p). In that case, accumulating
over multiple diseasesDj, with j = 1, . . . ,K, the expectation of the total disease count
becomes:
E[Dtot |M = m] = K−
1
m
K∑
j=1
(1− pmj )/(1− pj) (32)
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D = 0
D = 1
1− pt
pt
1
1) age-independent model: pt = p
2) age-dependent model: pt = peC1+Age(t)/C2
3) history-dependent model: pt = peC1+His(t)/C2
withHis(t) the number of diseases present at t− 1
Figure 3.3: Discrete-time Markov chain model of a chronic diseaseD, with possible disease sta-
tus 0 (absent) or 1 (present). For each time slice there is chance with probability pt
of staying healthy, and with probability 1−pt of becoming ill. Once ill, this sustains
in the next time slices (probability 1). We speak of a time-homogeneous model (e.g.,
a) in case pt is time-invariant, i.e., pt = p, and a time-heterogeneous model (e.g., b
and c) otherwise.
When the maximal age goes to infinity the expected value obviously becomes K, i.e.,
all diseases are present. As this is unrealistic, let us take a close look at the range of
ages between fifty and hundred. Suppose we are counting diseases, all with an annual
incidence of 0.1%, i.e., pj = 0.001. In case the probabilities pt are time-heterogeneous
– see models 2 and 3 in Figure 3.3 – we choose the model parameters in such a way
that the annual incidence is gradually increasing to 0.25% at the age of hundred. The
total disease counts by age in percentage of the number of diseases counted are then
shown in Figure 3.4.
One can see that the two different time-heterogeneous models are close to each
other. There is a slight difference in shape observable; however, if one would try to fit
real-world counts, each model will probably not outperform the other. Moreover, when
using observational data, disease counts are already biased by disease interactions, and
the true annual incidences are therefore hard to estimate. For example, we could have
chosen the individual annual incidences for the time-homogeneous model in such a
way that it resembles close to one of the time-heterogeneous models.
In summary, because of the exponential nature of disease counts, all regression mod-
els with a log or logit link will show a good fit. Therefore, such count models are useful
to analyse the total burden of multimorbidity for specific explanatory variables, e.g.,
age. However, to gain more insight into disease interactions one needs other metrics.
3.6 PA I RW I S E A S S O C I AT I O N S B E T W E E N C H RO N I C D I S E A S E S
There are several ways to express the association between pairs of diseases. The rel-
ative risk is the preferred measure of association in clinical epidemiology and odds
ratios are used as an approximation in case-control designs. The popularity of the odds
ratio is principally due to the ease of its calculation (being simply the cross-product
from a two-by-two table) and to the fact that it provides a good estimate of the rela-
tive risk, although when disorders are more prevalent its value becomes progressively
larger than that of the risk ratio. For example, narcolepsy, a neurologic disorder, shows
associations with many psychiatric disorders, something which has been recently ex-
pressed in terms of odds ratios [41, 42, 43]. Odds ratios have also frequently been used
in multimorbidity research, see e.g., [177, 68, 19, 215].
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Figure 3.4: Average disease counts, in percentage of the total number of diseases being counted,
of the discrete-time Markov chain chronic disease models described in Figure 3.3
for ages between 50 and 100. The black, red, and blue lines correspond with the
time-homogeneous, age-dependent, and history-dependent models respectively. For
the time-heterogeneous models the parameters C1 and C2 are chosen in such a way
that they reach the same disease count at age of hundred to make a comparison be-
tween the shapes possible.
Odds and risk ratios estimate the overall strength of association between disorders
but fail to separate cluster from coincidental comorbidity. The multimorbidity coeffi-
cient tries to correct for this phenomenon in as far as it is attributable to coincidental
(expected) co-occurrence of disorders. Consider Table 3.3 that is assumed to reflect the
number of observations for two diseases, disorder D1 and D2. Then the odds ratio
(OR for short) is defined by:
OR =
ad
bc
whereas the multimorbidity coefficient (MC, discussed in [13]) is defined by:
MC =
a/N
[(a+ c)/N][(a+ b)/N]
=
aN
(a+ b)(a+ c)
The relative risk (RR) is not symmetric and can be defined for both diseases:
RR1 =
a/(a+ c)
b/(b+ d)
=
a(b+ d)
b(a+ c)
RR2 =
a/(a+ b)
c/(c+ d)
=
a(c+ d)
c(a+ b)
The MC favours pairs of low prevalences, and to lower this tendency a pseudo-count
of one can be added to the numerator and denominator of the MC, which was done in
the work of Roque et al. [174].
The MC is just an example of many multimorbidity coefficients, and it coincidences
with the relative risk for disease pairs (RR12) as defined in the network medicine frame-
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Disorder D1
present absent totals
Disorder D2
present a b a+b
absent c d c+d
totals a+c b+d a+b+c+d=N
Table 3.3: two-by-two table reflecting the number of observations for two diseases
work, which was recently introduced by Barabási et al. [10]. As an alternative approach
they used also the φ-correlation coefficient.
φ12 =
aN− (a+ b)(a+ c)√
(a+ b)(a+ c)(N− (a+ b))(N− (a+ c))
From the literature it is known that the odds ratios and relative risks tend to overesti-
mate the association between two variables. In particular, in large samples a statistically
significant association may be easily found, although the level of comorbidity is not of
clinical importance. Various concordance statistics have been proposed, and just re-
cently a comparison, applied to comorbid diseases, was performed between the Kappa
statistic, Somers’ D, Kendall’s Tau-b, the Gamma statistic, and the adjusted Rand in-
dex. It was concluded that the asymmetric Somers’ D and Kendall’s Tau-b statistics
have the highest power to detect non-random comorbidity [139]. These two statistics
are calculated in terms of concordant pairs P = ad, discordant pairs Q = bc, and the
tied pairs Trow = (ab+ cd) and Tcol = (ac+ bd):
Somers’ D =
P−Q
min(Wrow,Wcol)
Kendall’s Tau-b =
P−Q√
WrowWcol
withWrow = P+Q+ Trow andWcol = P+Q+ Tcol. In comparison, the Gamma
statistic ignores the tied pairs and is defined as (P−Q)/(P+Q).
Alternatively, odds ratios can also be corrected for other patient related variables by
using logistic regression. Marengoni et al. [124] used this methodology to correct the
odds for age, sex, education, and other diseases. Nuyen et al. [142] used regression
methods to analyse the effects of somatic and psychiatric co-morbidity on depression.
However, to the best of our knowledge, there is no such methodology for the multimor-
bidity coefficient yet.
When looking more closely to the cumulative incidences by age of chronic diseases,
they resemble a sigmoid curve. From growth analysis in biostatistics there are some
widely used distributions available to model such cumulative incidences. The most
common model is the logistic model. This curve is defined by three parameters: the
maximal probability A that can be reached when the age→ ∞, a maximum slope µ,
and the parameter λ representing in some sense the onset. The cumulative incidence of
any set D of co-occuring diseases, and thus also a single disease, is then modelled as:
P(D = d | Age 6 t) = A
1+ exp(4µA (λ− t) + 2)
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withD = dmeaning that for allDi ∈ D it holds thatDi = True. Alternative sigmoid
curves are the ones defined by Gompertz and Richards [168].
To illustrate the logistic model, we used it to estimate the prevalences and cumula-
tive incidences of hypertension, diabetes mellitus, and their co-occurrence. Figure 3.5
shows that the logistic models are suitable to model the incidences, in particular the
cumulative incidence. Obtaining the expected curve for the co-occurrence of hyperten-
sion and diabetes mellitus, by multiplying the individual curves – assuming no interac-
tion between diseases – shows that the observed curve is approximately twice as high,
see Figure 3.6.
The cumulative incidence of hypertension or diabetes mellitus in the presence of
the other, shows that both estimated curves are higher than in the overall population.
However, where hypertensive patients show a more gradual onset of diabetes mellitus,
the onset of hypertension in diabetics has a very steep slope between 40 and 60 years,
see also Figure 3.6.
3.7 C L U S T E R I N G C H RO N I C D I S E A S E S
Clustering techniques are in particular popular in psychiatry; they are often used to
link different psychiatric phenotypes to clinical measurements. For example, the phe-
notypes of autism, attention deficit hyperactivity disorder, and borderline disorder are
sometimes hard to distinguish within patients. Especially, when combinations of such
disorders occur, clustering techniques provide more insight into the distribution of dif-
ferent combinations of these phenotypes among patients [14, 136, 210, 212, 213].
There are several methods to cluster variables or individuals in a patient dataset.
One of them, exploratory factor analysis (EFA), is used to uncover the underlying
structure of a relatively large set of variables by the use of latent variables. Its usage to
examine co- and multimorbidity within somatic diseases remains subtle. Only recently,
EFAs were used as an approach to identify clusters of chronic diseases that share an
underlying (hidden) factor [147, 179, 90, 81, 92].
In a confirmatory factor analysis (CFA) one hypothesises beforehand the number of
factors in the model, and usually the researcher will also posit expectations about which
variables will load on which factors. Johnson and Wolinsky [90] use CFA to explore an
interesting model of multiple diseases, disability, functional limitations, and perceived
health amongst elderly.
Similar to factor analysis, latent class analysis (LCA) aims at finding a reduced set
of dimensions that explains the relations between the variables. Unlike factor analy-
sis, LCA assumes that the latent variable is categorical, and indicators can be nominal.
Latent class analysis was used by Schüz et al [182]. Their analysis shows how multi-
morbidity amongst elderly can be divided into four different profiles.
The grade of membership method, introduced by Manton and Woodbury [123], is
used less frequently in multimorbidity research. Portrait et al. [161] used it to measure
multimorbidity in the longitudinal ageing study of Amsterdam. In this research, the
method tries to link multiple observations to multiple health dimensions.
Here we used LCA to cluster chronic diseases. Using the set of chronic diseases de-
fined in Table 3.1 and the LINH dataset we calculated the decision metrics for solutions
up till nine classes, see Table 3.4. It turns out that a solution with eight classes has the
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Figure 3.5: Prevalence (top) and cumulative incidence (bottom) by age; for hypertension (black),
diabetes mellitus (blue), and their co-occurrence (red); in the Netherlands. Solid lines
represent the logistic curves obtained by non-linear least squares estimation using
patient data from 90 general practices covering 273,395 patients.
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x
%
0.05
0.10
50 100
Aht|dm = 0.3851
Adm|ht = 0.2362
Aht = 0.1314
Adm = 0.0636
Adm,ht = 0.0298
P(HT = 1 | age 6 x,DM = 1)
P(DM = 1 | age 6 x,HT = 1)
P(HT = 1 | age 6 x)
P(DM = 1 | age 6 x)
P(DM = 1,HT = 1 | age 6 x) observed
P(DM = 1,HT = 1 | age 6 x) expected
y = µ(x− λ)
Figure 3.6: Non-linear least square estimations of the cumulative incidences of hypertension, di-
abetes mellitus, and their co-occurrence. Parameters of the model (other thanA) are:
µht = 0.003675, µdm = 0.001522, µdm,ht = 0.000952, λht = 44.66,
λdm = 43.89, and λdm,ht = 51.51.
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Number of p-value p-value
Classes AIC BIC SSA-BIC VLMR LMR-adjusted
2 1317878 1320570 1319671 0.0000 0.0000
3 1298402 1302445 1301094 0.0000 0.0000
4 1292449 1297843 1296041 0.0000 0.0000
5 1288273 1295017 1292764 0.0000 0.0000
6 1285151 1293247 1290542 0.0200 0.0202
7 1283816 1293262 1290106 0.0927 0.0933
8 1282275 1293072 1289466 0.0000 0.0000
9 1289534 1293593 1289534 0.0212 0.0214
Table 3.4: Decision parameters of the LCA results obtained for the LINH data.
lowest values for AIC, BIC, and SSA-BIC. The VLMR and LMR-adjusted test show
that the solution is significantly better than the one with seven classes.
Thus, a model in which chronic diseases are clustered in eight groups offers the
best explanation for the different profiles of co-occurring diseases one observes in gen-
eral practice in the Netherlands. Table 3.5 shows all the diseases that had a relatively
high prevalence within at least one these groups. Elements of the metabolic syndrome,
i.e., hypertension, diabetes mellitus, lipid disorder, and obesity are present in four
groups. One can distinguish a group with isolated metabolic diseases, a group with
metabolic diseases co-occurring with gastric and musculoskeletal diseases, a group
with metabolic diseases co-occurring with cardiovascular diseases, and a group with
metabolic diseases co-occurring with cerebrovascular diseases. Then, there are three
other groups that cover particular musculoskeletal syndromes, psychiatric disorders,
and respirator and dermatologic diseases. The remaining group involves patients hav-
ing only one or two chronic diseases, which therefore do not contribute to any profile.
3.8 M O D E L L I N G E F F E C T S O F C H RO N I C D I S E A S E S
In case of longitudinal data, one can make predictions about the effect over time, e.g.,
mortality or quality of life, given a specific set of conditions at baseline. In a regres-
sion model, the relation between time and other variables, can be expressed using a
dependence on the temporal variable itself and on the product of this variable and all
other explanatory variables. The latter represents the interaction between explanations
and time, and this model is known as the ‘repeated measures model’. However, in mul-
timorbidity research, Cox regression, also called proportional hazard modelling – the
most popular survival analysis model – is mostly used. It is a statistical technique that
determines the relationship between survival and several independent exploratory vari-
ables. It is useful for modelling the time to a specific event based upon the value of a
given covariate.
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Disease Organic Class i
System 1 2 3 4 5 6 7 8
% Patients 8.3 2.9 2.6 3.9 9.7 7.5 7.4 57.7
Average Age 64 65 75 75 55 44 26 34
Hypertension Metabolic 3 3 3 3
Diabetes Mellitus Metabolic 3 3 3 3
Lipid Disorder Metabolic 3 3 3 3
Obesity Metabolic 3
Hypothyroidism Metabolic 3
Gout Metabolic 3
Reflux Gastric 3
Irritated Bowel Syndrome Gastric 3
Vertigo Vestibular 3
Spondylosis Musculoskeletal 3
Osteoarthritis Musculoskeletal 3
Shoulder Syndrome Musculoskeletal 3
Tendinitis Musculoskeletal 3
Osteoporosis Musculoskeletal 3
Carpal Tunnel Syndrome Musculoskeletal 3
Spinal Disc Herniation Musculoskeletal 3 3 3
NOS Musculoskeletal 3 3 3
Varicosis Cardiovascular 3
Angina Pectoris Cardiovascular 3
Myocardial Infarction Cardiovascular 3
Coronary Sclerosis Cardiovascular 3
Atherosclerosis Cardiovascular 3
Atrial Fibrillation Cardiovascular 3
Heart Failure Cardiovascular 3 3
TIA Cerebrovascular 3
CVA Cerebrovascular 3
Dementia Cerebrovascular 3
Renal Insufficiency Urologic 3
Benign Prostate Hypertrophy Urologic 3
Cataract Eye 3
Neuropathy Neurologic 3
Migraine Neurologic 3
Anxiety Psychiatric 3
Depression Psychiatric 3
Neurasthenia Psychiatric 3
COPD Respirator 3
Tonsillar Hypertrophy Respirator 3
Asthma Respirator 3
Seborrhoeic Eczema Dermatologic 3
Atopic Eczema Dermatologic 3
Acne Dermatologic 3
NOS Dermatologic 3 3
Table 3.5: Chronic diseases having a clinical relevance in one the classes belonging to the eight-
class LCA solution in Table 3.4.
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Weight Conditions
1 myocardial infarct, congestive heart failure, peripheral vascular disease,
cerebrovascular disease, dementia, chronic pulmonary disease, connec-
tive tissue disease, ulcer disease, mild liver disease, diabetes
2 hemiplegia, moderate or severe renal disease, diabetes with end organ
damage, any tumour, leukaemia, lymphoma
3 moderate or severe liver disease
6 metastatic solid tumour, AIDS
Table 3.6: Weighted indices used in the Charlton comorbidity index.
For example, Glynn et al. [61] used Cox’s regression to evaluate the effect of the
presence of chronic kidney disease and diabetes on mortality and morbidity among
patients with established cardiovascular disease. Lin et al. [112] used proportional haz-
ard models to evaluate depression, cardiovascular disease, and increased mortality in
diabetes. Putter et al. [163] describe more advanced survival-analysis methods that
handles competing risks and multi-states models.
A special case of a Cox regression is the CCI, which is a weighted index that pre-
dicts the 10-year survival of patients with multiple disorders. The relationship between
potential prognostic diseases and survival was assessed using Cox regression method.
The resulting index-methodology works as follows. First, a composite score is deter-
mined based on age and the presence of specific comorbid disorders. In this score each
decade of age over 40 adds one point. Each disorder from a predefined comorbidity
list adds another specific amount of points, see Table 3.6. Secondly, the score is then
used to predict the 10-year survival. It is assumed that the overall 10-year survival in an
average low-risk population is 98.3%. The predicted 10-year survival probability P10
is then calculated as:
P10 = 0.983e
0.9·score
For example, a patient aged 60 years with congestive heart failure and diabetes with
end organ damage, has a score 2 + 1 + 2 = 5. The prediction is than calculated as:
e0.9score = e4.5 = 90 and 0.98390 = 0.213, implying a predicted 10-year survival
probability of approximately 21%.
3.9 D I S E A S E N E T W O R K S
Recently, networks of associated diseases – referred to as network medicine – were
proposed as a solution to discover different phenotypes of multimorbidity [10]. In such
networks, diseases are represented as vertices, and their associations are represented
by undirected edges. In the networks of [10] edges were drawn between each pair of
diseases with a significant association based on the multimorbidity coefficient. How-
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Behcets syndrome, Reiters syndrome, patella chondromalacia, Pagets (bone)
disease, muscular dystrophy, lupus erythematosus, osteitis, osteitis deformans,
polymyositis, progressive system sclerosis, repetitive strain injury, diffuse or
localised scleroderma.
Table 3.7: Chronic musculoskeletal diseases which are grouped together as ’not otherwise speci-
fied’ (NOS) in the definition of chronic diseases in [144].
ever, this approach does not correct for confounding effects; a significant association
between two diseases can still be caused due to a third disease having an effect on both
the others. Learning a structure in such a way that these effects are abandoned from
the network, is exactly what is happening when learning the structure of a Markov
network.
In case a direction is given to all the edges, this is called a Bayesian network. To
illustrate the concept of a disease network we took all the diseases from the latent
classes present in Table 3.5 and used bootstrapped structure learning of Bayesian net-
works to build the network. In Chapter 5 we will elaborate more on this technique, for
now we only show what it is capable of and the result is presented in Figure 3.7. One
can see that most of the edges in Figure 3.7 are between disease vertices that are in the
same cluster as determined by the LCA. However, now both the inter-cluster and the
intra-cluster interactions between chronic diseases are visualised.
The number of edges in Figure 3.7 is approximately 10% of the maximum num-
ber of edges possible for this network, i.e., when all vertices are directly connected
which each other. In comparison to the undirected disease network, where edged are
determined by pairwise assocations, the number of edges is significantly lower. For
example, taking all pairwise associations with a multimorbidity coefficient > 2 results
in an undirected network with approximately 60% of the maximum number of edges
possible. To obtain the same density of edges, as in Figure 3.7, one should take associa-
tions with a multimorbidity coefficient approximately > 7. The same conclusion holds
for the odds ratio.
Furthermore, it turned out that the elements of the metabolic syndrome, i.e., hyper-
tension, lipid disorders, and diabetes mellitus, and musculoskeletal disorders NOS are
the major confounders of all other chronic disorders. From the metabolic syndrome
this was already known. For the musculoskeletal disorders NOS, which are listed in
Table 3.7, this was less obvious. It might be that it represents a kind of latent patho-
physiology, e.g., an autoimmune disease or genetic predisposition of unknown origin.
Something which is comparable with hypertension, of which the aetiology is also not
entirely known. In fact, in 95% of the patients with hypertension, the cause is not being
identified [25].
Network models can also be useful to detect conflicts within clinical guidelines due
to interactions between diseases. For example, the clinical guidelines of hypertension
and dementia share common risk factors, symptoms and signs, suggesting there are
pathological pathways contributing to both diseases. In treatment there can be many
interactions between disorders and drugs, such as positive and negative additive syner-
gies, and drug antagonism when the drugs cancel each other effects. To illustrate this,
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both guidelines were analysed with the aim of constructing a model that could be used
as a start for detecting interactions between hypertension and dementia. The result of
such an analysis is shown in Figure 3.8.
From the picture one can see that both diabetes mellitus and cardiovascular diseases
have their influence on the pathophysiologic processes of dementia. Not only by their
effect on vascular pathologies, but also by their effect on cerebral perfusion. The clin-
ical meaning of this is that, treating one disease affects the other. For example, blood
pressure regulation by antihypertensive drugs can affect the onset of dementia both in
a positive and in a negative way. Indeed, high blood pressure may accelerate cerebral
white matter lesions, but white matter lesions have also been found to be facilitated by
excessive fall in blood pressure, including orthostatic dysregulation and postprandial
hypotension [135]. Moreover, just recently, it was shown that one of the blood pressure
regulation mechanisms – more precise: the baro-reflex – is compromised in patients
with Alzheimer. Pharmacotherapeutic agents (cholinesterase inhibitors) for the treat-
ment of dementia, also partly restored this blood pressure regulation mechanism [101].
smoking diabetes
mellitus
lipid disorder
hypertension athero-
sclerosis
age
heart disease
cerebral
vascular
disease
alzheimer
pathology
lewy body
pathology
cerebral
perfusion brain atrophy
neuro-
degeneration
frontal
temporal
pathology
white matter
lesions
clinical
dementia
outcome
of neuro-
psychiatric tests
education
level
Figure 3.8: Simplified network model derived from cardiovascular and dementia clinical guide-
lines.
3.10 D I S C U S S I O N
In this chapter, we provided information about the storage of patient data in general
practice into electronic health records. A part of this large collection of patient data
– called the LINH data – is used for analysis throughout this thesis. Secondly, we re-
viewed and discussed the current methodologies that are frequently used in multimor-
bidity research, and illustrated some of them by applying them to the LINH data.
Total disease counts are useful to provide insight into how they evolve when people
age. Except for childhood and ages above eighty, total disease counts for the LINH
data were proportional with age on a logarithmic scale. However, from the total figures
one cannot determine whether this exponentional growth is due to disease interactions
or due to the effect of ageing itself.
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Pairwise disease associations provide more insight into the interaction between dis-
eases. Although there are several metrics in this area, in multimorbidity research the
multimorbidity coefficient (MC) is preferred. Odds ratios can be estimated using lo-
gistic regression, which makes them capable of correcting for age or other explantory
variables. However, the MC cannot be corrected in the same way. At a specific age,
the MC is reflected by the individual cumulative incidences (CI) and the CI of its co-
occurrence. Modelling the CI by a sigmoid curve we showed that the product of the
individual curves – reflecting the expected CI of the co-occurrence – can be easily com-
pared with the observed CI. Here we showed that the observed CI of diabetes mellitus
and hypertension together was significantly higher than expected for ages above fifty.
The next step in multimorbidity research is very often the detection of groups of
diseases, assuming there are latent variables that are responsible for the observed as-
sociations. Here we applied a latent class analysis on the LINH data, showing that
chronic diseases can be divided into eight groups. Elements of the metabolic syndrome
are present in four of these groups, stressing out their impact on multimorbidity figures.
Using the pairwise associations one can build a network in which diseases are con-
nected when the observed association reaches a pre-defined significance. However,
in this way conditional independence is not always incorporated. From probabilistic
graphical modelling they are ways to learn the conditional independences. Here we
applied Bayesian network structure learning – something we will elaborate more on in
Chapter 5 – on the set of chronic diseases that were most discriminating in the latent
class analysis. Hypertension, diabetes mellitus, lipid disorders, and musculoskeletal
disorders turned out to be responsible for many pairwise disease associations, making
the resulting network more comprehensible than a network of pairwise associations.
In Chapter 6 we will show how Bayesian networks can be made suitable for dealing
with the fact that patient data is biased due to practice related effects. In this chapter,
we also discussed some temporal models used in multimorbidity. In Chapter 7 we will
elaborate more on this by exploring the use of temporal Bayesian networks.
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P RO BA B I L I S T I C C AU S A L M O D E L S O F M U LT I M O R B I D I T Y
C O N C E P T S
A B S T R AC T
Multimorbidity, i.e., the presence of multiple diseases in one person, is a significant
healthcare problem for western societies: diagnosis, prognosis, and treatment in the
presence of multiple diseases can be complex due to the various interactions between
diseases. A literature review revealed that there are a variety of definitions that describe
different concepts with respect to multimorbidity, both for the cause of multimorbidity
as well as for the implications of multimorbidity. To develop computerised decision-
support systems that are able to provide personalised patient care, and that would
be suitable for replacement of current guideline documents, multimorbidity aspects
need to be captured rigorously in a formal language. In this chapter, we employ causal
Bayesian networks to propose a novel framework that can be used to model a spectrum
of aspects of multimorbidity. We conclude that this framework offers a foundation for
modelling interactions between multiple diseases.
4.1 I N T RO D U C T I O N
As discussed in the previous Chapter, there are various ways to measure multimorbid-
ity. The use of indices, which has its origin in the analysis of comorbidity, see also
Section 1.4, already shows a large variety in the point of view of researchers. Recently,
a systematic literature research [39] emphasised this heterogeneity in multimorbidity
indices. Although these indices show us the size, impact, and growth of the multimor-
bidity burden, they do not give much insight into the underlying causal relationships
between different chronic diseases that occur simultaneously in patients.
The need for integral, optimal management of a patient with multiple diseases, and
the need to do so using decision-support technology, implies the need for an integral re-
search methodology for multiple diseases. It is unlikely that such methodologies will be
based upon traditionally statistical methods, such as logistic regression, as this focuses
on the predictive power of specific variables for the presence or absence of one partic-
ular disease [218]. In this chapter, we will argue that probabilistic graphical models,
such as Bayesian networks [149], provide a good starting point for modelling interac-
tions between multiple diseases. The edges of a graphical model represent statistical
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relationships between variables, which generalises to multiple diseases in a natural
way.
Some examples exist in clinical research that model specific diseases within a mul-
timorbidity setting [162, 184, 217]. However, to provide a more generic framework,
we need precise probabilistic definitions of the existing concepts in multimorbidity.
Firstly, we summarise existing classifications and terminologies used in definitions
used in multimorbidity research and point out their similarities and differences. Sec-
ondly, we will provide a rigorous probabilistic framework of multimorbidity concepts,
using causal Bayesian networks, that fits these classifications and terminologies. Exist-
ing definitions of multimorbidity aspects are analysed on the basis of this framework.
4.2 B AC K G RO U N D
4.2.1 Comorbidity and multimorbidity
In this chapter, the principal focus is on multimorbidity, but since this is closely re-
lated to comorbidity, we also study the concepts related to comorbidity. Recall that
comorbidity was defined in relationship to a specific index condition by Feinstein [50].
Details about multimorbidity and comorbidity can be found in Chapter 3. As argued
there, much of the medical research relies on regression models which are applied to a
single disease, and, thus, ignore the complexity of multimorbidity. Prevalence of mul-
timorbidity has been studied in family practices [207, 53], sometimes with clustering
of specific diseases [124], or a factor analysis to reveal patterns of co-occurrence of
diseases [179]. These methods show that cardiovascular diseases often co-occur with
metabolic diseases, and psychiatric diseases often co-occur with neurologic and so-
matic diseases causing chronic pain and disability.
These results illustrate the impact and complexity of multimorbidity, but give little
insight into interactions between diseases. A systematic review on ageing with mul-
timorbidity [125] identified twelve cross-sectional studies on multimorbidity, four on
incidence and risk factors for multimorbidity, twenty-two on consequences of multi-
morbidity, nine on function status, six on quality of life, eight on healthcare utilization
and six on models and quality of care. One of the major conclusions is that little is
known about causality in multimorbidity.
Recently Valderas et al. [204] summarised several conceptual problems. Differenti-
ating the nature of conditions is critical to the conceptualisation of comorbidity. For
example, conditions can be part of a certain syndrome and should perhaps not be clas-
sified as having comorbidity. The question of which condition should be designated
as the index and which as the comorbid condition is not self-evident and may vary
in relation to the research question, the disease that prompted a particular episode of
care, or of the speciality of the attending physician. In that respect, the sequence in
which comorbidities appear may have important implications for genesis, prognosis,
and treatment.
From a patient and physician’s point of view, multimorbidity is part of a bigger con-
cept, i.e., the multimorbidity burden, which adds parameters such as polypharmacy,
sex, age, frailty and other health-related individual attributes and the patient’s com-
plexity (adding non-health-related individual attributes). For polypharmacy, multiple
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definitions are utilised in the literature. Basically, a certain minimal number of drugs
have to be used, but additional definitions include the minimal time of subscription, reg-
ular daily consumption of multiple medications, and the use of high-risk medications
and questionable dosing. A literature review on polypharmacy in the elderly [58] stated
that selecting appropriate limits for numbers of medications may be counter-productive
in populations with multiple comorbidities.
4.2.2 Causal relations within multimorbidity
A part of the context of the multimorbidity burden is illustrated by Figure 4.1, which
provides an abstract view on the problem. We make the assumption that a disease
always corresponds to a particular pathophysiology, in contrast to syndromes. Syn-
dromes represent a certain symptomatology which can be caused by several pathophysi-
ologic processes. Furthermore, within gerontology certain combinations of diseases are
defined as a geriatric syndrome, meaning a combined set of specific symptomatology
that leads to impaired daily functioning. For example, the combination of polyneu-
ropathy, impaired vision, and the usage of drugs that affect the patient’s consciousness
(e.g., benzodiazepines), often leads to higher risks of falling, the latter being defined as
a geriatric syndrome.
A therapy does not necessarily have to act directly on the underlying pathophysiol-
ogy of the disease intended to treat. In many cases another physiologic process is used
to suppress the symptoms of the disease. For example, within hypertension diuretics
use kidney function to lower the blood pressure, although the actual cause of the hy-
pertension within a particular patient may be due to another pathophysiologic process.
Another issues is that where a therapy typically acts on a designated (patho)physiology,
it may also act on another physiologic processes, causing side effects. Accumulation
of side effects due to polypharmacy can have a major impact on the quality of life.
Whereas the single disease model is fairly simple, mutual dependences within the
multiple disease model may concern the pathophysiology, symptomatology, therapy,
and prognosis. By modelling these interactions explicitly, better decisions can be made
for patients who have multiple diseases. Moreover, single disease models often contain
a lot of overlap; this redundancy may be avoided by integrating different disease mod-
els into a single model. For example, consider a physician facing a patient with a history
of multiple chronic diseases, now having a new problem. How could the physician tell
if the problem is caused by either a new disease, existing morbidity, a side effect of
existing pharmacotherapy, or just a natural phenomena due to ageing or ageing related
stress factors? Treating it just as a new problem (whether introduced by existing dis-
eases and treatments or not) is often the most pragmatic solution. However, with each
newly introduced treatment the overall personal multimorbidity puzzle becomes more
and more complicated.
As an example consider diabetes mellitus (DM), in which two types are distin-
guished: type I, due to impaired insulin production caused by destruction of β-cells
in the pancreas, and type II, due to insulin resistance of peripheral tissue. Both types
cause uncontrolled high blood glucose levels. Measuring this feature of the disease,
i.e., high blood glucose levels, is the corner-stone of the diagnosis and pharmacologi-
cal control of DM. The main consequences of sustained high blood glucose levels are
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Figure 4.1: Abstract model of a single disease (a) and multiple diseases (b).
neuropathy and blood vessel damage, the latter causing new diseases, e.g., retinopathy,
renal failure, heart failure, impaired wound healing etcetera. So, a sustained pathophys-
iological condition caused by a chronic disease, which can be measured using a specific
laboratory test, is often the cause of new diseases. In fact, we can do the same exercise
for condition like a sustained high blood pressure (mostly of unknown cause) or high
levels of blood lipids (mostly of dietary cause). In general practice, the presence of
such secondary diseases strengthens the diagnosis.
4.3 M E T H O D S
To model and analyse multimorbidity concepts, we will employ Bayesian networks
(for details see Chapter 2), which have the ability to model more complex structures
involving disease variables than traditional regression models. While regression mod-
els can only represent functions with just one dependent variable, e.g., a single dis-
ease, Bayesian networks allow for inference about multiple diseases at the same time.
Moreover, it has been shown that in complex medical domains, Bayesian network can
outperform the predictive power of regression models [105].
Causal Bayesian networks are Bayesian networks where the directed edges in G
represent causal influences between variables [151], i.e., an arc betweenC and Emeans
that C is a cause of E. In these models, we can consider probability distributions after
interventions, written as P(x1, . . . , xn | do(xi)), e.g., a probability distribution after
modifying a certain risk factor. This probability distribution can be computed by:
P(x1, . . . , xˆi, . . . , xn | do(xi)) ={ ∏
v∈V ,v 6=i P(xv | xj for all j ∈ pi(v)) if xˆi = xi
0 otherwise
In order to represent qualitative relationships between variables, we use qualitative
causal influences and synergies resembling those of qualitative probabilistic networks
[221, 76] (see Section 2.3). The semantics of these qualitative signs is slightly different
50
4.4 R E S U LT S
D1 D2
F1
F2
P(f1) = 0.40
P(d1 | f1) = 0.20
P(d1 | f1) = 0.50
P(d2 | f1) = 0.30
P(d2 | f1) = 0.60
P(f2 | d1,d2) = 0.10
P(f2 | d1,d2) = 0.80
P(f2 | d1,d2) = 0.70
P(f2 | d1,d2) = 0.90
(a) Causal Bayesian network
D1 D2
F1
F2
+
++
+
−,+
−
(b) Qualitative influences
Figure 4.2: Example domain with two diseases and two features: F1 causes D1 and D2; D1
and D2 both cause F2. On the left a causal Bayesian network with its associated
conditional probability distribution. On the right, the same network with its qualitative
signs. All the influences between variables are positive, the additive synergy between
D1 andD2 is negative and the product synergy betweenD1 andD2 is negative if
f2 and positive if f2.
in order to express comorbidity and multimorbidity concepts. Concretely, if we have
an arc C→ E, then we say C causally positively influences E if:
P(e | do(c)) > P(e | do(c))
Negative causal influences can be defined similarly. We can also consider synergies,
e.g., positive additive synergies express that the joint causal influence of C and C ′ is
greater than their separate influence on their child E, i.e.,
P(e | c, c ′) + P(e | c, c ′) > P(e | c, c ′) + P(e | c, c ′)
Finally, we define causal product synergies that expresses how the value of one variable
influences the probability of the values of another variable in view of a third variable.
A negative product synergy of C and C ′ on variable E with value e means that if C is
the case, then this renders C ′ less likely, which can be expressed by:
P(e | c, c ′) · P(e | c, c ′) < P(e | c, c ′) · P(e | c, c ′)
Similarly, negative additive and positive product synergies can be defined. See Fig-
ure 4.2, which illustrates a causal Bayesian network and the qualitative influences and
synergies derived from the probability distribution.
4.4 R E S U LT S
We will first list existing concepts with respect to comorbidity and multimorbidity from
literature. Then we systematically discuss causal network structures with qualitative
signs and provide an formal analysis with respect to these existing concepts.
4.4.1 Existing comorbidity and multimorbidity concepts
We searched the literature for possible relationships between comorbid and multimor-
bid diseases. The result of this search is summarised in Table 4.1. Each of these papers
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introduces concepts related to comorbidity and multimorbidity, which are sometimes
mutually exclusive, but often overlapping.
The classification made by Kraemer [98], was one of the first, classifying comorbid-
ity into random, clinical (C-comorbidity), familial (F-comorbidity), and epidemiologic
comorbidity (E-comorbidity). While clinical and familial comorbidity are defined, the
focus of this paper is mostly on the measurement and interpretation of E-comorbidity.
An analysis of C-comorbidity and F-comorbidity is not given. The classification pro-
posed by Van den Akker et al. [207], based on the categorisation of Schellevis [180],
is a hierarchical classification. Obviously, all instances of comorbidity fulfil the defi-
nition of concurrent comorbidity. Some of these comorbidities will occur in numbers
greater than expected by chance and hence should be classified as cluster comorbidity.
Some of those statistically significant comorbid associations represent known causal
relationships and should be defined as causal comorbidity. This classification is taken
significantly further in the work by Valderas et al. [204]. In this paper there are three
ways that lead to associations between diseases: by direct causation, by associated risk
factors, or by heterogeneity in risk factors. In the direct causation model, the patho-
physiology of one disease leads to another disease. In the associated risk factor model,
risk factors are correlated (e.g., one causes another). Finally, in the heterogenic risk fac-
tor model, the risk factors are independent, but influence both diseases. For two given
diseases, these models can occur at the same time.
Besides the mechanisms for the co-existence of multiple diseases, differences in
implications for multimorbid diseases on clinical care is also relevant. For example,
Kaplan et al. [50, 91] distinguished between diagnostic and prognostic comorbidity. In
diagnostic comorbidity different diseases can share specific symptomatology, making
the diagnosis harder. In prognostic comorbidity, comorbid diseases alter the prognosis
of the patient (mostly negative), sometimes as expected (cogent), but sometimes also
unexpected (non-cogent). Closely related to diagnostic comorbidity is the work done
by Angold et al. [7], who classified comorbidity into homotypic and heterotypic. These
terms are typically used in psychiatric comorbidity, where in homotypic comorbidity,
diseases belong to the same diagnostic group, e.g. depression and a dysthymic dis-
ease, and in heterotypic comorbidity, diseases belong to a different diagnostic group,
e.g. depression and a personality disease. Finally, Piette et al. [159] classified multi-
ple diseases into concordant and discordant. Concordant diseases are part of the same
pathophysiology, e.g., cardiovascular diseases due to atherosclerosis, or share a spe-
cific therapy, e.g., β-blockers are used for both hypertension and cardiac arrhythmias.
Discordant diseases do not share a part of the pathophysiology or similar types of man-
agement.
4.4.2 Aetiological probabilistic models of multimorbidity
From a probabilistic point of view, there are only a few essential differences in the co-
occurrence of multiple diseases. The first possibility is that the co-occurrence between
diseases is random, which means that the co-occurrence of these diseases is exactly
from what can be expected by chance. Adopting the standard probabilistic terminology,
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C1 C2
D1 D2
+ +
Figure 4.3: Non-aetiological multimorbidity, where diseasesD1 andD2 are caused by indepen-
dent factorsC1 andC2.
we will call this notion independent multimorbidity, and can be expressed in probability
theory by:
P(d1,d2) = P(d1)P(d2)
Assuming the binary random variables D1 and D2 represent the occurrence of each
disease, it follows that D1 is independent of D2, e.g., the absence of d2 also will not
have an influence on d1 as
P(d1 | d2) =
P(d1,d2)
P(d2)
=
P(d1) − P(d1,d2)
1− P(d2)
=
P(d1) − P(d1)P(d2)
1− P(d2)
=
P(d1)(1− P(d2))
1− P(d2)
= P(d1)
This notion completely coincides with the notion of random co-occurrence [98] and
non-aetiological associations [204]. In these models, there is no direct causation be-
tween diseases, nor are the causes of the diseases related. See Figure 4.3 for a simple
example of non-aetiological multimorbidity. In non-aetiological multimorbidity mod-
els, it holds that D2 is d-separated from D1 by ∅. Therefore, it holds that D1 and D2
only occur because of independent multimorbidity.
We propose to call the opposite of independent multimorbidity associative multimor-
bidity, which means that there is some relationship between two diseases which cause
co-occurrence of diseases to be different from expectation by chance. Formally speak-
ing, in the terminology of Kraemer, this notion is called epidemiological comorbid-
ity [98]. However, Kraemer requires that this association should also be epidemiolog-
ically measurable (making it independent from F-comorbidity, see below). Typically,
one is interested in positive associative multimorbidity, i.e., if
P(d1,d2) > P(d1)P(d2).
This coincides with what Van den Akker et al. call cluster comorbidity, i.e., if d1 is
the index disease, then d2 is more likely to occur than expected if d1 and d2 would
have been independent. Negative associative multimorbidity can also occur, e.g., it
seems that myopia is protective against diabetic retinopathy [111]. For patients with
diseases that are negatively associated, Van den Akker et al. then speak of concurrent
comorbidity as this co-occurrence is caused by ‘chance’ rather than the association.
The division into types of association according to Valderas et al. [204] is listed in
Figure 4.4. The direct causation model coincides with the definition of causal comor-
bidity by Van den Akker et al. [207], whereas the other two (associated risk factor
model and heterogenetic risk factor model) are considered cluster comorbidity. From
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D1 D2
+
(a) Direct causation
C1 C2
D1 D2
{+,−}
+ +
(b) Associated risks
C1 C2
D1 D2
+ +
+ +
(c) Heterogenic risks
Figure 4.4: Example causal network structures of comorbidity relations as defined in by Valderas
et al. [204] where diseases are associated. In the associated risk factor model,C1 and
C2 can be associated by any causal mechanism.
C
D1 D2
+ +
(a) Patient characteristic
G
D1 D2
+ +
(b) Genetic
E
D1 D2
+ +
(c) Environmental
Figure 4.5: Primary classes of single risk factors inducing multimorbidity, withDi diseases,C a
patient characteristic,G a genetic factor, and E an environmental factor.
a formal point of view, the focus in these models on risk factors, rather than causes of
diseases could be considered problematic. For example, the authors write that if “the
risk factors for 1 disease are correlated with the risk factor for another disease” (i.e.,
in the associated risk model) then this makes “the simultaneous occurrence of the dis-
eases more likely”. However, this conclusion is only valid if the risk factors are of a
causal nature as it is depicted in Figure 4.4. Consider, e.g., diabetes and familial hyper-
cholesterolemia, which both causes elevated LDL cholesterol. While an elevated LDL
cholesterol is a (non-causal) risk factor for both diseases, these diseases themselves are
not associated.
Besides the way in which the association between diseases is structured, we can
also consider which types of causes lead to a positive association between diseases. In
Figure 4.1 we introduced an abstract framework with mechanisms that diseases can be
related, which directly yields number of possibilities. In general, there are a large num-
ber of possible combinations of risk factors. Focusing on a single disease, there are
three primary causal risk factors: environmental, genetic and those related to patient
characteristics. Example models are given in Figure 4.5. In biomedical research, they
play a distinct role: in practice, controlled studies are only performed to study influ-
ences of patient characteristics on diseases; environmental factors can only be studied
well using epidemiological research; finally, genetic factors are often researched in
observational studies using DNA samples, or twin studies.
Each of the single risk factors causes associations between diseases. Nonetheless,
as mentioned, Kraemer notes that familial comorbidity, i.e., comorbidity which has a
genetic cause, is compatible with independent multimorbidity, i.e., familial comorbid-
ity is compatible with the absence of epidemiological comorbidity. However, this is
only true if in some families there is a positive association between diseases and in
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some other families there is a negative association between the same diseases. Further,
the association may not be epidemiologically relevant if the particular gene causing
an epidemiological comorbidity has a low prior probability. Consider for example a
familial comorbidity between D1 and D2 caused by a genetic factor G. If P(g) ≈ 0
and P(Di | g) ≈ P(Di), then:
P(D1,D2) =
∑
G P(D1 | G)P(D2 | G)P(G)
≈ P(D1 | g)P(D2 | g)P(g) ≈ P(D1 | g)P(D2 | g) ≈ P(D1)P(D2).
Clearly, familial comorbidity might not be epidemiologically measurable if the dis-
eases are almost independent.
4.4.3 Probabilistic models for reasoning about clinical impact of multimorbidity
In practice, the impact of multimorbidity might be more relevant than the actual cause
of the co-existence of multiple diseases. The literature describes several dimensions
through which the interactions between diseases may be relevant, namely if there are
diagnostic, prognostic, or therapeutic interactions.
We say that there is a diagnostic multimorbidity problem if there are interactions
between diseases that complicate the diagnosis of one of these diseases. In essence,
making such a diagnosis involves the consideration of multiple diseases that might be
the cause of the presented symptomatology within a patient. While in case of single
disease management, eventually one disease from this set of diseases is considered to
be the one and only cause of the presented symptomatology, in case of diagnostic mul-
timorbidity it might be the case that more than one disease is involved in the presented
symptomatology. Formally, given a sign or symptom S, the diagnostic value of S for a
given disease D is typically defined by the so-called diagnostic odds ratio, i.e.,
DOR(s | d) =
odds(s | d)
odds(s | d)
Multimorbidity has an impact on the diagnostic value of S for D1 in the presence of
another disease D2 if it alters its diagnostic odds-ratio, e.g., negatively, which can be
expressed formally by
odds(s | d1,d2)
odds(s | d1,d2)
<
odds(s | d1,d2)
odds(s | d1,d2)
which can be shown to be equivalent to:
P(s | d1,d2) · P(s | d1,d2) < P(s | d1,d2) · P(s | d1,d2)
i.e., a negative product synergy. Valderas et al. [204] gives an example of such a prob-
lem: patients with diabetes mellitus (dm) may have altered pain sensation, e.g. angina
pectoris (ap), thereby interfering with and making it more difficult to diagnose coro-
nary heart disease (chd). It thus holds that:
P(ap | chd, dm)
P(ap | chd, dm)
<
P(ap | chd, dm)
P(ap | chd, dm)
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D1 D2
S
+ +
−
Figure 4.6: Diagnostic multimorbidity problem:D1 andD2 positively influence S. A diagnosis
forD1 negatively influences the diagnostic value of s forD2, and vice versa.
D1 D2
P
− −−
(a) Synergistic prognostic
multimorbidity problem
D1 T D2
S P
+ − − −
(b) Therapeutic prognostic multimorbidity prob-
lem
Figure 4.7: Two types of prognostic multimorbidity. In the synergistic prognostic multimorbidity
problem, the negative effects on the prognosis P has an additional negative additive
synergy, i.e., the prognosis is worse with multiple diseases compared to the effects
of the single disease on the prognosis. In the therapeutic prognostic multimorbidity
problem, the therapy given forD1 – as it negatively influences the symptom S – has a
negative impact on the prognosisP forD2. The effect of T on S is mediated by either
the pathophysiology ofD1 or by some other physiological process (cf. Figure 4.1).
expressing that ap has less diagnostic value for chd in the presence of dm. Such diag-
nostic multimorbidity can be illustrated by a product synergy as shown in Figure 4.6.
A prognostic multimorbidity problem occurs if diseases have a (negative) influence
on the prognosis of another disease, due to the anticipated effects on therapy and syner-
getic influence on prognostic factors such as quality adjusted life expectancy (QALYs).
This definition is similar to the definition of prognostic comorbidity by Kaplan et
al. [91]. For example, diabetes mellitus (DM) and lipid disorders (LD) contribute to
biochemical processes that lead to vascular dementia and Alzheimer dementia (AD).
Moreover, there is an additive synergy between these two diseases on the prognosis of
Alzheimer dementia [100], i.e.,
P(pAD | dm, ld) − P(pAD | dm, ld) < P(pAD | dm, ld) − P(pAD | dm, ld)
Moreover, the prognosis of a disease can be influenced by therapeutic effects given
for another disease. For example, using the example of Valderas et al. [204], corticos-
teroids (cs) prescribed for chronic obstructive pulmonary disease in the same patient
will have an antagonistic effect on the prognosis of diabetes (pDM), i.e., it is a negative
causal influence:
P(pDM | do(cs)) < P(pDM | do(cs))
Examples of such models are illustrated in Figure 4.7.
A therapeutic interaction problem occurs when two therapies interact with each
other. Agonistic and antagonistic effects can be modelled using qualitative causal influ-
ences (cf. Figure 4.8a and 4.8b), although the diseases that are intended to be treated
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T1
−
T2
−
S
(a) Agonistic effect
T1
−
T2
+
S
(b) Antagonistic effect
D1
+
T1
− +
T2
−+
+
D2
+
S1 S3 S2
(c) Interaction that induces new symptomatology
Figure 4.8: Therapeutic interactions between independent diseases. In (c) therapy T1 is used to
treat D1; therapy T2 is used to treatment D2; T1 and T2 lead to synergetic side-
effects (expressed in S3).
could be independent of each other from a pathophysiologic point of view, i.e., inde-
pendent multimorbidity. Sometimes, combinations of therapies can even induce new
problems. For example, the combination of diuretics (as anti-hypertensive treatment)
and NSAID’s (as treatment for some independent pain syndrome), can easily lead to
dehydration within the elderly. Schematically, this is shown in Figure 4.8c. Hyperten-
sion, diuretics and blood pressure, are then represented byD1, T1, and S1 respectively.
The same applies to the pain syndrome, represented by D2, T2 and S2. The variable
S3 then represent a side effect of both T1 and T2, which prevalence can be even higher
than expected due to synergistic effects between T1 and T2.
4.5 D I S C U S S I O N
In this chapter we reviewed multimorbidity concepts and proposed a framework using
causal Bayesian networks that define many of these concepts in a precise and formal
manner. These results show that sometimes concepts are similar from a probabilistic
point of view, whereas in other cases, concepts can be sub-categorised into different
types of causal networks. The advantage of translating multimorbidity concepts into
a causal Bayesian network form is that it supports the explicit modelling of the de-
pendences and independences between the disease variables of concern. This way we
obtain a basis for decision-support systems that can be used to manage multimorbidity
in patients. While in this chapter we focused on multimorbidity with two diseases, the
results presented here generalise to more complex situations, e.g., by also considering
qualitative synergies in the presence of more than two causes.
Some concepts from the literature are not explicitly modelled in this framework.
Firstly, the definition of clinical comorbidity by Kraemer [98] can be used to designate
a variety of comorbid concepts. She states that any disease that has an altering effect on
some kind of response to an index disease is of clinical importance. In this definition the
response variable can be anything, e.g., age of onset, therapeutic response, prognosis,
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which, in a causal network framework, are special cases of prognostic and therapeutic
multimorbidity problems. This explains why this concept is not explicitly mentioned.
A similar remark can be made for homotypic and heterotypic multimorbidity. From
a diagnostic point of view, homotypic diseases are closer related to each other than het-
erotypic diseases. This classification has its origin in the aetiology of diseases where
the biological substrates are yet unknown to clarify the observed symptomatology,
e.g., psychiatric disorders. Very often, latent variable methods, e.g., the ones described
in section 2.5.3, are used to explain the observed differences in symptomatology. These
models cannot be translated to causal Bayesian networks; after all, the latent variables
cannot be observed. Still, the technique of using latent variables can be useful for mean-
ingful predictions in case of a general Bayesian network. In case there are many arcs
between the latent variables and the observed variables, i.e., in case of homotypic dis-
eases, this, however, may still lead to diagnostic multimorbidity problems.
Finally, the concepts of cogent and non-cogent prognostic comorbidity can be con-
sidered concepts beyond causal or probabilistic meaning, as they rely on expectations
of the medical researcher.
In Chapter 8, we consider cyclic models, e.g., when diseases contribute to each
other’s pathophysiology. From a formal point of view, acyclic models can also be used
for this purpose by modelling the progression and interaction of diseases over multiple
time slices. Cyclic probabilistic graphical models [151] may also be considered as an
alternative for providing a succinct representation of such interactions.
In conclusion, the models presented here provide insight into the different aspects of
multimorbidity: both in the aetiological relationships between multiple diseases as well
as in the impact that multimorbidity has on clinical practice. Aetiological relationships
will be further exploited in Chapter 5, by means of critical risk factors, and in Chapter 6,
by means of multilevel analysis. The clinical impact of multimorbidity is further shown
in Chapter 7, i.e., we analysed the longitudinal impact of commonly observed health
conditions, e.g., hypertension, on the prevalence of cardiovascular diseases.
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F I N D I N G C R I T I C A L FAC T O R S I N D I S E A S E
C O - O C C U R R E N C E
A B S T R AC T
To better understand the problem of multimorbidity, we have used Bayesian-network
structure-learning methods to discover how risk factors of diseases interact. First, we
determined how sensitive structure learning is to the low prevalence of certain diseases.
The constraint-based learning methods appeared to be suitable for learning all the sig-
nificant associations, even though the arc directions were often incorrect. The search-
and-score-based algorithms yielded correct arc directions in most cases. However, for
these algorithms only the Akaike information criterion seemed to be suitable as a scor-
ing method. Using the Bayesian information criterion, significant clinical associations
were penalised away during the learning process. We applied a search-and-score-based
algorithm to several sets of chronic diseases using data from general practices. A novel
measure for uncovering structural relationships in the co-occurrence of diseases, so
called critical factors, is proposed and studied.
5.1 I N T RO D U C T I O N
In this chapter we explore the value of Bayesian-network structure learning algorithms
in uncovering interactions between diseases. The aim is to develop a new measure that
sheds light on the causal risk factors of multimorbidity. The problem of multimorbidity
has been described in detail in Chapter 3. Rather than focusing on interactions between
diseases of which much is already known, in this chapter we will use the developed
methods to detect disease interactions of which much less is known.
A typical example of such a disease type is cancer, i.e., malignant tumours. Although
multimorbidity is increasingly attracting attention from oncologists, yet little is known
about the interaction between cancers [170]. As cancer is becoming more and more a
manageable chronic disease, and because in the ageing Western society more people
are at risk for cancer, there is a growing number of patients with multiple malignan-
cies [127]. These multiple cancers affect the survival estimates based on each tumour
site, obviously because a primary tumour may have metastasised, but also because
there may be multiple primary malignancies [175]. There are quite some risk factors
that are implicated in the development of multiple primary malignant tumours, ranging
from ageing, environmental and life-style factors, and genetic predisposition. Both for
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the development of clinical prediction models and the prevention of multiple malignant
tumours, understanding the cause of their co-occurrence is important.
Several conceptual frameworks of multimorbidity have appeared in literature, of-
fering distinct ways to clarify how diseases are related. Recently, we proposed a new
framework of multimorbidity, based on Bayesian networks, that can be used as a basis
for modelling a spectrum of multimorbidity aspects and that is described in Chapter 4.
In this chapter, we build upon this work by developing a new method for the identifica-
tion of aetiological interactions between diseases from data. In particular, we propose
a number of measures that express the interaction between diseases. Furthermore, we
identify the critical factors that relate the diseases: these factors indicate which mech-
anisms best explain their co-occurrence.
We evaluate this approach on the most common co-occurrences of malignancies,
and show that we can identify the relationships between malignancies and their critical
factors. Before doing so, we first need to determine which of the structure learning al-
gorithms is the most suitable for the used dataset. For this purpose, we compare several
structure learning algorithms on large datasets in the following section. Thereafter, we
turn back to the aetiologic interactions in oncology.
5.2 S T RU C T U R E L E A R N I N G O F B AY E S I A N N E T W O R K S
A N D L A R G E DATA S E T S
5.2.1 Algorithms and data
There are several methods to learn the network’s structure (see the preliminaries in
Chapter 2), and during the last two decades, many new structure learning algorithms
for Bayesian networks have been proposed. The main question here is whether the
results for synthetic data of such learning algorithms carry over to the real-world data
of the multimorbidity domain. Therefore, it is necessary to know which of the learning
algorithms are most suitable for this purpose. Compared to other domains, in general
practice data there is large range in frequency of occurrence of particular events. Where
in some domains structure learning algorithms that favour sparsity of connecting edges
are more suitable, we do not know whether this holds for our domain. From a medical
point of view each significant association that helps understanding the complex domain
of multimorbidity would be valuable.
For example, cardiovascular disease prevalences were recently calculated in patients
with inflammatory arthritis, osteoarthritis, and diabetes mellitus for a nationwide pop-
ulation in the Netherlands [141]. One of the results is that the prevalence of acute my-
ocardial infarction ranges from 0.7% (controls) to 2.8% (diabetes mellitus). Although
the absolute differences in prevalences are relatively low, the reported odds range up to
4. This suggests that treating one of these diseases is also of clinical importance in the
light of cardiovascular risk management.
As described in some detail in Chapter 2, one class of the Bayesian network learn-
ing algorithms are the search-and-score-based methods. They attempt to identify a
model that best fits the data by searching through the space of candidate models and
selecting the one with the highest score. The search is guided by various heuristics,
such as hill-climbing and tabu search. Typical scoring methods are the Bayesian in-
62
5.2 S T RU C T U R E L E A R N I N G O F B AY E S I A N N E T W O R K S A N D L A R G E DATA S E T S
formation criterion (BIC), the Akaike information criterion (AIC), and the Bayesian
Dirichlet equivalence (BDE) score. Another class of approaches, the constraint-based
methods, estimate from the data whether certain conditional independences between
the variables hold. Networks that are consistent with these independences are selected.
Bayesian network learning algorithms have several limitations. For example, search-
and-score-based methods may end up in a local maximum. On the other hand, the
constraint-based methods rely on the assumption that there exist no unobserved vari-
ables in the domain that explain (in)dependences between variables; this assumption
almost never holds in reality. Nonetheless, it is well known that Bayesian networks
learned from data typically perform quite well compared to simpler models, such as
naive Bayes, when used for classification [121]. Furthermore, there have been signifi-
cant efforts to ensure that the learned structure is correct [200]. Despite all the work on
new learning algorithms, little is known, however, about how well they perform on a
real-world dataset in the domain described here.
We used the following, special methodology for the purpose of the research. In the
well-understood domain of cardiovascular medicine, a Bayesian network was drafted
manually, based on expert knowledge from clinical guidelines. The choice for this
clinical problem domain ensured that we were not faced with the typical problem in
medicine that interactions between variables were only partially known. The structure
of this network was used to generate synthetic datasets. The real-world data we used
comes from general practices in the Netherlands, the same as used in [141]. The large
size of this dataset makes it very likely that the statistics of the data conform to those
in the guidelines. We compared different structure learning algorithms on both the syn-
thetic and real-world data. We chose to evaluate a selection of algorithms – representing
constraint based, search-and-score, and hybrid algorithms – that are scalable and often
used.
5.2.2 Related work
Evaluating the performance of different model selection criteria has been done before,
see e.g., [205] and [226]. However the results vary. Scoring methods such as BIC,
AIC, and BDE have their own advantages and disadvantages in specific settings. Other
related empirical work by de Jongh and Druzdzel [36], who investigated structural eval-
uation measures for Bayesian networks rather than scoring functions. They concluded
that the structural Hamming distance, explained below, is especially useful when look-
ing for causal structures.
In most studies the data used in the research has been generated: either the training
data, the ground truth data, or both are synthetic. Based on such studies it is hard
to conclude anything about the usefulness of particular methods for the analysis of
real-world data. More recently Liu, Malone, and Yuan [115], carried out an empirical
evaluation of scoring functions for Bayesian network selection using datasets from
the UCI machine learning repository 1, which are notoriously unreliable. Their results
showed that the BIC outperforms several other scoring measures, including AIC and
BDE. However, as the biomedical datasets – our field of interest – in this repository
1 http://archive.ics.uci.edu/ml/
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have only a limited number of patients (between 100 and 700), they generated larger
datasets by sampling from these datasets.
A comparison of several structure learning methods for Bayesian networks, on a
large medical dataset, was done by Acid et al [1]. They used several performance mea-
sures, e.g., the Kullback-Leibler distance, to evaluate how well the learned models
fitted the data. Their research is closely related to our work. We also compared con-
straint based, search-and-score, and hybrid algorithms. The major difference is that in
our research we compare such algorithms in a more qualitative manner by comparing
the learned structures with the true underlying structure (assuming this is known).
Other work on evaluating Bayesian network scoring criteria was done by Jiang et
al. [88, 89], where Bayesian networks were used to learn genetic interactions. In this
medical domain, it is assumed that most of the single genetic variables (called SNPs)
are not correlated with a disease, but that in contrast combinations of them are cor-
related. Although dealing with genetic data involves dealing with extreme low prob-
abilities as well, the condition that single variables cannot explain a disease does not
hold in the multimorbidity domain, e.g., single diseases, such as hypertension or di-
abetes, are also correlated with the onset of other chronic diseases. Another differ-
ence is that, in genetics, the direction of the arcs in a Bayesian network are obvious
(gene G → disease X). In multimorbidity, however, this is not always the case. Ei-
ther disease X → disease Y, or disease Y → disease X may hold, and they may
also interact in a way making it impossible to decide on the direction.
5.2.3 Comparing Bayesian network structures
Information about structural similarity and differences between two Bayesian networks
is usually determined by a metric called the structural Hamming distance. This metric
is defined in terms of additional (arcs in the learned network not present in the true
network), missing (arcs in the true network not present in the learned network), and
reversed arcs (arcs in the learned network that has the opposite direction).
Multiple Bayesian network structures with arcs in different directions may belong
to the same equivalence class. Intuitively, the distance between Bayesian networks in
the same equivalence class should be zero. An equivalence class is represented by a
partially directed graph (PDAG), also called essential graph, in which some edges
are directed and some undirected. The undirected edges can be orientated arbitrary
as long as no new v-structure in which multiple variables share a child is introduced.
The SHD then counts the number of directed and undirected edge additions, deletions,
and reversals to transform one PDAG into the other as the distance between two corre-
sponding Bayesian networks. For details on the SHD consult [200]. Besides the SHD,
the Hamming distance on the skeletons were also calculated. Skeletons are undirected
and therefore only involves counting additions and deletions.
5.2.4 Limitations of structure learning
There are some limitations of Bayesian network structure learning. For example, the
constraint-based methods rely on the assumption that there are no unobserved vari-
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Sample Grow Tabu Search MMHC
Size pi Shrink BIC AIC BDE BIC AIC BDE
1000 0.25 62 55 78 73 55 84 73
0.10 8 3 27 11 3 28 10
0.05 2 1 11 4 1 6 2
10,000 0.25 94 99 89 98 99 94 98
0.10 58 32 77 53 32 84 53
0.05 8 2 26 5 1 30 5
Table 5.1: Structure learning performance of the structure u → v ← w for different sample
sizes and different probabilities distributions as in equation 33. Shown is the percentage
of correctly identified structures for 1000 simulations.
ables in the domain that explain (in)dependences between variables. This assumption
is almost never satisfied. For example, in the general practice data we used only mea-
surements that were present in the data. Very often in clinical data tests with a negative
result are missing.
Score-based methods are less sensitive to the assumption of no hidden variables.
However, from previous studies one can conclude that search-and-score-based methods
have the tendency to construct graphs that are sparser than the true underlying Bayesian
network structure. Schulte et al. [181] showed that even for the simple three-vertex
network u→ v← w, the BDE scoring method does not find the true structure in over
50% of the cases for uniform randomly generated distributions and sample sizes below
1000.
We repeated this experiment for binary variables with a very simple binomial distri-
bution as follows:
u← binomial(p = 0.30)
w← binomial(p = 0.20)
v← binomial(p = 0.10+ pi · u+ pi ·w) (33)
If we run this experiment a 1000 times for different values of pi and two different
sample sizes, we obtain the results in Table 5.1. One can see that for lower values of pi
and for a lower sample size the performance decreases rapidly. The search-and-score-
based methods using the AIC performed the best. Altering the probabilities of u and
w, or the type or error-size (α) of the conditional independence tests, lead to the same
conclusions. This is a major concern since the risk attributions, for pi = 0.05 in our
case, still imply an odds ratio of 2 when both conditions are present. In medicine such
a result is still considered of clinical value.
Although the gap between the GS algorithm – as second best – and search-and-score-
based algorithms using the AIC as score is quite large, the GS algorithm performs
equally well when learning the skeletons. The major problem of the GS algorithm is
the need to orientate the direction of edges. The other scoring methods (BIC and BDE)
lead to more sparsity of the learned structures. In the following section we will explore
this further for synthetic datasets and the real-world medical dataset.
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Gen Age
Smo SBP
IHD CVA
(a)
Gen Age
Smo SBP
IHD CVA
(b)
Figure 5.1: Bayesian network structure determined from a clinical guideline (a), which is used for
the experiment with synthetic data, and its equivalence class (b). Dashed arcs represent
the undirected arcs of the equivalence class.
5.2.5 Structure learning from a large patient dataset
The structure learning algorithms were applied to a synthetic dataset (SD) and a patient
dataset (PD). The PD was extracted from the LINH data (see Chapter 3). We applied
the algorithms to all possible clusters of three diseases taken from the diseases that
were investigated in [141], i.e., inflammatory arthritis, osteoarthritis, diabetes mellitus,
hypertension, hypercholesterolemia, acute myocardial infarction, transient ischemic at-
tack, and cerebrovascular accident. The average number of significant edges identified
by the GS algorithm was 2.0, however only 44% of these edges could be directed. Tabu
search and MMHC using the AIC identified an average of 2.2 and 2.0 respectively (all
directed). These numbers drop to 1.5 when using the BIC or BDE.
In a second experiment, the Dutch clinical guideline on cardiovascular risk man-
agement [223] was examined thoroughly to determine a network with cardiovascular
disease related variables. Figure 5.1 shows the model that was used to generate the
synthetic dataset, and which is assumed to be the true model of the dependences and
independences between the variables age (Age), gender (Gen), smoking (Smo), sys-
tolic blood pressure (SBP), ischemic heart disease (IHD), and cerebrovascular accident
(CVA). This simple model already shows a high density of associations between the
disease variables. In fact, the skeleton is already close to a fully connected graph. How-
ever, it is assumed that IHD and CVA are more or less independent given age, gender,
smoking, and systolic blood pressure. Other factors may be necessary as well to ob-
tain conditional independence, e.g., lipid profiles, but were not used in our approach.
The guidelines states that gender has a significant role in IHD. For CVA this is far less
significant and therefore an arc between them is not present in the model.
In the synthetic dataset, gender was binomially distributed with a probability of 50%.
The variable age was uniformly distributed between 40 and 100 years. Smoking was
binomially distributed with a probability of 20%, being a female adds another 1%.
The SBP was normally distributed with a mean of 120 and a standard deviation of 10.
However, for each 10 years above 40, or being a male, or being a smoker, the mean was
increased with 5, making the true mean of SBP approximately between 135 and 140.
IHD and CVA were binomially distributed, both depending on age and SBP, where
IHD depended more on age, and vice versa CVA more on SBP. For males 5% was
added to the probability of IHD. For smokers 5% was added to both the probabilities
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of IHD and CVA. These distributions are comparable with the distributions found in
the PD when the variables are analysed with general linear regression methods. The
following equations summarise the distributions describe above:
gen← binomial(p = 0.50)
age← uniform(interval = [40, 100])
smo← binomial(p = 0.20+ 0.01(gen = female))
SBP← normal(mean = 120+ 0.5(age− 40)
+ 5(gen = male) + 5(smo = yes), sd = 10)
IHD← binomial(p = 0.05(gen = male) + 0.002 · age
+ 0.05(smo = yes) + 0.001(sbp− 120))
CVA← binomial(p = 0.001 · age+ 0.05(smo = yes)
+ 0.002(sbp− 120))
The same variables were extracted from the PD for patients older than 40 years. This
left us with approximately 150,000 patients, for which the SBP represents an average
of all SBP measurements over a period of five years. Both the age and the SBP are
discretised in intervals of ten.
For both datasets Bayesian network structures were learned using the following al-
gorithms: the GS algorithm; TABU with the scoring functions BIC, AIC, and BDE;
and the MMHC algorithm, again with the same scoring methods. The experiments
were repeated for datasets containing 250, 1000, 10.000, and 100.000 sampled patients
respectively. For each sample size we sampled a thousand times and calculated the
average SHD of the PDAGs and Hamming distance of the skeletons. Eventually the
structure learning algorithms were applied to the entire PD, see Table 5.2.
In the resulting models of the experiments, it appeared that in the PD the arcs
gender → age and age → smoking were learned systematically in most of the
models, even for low sample sizes. Figure 5.2 shows the evolution of the model for
increased sample sizes. A close analysis of the PD for these variables (not shown here),
shows that females are on average one year older than males, and that non-smokers
are on average five years older than smokers. After adding these arcs to the true model,
Table 5.3 shows the newly calculated Hamming distances of the sampled real-world
data from the PD. In the learned model for the overall population, using MMHC with
AIC, the only difference with this adjusted model is that instead of an arc SBP→ CVA
there is an arc IHD→ CVA.
For the synthetic dataset, the tabu-search algorithm with the AIC as scoring function
performed best for smaller datasets. With larger sample sizes, it was outperformed by
the MMHC. The same conclusion held for the real-world datasets, except for determin-
ing the skeleton when the sample size was large. In that case, the GS algorithm outper-
forms the search-and-score-based methods. Still, even when the skeleton as discovered
by GS was given, it had difficulty in orientating the arcs properly. Again, altering some
of the parameters in the learning methods (α, restarts, perturbations), led to the same
conclusions (not shown here).
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Sample Dataset Hamming Grow Tabu Search MMHC
Size Distance Shrink BIC AIC BDE BIC AIC BDE
250 synthetic skeleton 9.10 10.7 7.95 8.83 10.8 9.07 9.48
structural 11.1 11.0 10.9 11.3 11.0 11.1 11.1
real-world skeleton 10.1 10.1 9.01 9.28 10.2 9.83 9.98
structural 11.7 11.1 11.0 11.6 11.1 11.5 11.5
1000 synthetic skeleton 7.83 8.95 5.49 6.67 9.31 7.60 8.09
structural 10.2 11.0 9.91 10.9 11.0 11.0 11.0
real-world skeleton 9.33 9.50 8.17 9.19 9.64 9.07 9.45
structural 11.8 11.8 10.8 11.4 11.6 11.1 11.3
10,000 synthetic skeleton 6.26 5.25 3.01 4.67 5.63 4.72 5.27
structural 8.19 10.6 5.13 8.04 10.6 7.19 8.48
real-world skeleton 7.04 7.76 7.46 7.22 8.31 7.25 7.58
structural 12.0 10.5 10.2 10.4 10.2 9.13 9.28
100,000 synthetic skeleton 2.47 2.34 1.56 2.08 2.39 1.53 2.25
structural 4.62 5.32 2.11 4.71 5.82 1.55 5.36
real-world skeleton 4.12 7.44 5.51 8.00 7.44 4.69 8.00
structural 10.8 9.89 8.69 11.8 9.44 6.03 10.0
154115 real-world skeleton 4 8 5 8 8 4 8
(complete) structural 11 10 6 13 10 5 10
Table 5.2: Average Hamming distances of the learned Bayesian network structures (row-lowest
values are in bold, MMHC=max-min-hill-climbing).
Whereas Liu et al. [115] report good results using the BIC for relatively small
datasets, we could not confirm their results using our real-world data. The AIC per-
forms best for small datasets with low marginal probabilities. This was expected as the
datasets from the UCI repository have distributions that differ in their characteristics
from the datasets we studied, in particular for our datasets there may be very low prob-
abilities for particular events. The sensitivity of structure learning methods to extreme
probabilities deserves a more thorough analysis, as this is something that occurs in
many medical domains.
A further observation is that the difference between the distance of the skeleton
and the distance of the PDAG to the true model is fairly constant for the synthetic
dataset when increasing the sample sizes. This applies more or less to all algorithms
used here. However, for the real-world data this is not true, i.e., most of the algorithms
failed to discover the correct direction of arcs when increasing the sample sizes. The
only exception was the MMHC algorithm with an AIC score, where the differences
remained fairly constant.
Some of the differences to the literature we found can be explained by the fact that
our models are more dense compared to randomly generated networks. In real-world
patient data it is hard to make comorbid diseases independent since there are several
confounders such as laboratory measurements and life style factors. These are typically
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Figure 5.2: Evolution of the learned model for the real-world dataset using the MMHC algorithm
with the AIC score. The models (a), (b), (c) and (d) are learned with a sample size
of 250, 1000, 10000 and 154115 (the complete dataset), respectively. Dashed arcs
represent arcs that were not present in the original model in Figure 5.1.
not all known in epidemiological data, which leads to even more dense networks. An-
other issue is that the true direction of arcs between such confounders is often not clear,
which made it difficult to use them in this evaluation.
5.3 M O D E L S O F C O - O C C U R R E N C E A N D T H E I R C H A R AC T E R I S AT I O N
In the previous section, we determined that, in case of a large patient dataset with low
disease prevalences, using a search-and-score-based method with a score that depends
on the AIC, performs well for learning the structure of a Bayesian network. Therefore,
we use this method to learn the structure of Bayesian network models for explaining the
observed associations between oncologic diseases. Before moving on to the character-
isation of such networks, we first briefly recall the measures of association frequently
being used in multimorbidity research.
5.3.1 Statistical measures of association in multimorbidity
Commonly used measures in medicine to describe associations are the relative risk
(RR) for disease pairs and the φ-correlation coefficient. These measures have been
used to investigate cancer metastasis patterns in a network-based manner, where edges
in a constructed network were added because of high enough strength of RR or φ-
correlation [28].
For readability, we recall the definition of the RR for disease pairs, which coinci-
dences with the multimorbidity coefficient. Let Ni be the number of patients with
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Sample Hamming Grow Tabu Search Max-min Hill-Climbing
Size Distance Shrink BIC AIC BDE BIC AIC BDE
250 skeleton 10.8 12.0 9.09 10.5 12.1 10.7 11.0
structural 12.9 13.1 12.1 13.0 13.0 12.8 13.0
1000 skeleton 8.99 10.2 7.13 9.21 10.4 8.57 9.71
structural 12.1 13.1 10.7 12.2 13.0 11.4 12.4
10,000 skeleton 5.08 5.84 5.46 5.22 6.39 5.25 5.58
structural 11.5 10.0 8.84 9.46 9.41 7.35 7.87
100,000 skeleton 2.12 5.44 3.51 6.00 5.44 2.69 6.00
structural 9.76 8.08 7.73 10.4 7.44 3.16 8.00
154,115 skeleton 2 6 3 6 6 2 6
(complete) structural 10 8 3 10 8 2 8
Table 5.3: Adjusted average Hamming distances of the learned Bayesian network structures (row-
lowest values are in bold).
disease Di, Nj the number of patients with disease Dj, Nij the number of patients
with both diseases Di and Dj, and N the total number of patients. The relative risk of
observing a pair of diseases Di and Dj affecting the same patient is then given by
RRij =
NijN
NiNj
=
P(di,dj)
P(di)P(dj)
(34)
The statistical significance of the RR depends on the sample size, the size of the preva-
lences involved, and the noise in the sample. Further characteristics of the RR and its
use in medicine are outlined in [190]. If we evaluate the RR for a specific subpopulation
by conditioning on a set of risk factors Q, we obtain:
RR
q
ij =
N
q
ijN
q
N
q
i N
q
j
=
P(di,dj | q)
P(di | q)P(dj | q)
(35)
with Nqij the absolute prevalence of both Di and Dj within the subpopulation of pa-
tients for which Q = q holds. Nq, Nqi , and N
q
j are defined likewise.
There are only a few situations in which multiple diseases occur together. The first
possibility is that their co-occurrence is at random, i.e., exactly from what can be
expected by chance. Adopting the standard probabilistic terminology, this notion is
called independent multimorbidity, see also Chapter 4, and it coincidences with an RR
= 1. The opposite of independent multimorbidity is called associative multimorbidity,
which means that there is some relationship between diseases which causes the co-
occurrence of the diseases to be different from expectation by chance. Typically, one is
interested in a positive associative multimorbidity, i.e., where RR > 1.
While independence measures provide some insight into which diseases might co-
occur more frequently, they do not give much insight into the aetiology as the are
a number of ways these diseases can be related [102]. To model and analyse such
relationships between diseases, we will use Bayesian networks, as these can be used to
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risk factor 1 risk factor 2
risk factor 3 risk factor 4
risk factor 5 risk factor 6
disease i
symptomatology
risk factor 1 risk factor 2
risk factor 3 risk factor 4
risk factor 5 risk factor 6
disease i disease j
symptomatology
Figure 5.3: Bayesian network of a single disease (left) and multiple diseases (right).
model more complex structural relationships between disease variables in comparison
to traditional regression models.
5.3.2 Structural measures of multimorbidity
To illustrate how Bayesian network modelling can contribute to understanding the rela-
tionship between diseases, consider Figure 5.3, which shows a Bayesian network of a
single and a multiple disease model. In both models there is a set of risk factors present,
which can be any subset of environmental, patient, genetic, and other disease related
variables. Between these risk factors (in)dependency can occur. For example, in both
disease models, the risk factors 2 and 3 are associated with each other through a third
risk factor 1, and the risk factors 4 and 6 are directly associated. The risk factor 5 is
independent from the other risk factors, however in the multiple disease model it is also
a common parent of both diseases.
There are a number of characteristics considered to be relevant in multimorbidity re-
search, see also Chapter 4, namely whether the diseases are: (1) causally related (direct
causation model), (2) related because of common risk factors (heterogenic risk factor
model), or (3) the diseases are related because of risk factors that are correlated (asso-
ciated risk factor model). Learning causal models is beyond the scope of this chapter,
so we will focus on characteristics of heterogenic and associated risk factors of dis-
eases. In the example above, risk factor 5 is a common risk factor, while, for example,
risk factor 3 and risk factor 6 are heterogenic risk factors. The quantitative measures
that we will use in this section, are the number of common risk factors and the num-
ber of associated risk factor combinations that lead to associations between diseases.
As these measures show the number of relationships between the most important risk
factors, they given an indication of the complexity of the reason for co-occurrences. If
both numbers are 0 and their is no direct path between the diseases, then we have the
simplest type of multimorbidity, i.e., independent multimorbidity.
5.3.3 Critical factors
While there can be many associations between diseases, often these diseases can be
explained by only a few risk factors. For example, in Figure 5.3, risk factors 1, 4, and 5
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completely explain the association between the diseases. If these risks can be prevented
or reduced through an intervention, both the chance of the occurrence of the individual
diseases and the multimorbidity burden is reduced, so these are the most critical factors
in the model. More formally, this means we are interested in sets of factors C such that,
given two diseases Di and Dj and a graph G:
1. all trails Di ← X1 ← · · · ← Xk → · · · → Xn → Dj in the graph G are
d-separated by C, i.e., C∩ {X1, . . . ,Xn} 6= ∅;
2. there is no C ′ ⊂ C for which the previous condition holds.
It is easy to see that there exists such a C such that every X ∈ C is an ancestor of
both Di and Dj. In our non-causal models, the ultimate causes are not necessarily
ancestors, hence, we take any of the minimal separating sets, which can be can be
found in polynomial time [199].
Using existing techniques, it is possible to find a conditioning set Q such that ∀q ∈
Q : RRqij = 1. If ∀q ∈ Q : RRqij = 1, using Equation 35 this implies that:
P(Di,Dj | Q)
P(Di | Q)P(Dj | Q)
= 1
so therefore we have:
P(Di,Dj | Q)
P(Di | Q)P(Dj | Q)
= 1⇔ Di ⊥ Dj | Q⇔ Q d-separates Di and Dj (36)
For example, the RR of a colorectal cancer and a respiratory cancer being a comorbid
combination is 5. If we condition on the presence of liver cancer, the RR drops to 1.3
and it remains 5when liver cancer is not present. In this approach, no distinction can be
made between direct causation and common risk factors, i.e., whether liver cancer is a
common risk factor or whether it is a metastasis of a colorectal cancer that will further
metastasise to the lungs. In Bayesian network structure learning, it is common practice
to include background knowledge during the learning of networks, e.g., knowledge that
metastatic spread of a cancer is common. Furthermore, in structure learning approaches
it is possible to use model selection that gives an indication of the best possible model,
which is significantly more difficult using relative risk or Pearson’s correlation.
5.3.4 Experiments
Recently, the LINH data was used to compare the occurrence of pre-existing and subse-
quent comorbidity among older cancer patients with older non-cancer patients in terms
of odds and hazard ratios [38]. Here we explore the co-occurrence of cancers and their
related comorbidity. In the remainder of this chapter we will denote malignant diseases,
e.g., skin cancer or breast cancer, by Mi. Remaining chronic, but benign, conditions,
such as chronic liver disease or benign prostatic hypertrophy, are denoted by Ck.
Table 5.4 shows prevalences of the most significant comorbid combinations of malig-
nant tumours, corrected for age and gender. A combination of two malignant tumours
Mi and Mj is selected when Mi 6⊥ Mj | {Age,Gender}, with a significance level
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< 0.05. For comparison, the RR and the φ-correlation coefficient are calculated as
well.
For each malignant tumour Mi present in Table 5.4, the set Ri consists of all asso-
ciated conditions Ck for which Mi 6⊥ Ck | {Age,Gender}, with a significance level
< 0.05, shown in Table 5.5. A distinction is made between disorders that are associ-
ated with the onset of a cancer, e.g. smoking, alcohol abuse, or a chronic liver disease
(Table 5.5(a)), and disorders that are probably a consequence of a cancer, e.g., anaemia,
depression, or cardiovascular disease (Table 5.5(b)).
Finally, we applied structure learning, using the R statistical software package bn-
learn [185], for each {Mi,Mj,Age,Gender} ∪ Ri ∪ Rj of each combination Mi and
Mj present in Table 5.4. Within each structure we determined the minimal d-separation
between Mi and Mj, and whether a direct association still remained between the two
malignant tumoursMi andMj. A pair of two associated risks Rk and Rl can be depen-
dent or independent when corrected for age and gender, i.e., Rk 6⊥ Rl | {Age,Gender}
or Rk ⊥ Rl | {Age,Gender}, respectively. Dependent risk factors can be grouped into
common parents and associated risks. The results are showed in Table 5.6.
In our results, we observe that in the majority of cases there is no direct arc between
two malignant tumours Mi and Mj if the RRij < 10, i.e., the association can only
be explained by a set of critical factors. Age and gender frequently act as a common
parent. Therefore, they are often part of the critical factors. Only on three occasions a
disease variable, other than age or gender, acts as a direct common parent: chronic liver
disease as common parent of pancreatic cancer and liver cancer; smoking as a common
parent of respiratory cancer and bladder cancer; and benign prostate hypertrophy as a
common parent of prostatic cancer and bladder cancer.
Figure 5.4a shows the local network structure that connects colorectal cancer and
respiratory cancer. These two malignant tumours do not share a direct common par-
ent, and there is no edge between these two variables in the network. However, the
aetiologic association can be explained by the critical factors and the elements of di-
rected paths, in this case: age, smoking, alcohol abuse, and liver cancer. Conditioning
on these variables should lower the RR significantly. Indeed, if we condition on the
facts that a patient smokes, has liver cancer, and is of age between 65 and 80, the RR
observing both cancers drops from 5 to 1.8.
Figure 5.4b shows the local network structure that connects liver cancer and pancre-
atic cancer, which also appears at the top of the list in Table 5.4b. There is a direct
association between liver cancer and pancreatic cancer. In this case, this is most likely
a direct causal pathway, i.e., it is due to metastasis of pancreatic cancer to the liver.
The remainder of the aetiology is totally explained by the direct common parents age
and chronic liver disease. Colorectal cancer is associated with liver cancer, but as risk
factor it is independent of pancreatic cancer.
5.4 C O N C L U S I O N S
The advantage of studying multimorbidity by means of Bayesian networks is that they
allow modelling relationships between multiple disease variables, whereas it is also
possible to learn these networks, to a large extent, from data. Structure learning has
been applied before to medicine, for example, to predict disease related mortality [31],
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Figure 5.4: Bayesian networks for comorbid combinations of cancer. Abbreviations: COPD =
chronic obstructive pulmonary disease; IBS = irritable bowel syndrome.
and also in the context of multimorbidity, e.g., in genome-wide association studies to
determine genetic links between chronic diseases [3]. In this chapter, we use these
methods to explain the co-occurrence of multiple diseases in terms of their risk factors.
As the types of relationships between risk factors varies, we proposed looking at the
critical factors that lead to co-occurrences.
We discussed the characteristics of disease networks, in particular that one has to
deal with low prevalences and a dense structure. We showed that this has certain im-
plications for the methods that are suitable for learning a Bayesian network structure.
In order to do this, we assessed several well-known BN structure-learning algorithms.
The aim was to obtain insight into whether the experimental results from the literature,
which mostly are based on synthetic data or low-quality datasets from UCI, carry over
to a real-world dataset when it comes to analysing multimorbidity. For that purpose,
we used a very large real-world dataset, acquired from general practices, and focused
on the well-understood domain of cardiovascular medicine. It appears from the results
that structure learning is fairly sensitive to extreme probabilities.
In a further evaluation, we applied structure learning methods to a dense model of
comorbid cardiovascular diseases with a relatively low average prevalence. In contrast
to the synthetic data with similar characteristics, we found that a constraint-based al-
gorithm outperformed the other methods when trying to find the correct skeleton of
the network if the sample size is large. This suggests that research results obtained
from synthetic data—quite typically something used to evaluate new structure-learning
algorithms—do not necessarily carry over to real-world data.
The full Bayesian network can best be discovered using a search-and-score-based
algorithm with the AIC as score method. While use of the AIC score may give rise to
inclusion of too many arcs [115], from a medical point of view, we can argue that it is
better to find all relevant associations, as this may significantly influence the patient’s
risk profile when making predictions based on the network. Although our database
contains data from a nationwide population, generalising the results would be too pre-
mature. In future work we aim to further validate these results.
Another question is whether the learning algorithms can be improved. For example,
the MMHC method uses a restricted search space based on learned skeletons. Since
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the skeletons learned by the GS algorithm outperform the rest, one might replace the
restricted search space by the skeletons obtained by the GS algorithm. In some pre-
liminary experiments, however, we were unable to detect significant improvements
using this idea. Nevertheless, we believe that there is a need for further improvement
of structure-learning algorithms to deal with large real-world medical datasets.
Using a search and score method, we learned Bayesian network structures for pairs
of oncologic diseases and their related comorbidity. The resulting networks are in line
with knowledge known from the oncology literature. For example, long sustained expo-
sure to chronic conditions, e.g., unhealthy lifestyles, is associated with high prevalence
of breast, colorectal, respiratory and prostate cancer [219]. In the networks learned
here, age and gender are often a direct parent of both malignant tumours. Other critical
risk factors, e.g., smoking and alcohol abuse, are often associated by directed paths of
pathophysiology to pairs of malignant tumours.
In some cases a direct edge remains in the network between the two malignant tu-
mours. Most probable, this reflects metastasis, however direct associations found be-
tween two malignant tumours may also have another explanation, e.g., a genetic predis-
position or another unknown confounder. Sometimes there a directed path of malignant
tumours. This might reflect metastasis to secondary locations, e.g., colorectal cancer
→ liver cancer → respiratory cancer. The same holds for associations between risk
factors, such as oesophageal reflux with diverticulosis, which may be explained by life
style factors or genetics that are not present in the data.
The methodology used here shows that, even though overall relative risks between
pairs of malignant tumours can be high, a direct association, such as metastasis, is
not always the obvious reason for that. Using structure learning and concepts such as
d-separation in Bayesian networks we identified other critical risk factors, e.g., age,
gender, smoking, and alcohol abuse, in the pathogenesis of co-occurring malignant
tumours. This shows that the method provides useful results for identifying critical fac-
tors of associated comorbid diseases where the role of such risk factors is less obvious.
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6
M U LT I L E V E L BAY E S I A N N E T W O R K S F O R T H E A NA LY S I S
O F H I E R A R C H I C A L H E A LT H C A R E DATA
A B S T R AC T
Large healthcare datasets normally have a hierarchical structure, that is captured in
terms of ‘levels’, as the data may have been obtained from different practices, hos-
pitals, or regions. Multilevel regression is the technique commonly used to deal with
such multilevel data. However, for the statistical analysis of interactions between en-
tities from a domain, multilevel regression yields little to no insight. While Bayesian
networks have proved to be useful for analysis of interactions, they do not have the
capability to deal with hierarchical data. In this chapter, we describe a new formalism,
which we call multilevel Bayesian networks; its effectiveness for the analysis of hi-
erarchically structured healthcare data is studied from the multimorbidity perspective.
The results are compared with those obtained by multilevel regression. Using multi-
level Bayesian networks we were able to obtain models with higher predictive power
and with a significant net reclassification improvement. The Bayesian-network models
offered considerable more insight into the interactions between the diseases through
their structure. Moreover, a multilevel Bayesian network model can be used for the
prediction of the occurrence of multiple diseases, even when some of the predictors
are unknown. Thus, multilevel Bayesian networks offer an attractive alternative to mul-
tilevel regression equations when analysing hierarchical healthcare data.
6.1 I N T RO D U C T I O N
Healthcare research is often done using clinical data that have a hierarchical structure
– they have levels as is said. This may be due to the fact that the data have been ob-
tained from different practices, hospitals, or regions. Since patients within the same
practice are often more alike than two randomly chosen patients, they will likely have
some correlation on variables related to the practice. Statistical analyses that ignore
these correlations will lead to results that are statistically invalid [167]. Commonly
used statistical techniques such as logistic regression do not allow incorporating the
characteristics of the different levels in the hierarchy. Therefore, multilevel regression
methods are often used to analyse such data. The books [9] and [83] offer an overview
of such methods.
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In the artificial intelligence literature, the use of probabilistic graphical models, such
as Bayesian networks [149], have had a significant impact on the modelling and anal-
ysis of patient data [120]. The edges in the graphical model represent probabilistic
relationships between specific patient variables for a disease of interest. Bayesian net-
works allow for the integration of medical domain knowledge, and clinical expertise
can be modelled explicitly. Moreover, clinical knowledge derived from clinical health-
care data can be used to further refine and validate the model.
In this chapter, we combine multilevel modelling and learning with Bayesian net-
work modelling. This can be useful in complex domains such as the epidemiology of
multimorbidity (see Chapter 3 for details). Multimorbidity is often analysed using mul-
tilevel regression, as it requires a large amount of data coming from different sources
in order to study the interaction between diseases. Moreover, it is a typical problem
where Bayesian networks can be useful, as expert knowledge is needed, and repre-
senting multiple diseases requires scaling up to models containing a large number of
variables.
Since Bayesian networks have already been successfully applied to model single dis-
eases [120, 8, 51, 97, 118, 119, 216], and also for multiple diseases [72, 73, 145, 146,
148], the research question is whether and how it is possible to adopt the multilevel
approach for Bayesian networks. In that way we would be able to explore complex
healthcare data that is hierarchically structured using Bayesian networks with the ad-
vantage that, in contrast to multilevel logistic regression, models are obtained that offer
a clear representation of the interactions between multiple diseases.
The main contribution of this chapter is that it introduces a new representation of
multilevel disease models using Bayesian networks, which we call multilevel Bayesian
networks. It has the advantage that it is at least as powerful as multilevel logistic regres-
sion, yet supports, in contrast to multilevel logistic regression, gaining new insights
into the interactions between multiple diseases.
Using patient data from family practices in the Netherlands, we applied this frame-
work to obtain a prediction model for multiple chronic diseases, namely diabetes mel-
litus and heart failure. The effectiveness of multilevel Bayesian networks has been
studied by comparing the resulting model to the traditional models based on multilevel
regression analysis.
6.2 R E L AT E D R E S E A R C H
Multimorbidity is the healthcare problem where we focus on in this chapter, although
multilevel Bayesian networks may have other applications as well. The problem of
multimorbidity has been extensive reviewed in Chapter 3 and the reader is referred to
this chapter for further detail. Here we only briefly summarise some relevant facts.
In most of the research in multimorbidity, the prevalence and significance of specific
factors for predicting the presence or absence of specific diseases is typically deter-
mined by means of (multilevel) regression methods, where the variance of the obser-
vations is minimised with respect to a linear or logistic model. Where multimorbidity
should be studied by exploring the interactions between diseases with associated signs
and symptoms in their full generality, in practice current research explores this only
in a very restrictive fashion. For example, there is some research where the prevalence
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of multimorbidity has been studied in family practices [207, 53] by means of cluster-
ing methods [124]. Multimorbidity indices are another way to measure specific types
of multimorbidity within a population [39]. These methods illustrate the size, impact
and complexity of multimorbidity, but all of them give little insight into interactions
between diseases.
Multilevel regression has many applications in the social sciences and in medicine;
however, it was not especially designed to model multimorbidity [15, 40, 75]. In [140]
complex hierarchical patient data were used to analyse the predictive value of car-
diovascular diseases for hypertension and diabetes mellitus. Since both diseases are
analysed separately, the results only give a preliminary view on correlations between
cardiovascular diseases.
Various Bayesian network models for multiple disease have been developed since
the beginning of the 1990s. Examples are Pathfinder [72, 73], Hepar II [146] and
MUNIN [198]. They deal with multiple diseases, although all of them belonging to
the same disease class. One of few existing exceptions is QMR-DT [189, 132], as it
covers a broad subset of internal medicine. However, it was never meant for actual use.
All these Bayesian network models have been constructed based on expert opinion and
engineering background knowledge. They did only incorporate known disease interac-
tions; they were not meant for uncovering new disease interactions. This explains why
dealing with multilevel data was not seen as a problem. In this chapter we make an im-
portant step forwards in this respect, as Bayesian network models are learned in order
to gain insight into the interactions between diseases. Without the capability to deal
with hierarchical data, using multilevel methods, models are obtained that may yield
predictions that are statistically unsound.
Bayesian networks have also been used in algorithms for learning patient-specific
models from clinical data to compare mixed treatments and to predict disease progres-
sion [162, 217]. Somewhat confusingly, the adjective ‘hierarchical’ is also used in con-
nection to Bayesian networks. For example, nested, hierarchical Bayesian networks
allow one to define genetic models that can be reused [194]. Hierarchical Bayesian
networks have also been proposed as an aggregating abstraction [70] that clusters vari-
ables closely related to each other. This all closely relates to object-oriented Bayesian
networks [94], but there is no relationship to multilevel analysis where the hierarchy
stands for nested data from different groups.
Eventually, one would like to have methods for the analysis of healthcare data that
can handle multimorbidity, and have the ability to be personalised as well, i.e., allow
entering observations of a patient into the probabilistic model and obtaining updated
parameters that specifically account for that patient. Such personalised models help
to generate specific advice that relates to the patient’s health status. The probabilities
of the underlying model could be extracted from existing clinical research or from
available patient data, using a valid method that takes interactions between diseases
into account.
To illustrate the types of relationships that can occur, the left-hand side of Figure 6.1
shows the typical relationships between variables for a single disease, whereas at the
right-hand side the integration of multiple diseases into one graphical model is depicted.
Representing multiple diseases in one model avoids redundancy of separate representa-
tions and has the advantage that it shows where diseases interact. Mutual dependences
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Figure 6.1: Abstract model of a single disease (left) and multiple diseases (right).
may concern diseases, therapies, pathophysiology, symptoms, signs, and lab results,
and modelling interactions explicitly allows us to make better decisions for patients
having multiple diseases. In fact, the architecture of networks such as MUNIN [198]
is similar, as it also models diseases in terms of their pathophysiology and patient find-
ings.
6.3 M U LT I L E V E L R E G R E S S I O N
To analyse multimorbidity problems one has to deal with large datasets in which vari-
ance is introduced by the fact that the data have been collected from different sources,
such as family practices and populations, either social, economic, or demographic. If
we would ignore this, identifying interactions between disease variables, such as patho-
physiology and laboratory results, could be difficult and even erroneous.
While Bayesian networks model a joint probability distribution, regression meth-
ods estimate conditional distributions. Linear regression tries to estimate a linear de-
pendency between the observations of a random continuous variable (assuming it is
normally distributed), denoted by O, and a set of (non-random) explanatory variables,
denoted by e. This is done by using an optimisation algorithm, such as the least square
method, that minimises the deviation of the observations with respect to the model
parameters.
If, additionally, the data is hierarchically structured, then at each level, the data can
be split into groups. Characteristics of each group are modelled by additional (non-
random) level variables, denoted by l. For example, if the different practices are mod-
elled by a grouping variable, a variable such as urbanity that will be shared among
practices is modelled by such a level variable. Multilevel analysis tries to explain the
variance caused by level variables that have an influence on the explanatory variables
e. For example, if we use linear regression, the intercept and slope, that determine the
linear dependency between two variables, may alter for different groups.
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More precisely, in multilevel regression we wish to explain an observation o with
respect to explanations e and l, assuming that the observations o are possible outcomes
of a random variable O. Let us first assume that there are only two levels to cope
with the grouped data. The explanations e represent the first level, i.e., they can be
different for each individual. The second level then represents the groups, which are
characterised by the explanations l. The explanations l can thus only differ per group,
and together with the explanations e they describe each individual.
Let there be r groups with n first-level explanations and m second-level expla-
nations. Then, for each qth group at the second level we define a linear regression
model for O, and allow dependency of the regression coefficients on the variables lj
and certain deviation from the overall mean. With e = (1, e1, . . . , ei, . . . , en)T , l =
(1, l1, . . . , lj, . . . , lm)T , i.e., n+m explanations, δq = (δ0q, . . . , δnq)T (the second
level noise), for q = 0, . . . , r, and β a matrix consisting of components βij (the effect
of lj on the explanation ei), the model then becomes: E[Oq | e, l] = (δq + βl)T e,
which, if the noise is normally distributed, can be interpreted as a conditional probabil-
ity distribution:
P(Oq | e, l) ∼ N(µq,σ) (37a)
µq = (δq +βl)
T e (37b)
for q = 0, . . . , r, where the expectation of the outcome variable E[Oq | e, l] = µq.
In this model, the outcome for each group is dependent of explanatory variables e
weighed by the coefficients β, the level variables, and random variables δiq, where
for each i, the δiq are normally distributed with expectation zero, and correlated with
a δiq′ . These correlations ensure that observations for one group have an impact on
other groups through this hierarchical structure.
Generally, multilevel models assume homogeneity of variance for all observations
on the first level, i.e., σ is constant, and does not depend on e, l, and q. Likewise, it is
also assumed that the variance on the second level is homogeneous, i.e., the variance
of δiq is equal to σ2i , and the covariance of δiq and δi′q is equal to σ
2
ii′ , and thus not
group specific. But there is no reason why this should be true in all applications. An
alternative is to allow heteroscedasticity, i.e., heterogeneity of variances among groups
on at least one of the levels. Heteroscedasticity, however, requires additional modelling
when estimating the different variances [20, 64, 96], and is not described in detail in
this chapter.
Adding the observations lj simply to the regression model as additional explana-
tory variables, i.e., e = (1, e1, . . . , en, l1, . . . , lm)T , with corresponding regression
parameters, i.e., β = (β0,β1, . . . ,βn,βn+1, . . . ,βn+m)T , we obtain a one-level
regression model with n +m + 1 degrees of freedom, which corresponds to stan-
dard linear regression. The number of degrees of freedom in the multilevel model is
q(n+ 1)(m+ 2). Figure 6.2 compares standard regression and multilevel regression
on a synthetic dataset with observations divided into two groups.
The concept can be extended to more levels, e.g., three levels. If the q subgroups
can be grouped further into s meta-groups, we can define a three-level model, with
l1 = (1, l21, . . . , lj, . . . , l2m1)
T , and l2 = (1, l21, . . . , l2k, . . . , l2m2)
T as the sec-
ond, and third level variables respectively, (the first level is the evidence e), and allow
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multilevel regression group A
multilevel regression group B
Figure 6.2: Multilevel regression, showing that the effect of x on y (the slope) is in fact lower
than computed from normal regression. This effect is due to the fact that multilevel
regression allows different a priori estimates (β0) for each group.
dependency of β on the third level variables as well. The coefficient β is now a three-
dimensional array consisting of components βijk. If the vector γqs, consisting of
elements γiqs, represents the third level noise (with homogeneity of variances), the
model becomes:
P(Oqs | e, l) ∼ N(µqs,σ) (38a)
µqs =
(
δq + ((γqs +βl2)
T l1
)T
e (38b)
where again the expectation E[Oqs | e, l] = µqs.
This last model assumes the random outcome variable O to be normally distributed,
but in case that O is dichotomous this no longer holds. In this case a specific trans-
formation of the outcome variable, e.g., the logistic function, is assumed to be linear
dependent of the explanatory variables. For logistic regression the transformation is
given by:
logit E[O | e] = log
E[O | e]
1− E[O | e]
,
and the logistic multilevel model therefore becomes:
logit E[Oqs | e, l] =
(
δq + ((γqs +βl2)
T l1
)T
e.
The conditional probability in case of logistic regression is defined as:
P(Oqs | e, l) ∼ Bernoulli(p) (39a)
logit p =
(
δq + ((γqs +βl2)
T l1
)T
e (39b)
When actually doing the multilevel regression we might not want (or expect) an effect
of certain higher levels variables on all lower level variables. In that case the corre-
sponding component βijk is fixed to zero, i.e., it is omitted from the model.
Multilevel regression requires less parameters in comparison to standard regression,
where the higher level variables are modelled as explanatory variables [83]. Param-
eters of multilevel regression models can be estimated using an iterative generalised
least square (IGLS) method. IGLS is a least square method that estimates the parame-
ters by alternating the optimising process between the fixed parameters (βij) and the
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stochastic parameters (δiq) until convergence is reached. Goldstein [62] proved that
this method is equivalent to the maximum likelihood estimation in standard regres-
sion, and improved it to restricted iterative generalised least square (RIGLS) which
coincides with restricted maximum likelihood (REML) in Gaussian models [63]. Pa-
rameters for dichotomous outcomes are estimated with marginal and penalised quasi-
likelihood (MQL/PQL) algorithms [18, 65]. Alternatively Markov chain Monte Carlo
(MCMC) methods such as Gibbs sampling can be used [187]. Further information and
comparison of Bayesian and likelihood-based methods for fitting multilevel models
can be found in [21]. Note that a regression method always tries to fit the model on ob-
served variables only, i.e., it does not consider unobserved variables. For more details
about multilevel regression models one is referred to [83].
6.4 D E A L I N G W I T H M U LT I L E V E L DATA B Y B AY E S I A N N E T W O R K S
In multimorbidity it is of interest to study in which way diseases interact. For ex-
ample, diseases D and D ′ might be unconditionally dependent of each other, i.e.,
D 6⊥ P D ′ | ∅, but they could become independent if an environmental factor F is
taken into account, D ⊥ P D ′ | F. This means that the factor F offers a complete
explanation of the interaction between the diseaseD andD ′. Moreover, when diseases
are represented in a Bayesian network, the Markov blanket of a diseaseD corresponds
to all factors, possibly other diseases, that are relevant for the prediction of this disease
D.
In this section, we introduce the multilevel Bayesian network (MBN) formalism as a
new model-based representation of multilevel data. As mentioned in the introduction,
this combines the multilevel methodology, used in multilevel regression, with Bayesian
networks, in such way that we are able to analyse interactions and probabilistic depen-
dencies between multiple diseases, using patient data obtained from multiple sources,
such as family practices.
6.4.1 Basic ideas
The advantage of a Bayesian network over regression models is that all variables are
treated as uncertain, where in regression, including multilevel regression, only the out-
come variable is treated as uncertain. If one is primarily interested in the interaction
between all relevant variables, and not only in prediction of outcome, in the context of
multiple diseases, this is a convenient way to model multiple diseases. Furthermore, as
multilevel regression models can be seen as conditional probability distributions, they
can be used as a factor in a Bayesian network (cf. Equation (1) in Chapter 2). In this
section, we explore this relationship by varying the amount of structure in such models
and compare this to the multilevel regression approach. However, the first challenge
that must be met is the incorporation of multilevel methods in the Bayesian-network
framework.
In multilevel regression, the random outcome variable O depends on the vectors of
explanations of (non-random) variables, i.e., e = (e1, . . . , en) and lj = (l11, . . . , l
j
mj),
with j = 1, . . . ,m, (sub)groups q, and m+ 1 different levels. For a Bayesian network
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Figure 6.3: Bayesian network representation of a multilevel regression model.
approach, we model O as a conditional probability distribution given the set of par-
ents {E1, . . . ,En}∪
⋃m
j=1 L
j, with Lj = {Lj1, . . . ,L
j
mj }, and an indicator variables Ij,
where j = 1, . . . ,m, that selects the group of objects at a certain level j. Figure 6.3
shows the corresponding Bayesian network with three levels, assuming no further de-
pendence between variables. Clearly, this model is still too restrictive for most health-
care applications, as no structure is present between the explanatory variables and we
have only one outcome variable of interest.
The idea of a multilevel Bayesian network is that the indicator variables I split the
domain into different categories with a deterministic effect on the group variables L
that is constant for a given category chosen by I. If not present, I variables can be
constructed, e.g., by the Cartesian product in case of categorical L variables. However,
multilevel analysis, and thus a multilevel Bayesian network, is typically designed for
hierarchically structured data, and then the indicator I variables are part of the database
definition.
Some of the explanatory variables are group-independent, though structure may ex-
ist between these variables. These variables correspond with the set of variables E in
an MBN. Other variables, depend both on grouping and other variables at the same or
higher levels. These variables correspond with the set of variables O in an MBN. The
Bayesian network is constrained in the sense that no edges exist from a lower-level
variable to a higher-level variable. This ensures that we keep the hierarchical structure
present in multilevel regression methods. Because of the deterministic relations we are
able to simplify the structure of the MBN using the following property.
Lemma 1. Let X and Y be two random variables such that Y is deterministically
dependent of X, i.e., there exists some function f such that Y = f(X). Then, for all sets
of random variables Z disjoint of X and Y it holds that Z ⊥ PY | X.
Proof. Take some arbitrary Z. If it is a discrete distribution, then it holds that:
P(Z | X) =
∑
Y
P(Z, Y | X) =
∑
Y
P(Z | X, Y)P(Y | X)
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Figure 6.4: Multilevel Bayesian network with 3 levels and discrete variables.
By the relationship between X and Y, it holds P(Y | X) = 1 if Y = f(X), and 0
otherwise, so it follows that:
P(Z | X) = P(Z | X, f(X)) = P(Z | X, Y)
Similarly, for continuous distributions, we have:
p(Z | X) =
∫
p(Z, Y | X)dY =
∫
p(Z | X, Y)p(Y | X)dY
=
∫
p(Z | X, Y)δ(Y − f(X))dY = p(Z | X, f(X))
= p(Z | X, Y)
where δ is the Dirac delta function.
We can apply this lemma to our initial MBN for two cases. Since P(Lji | Ij) is
deterministic, we obtain O ⊥ PLji | Ij. The implication of this, is that no arcs exist
between the group vertices in L and the outcome and explanatory vertices in O ∪ E.
Since the probability distribution P(Ij+1 | Ij) is deterministic too, we obtain O ⊥
PIj | I1 for all j. The implication of this is that within the indicator vertices I there are
only arcs from Ij+1 to Ij, for all j, and between the indicator vertices I and outcomes
O there are only direct arc from I1 to any Oi. These restrictions greatly simplify the
structure of an MBN. When making predictions based on the parameters of the MBN,
the indicator variables are mostly unknown. However, the structure still allows us to
use the higher level variables to explain the outcome variable.
We now give a precise definition of MBNs. To shorten the definition, members of
the various sets S are denoted by Si, and S \ {Si} with S− Si.
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Definition 7. A Bayesian network B = (G,XV ,P) is a multilevel Bayesian network,
or MBN for short, if its set of vertices V is described by the tuple (m,O,E,L, I), with
pairwise disjoint sets O,E,L, I ⊆ VG, such that:
• m ∈ N denotes the number of levels of the MBN, where level 0 is called the
base level;
• O, the set of outcome variables, is at base level such that if (V → Oi) ∈ AG,
then V ∈ E∪ (O−Oi)∪ I;
• E, the set of explanatory variables, is at base level, such that if (V → Ei) ∈ AG,
then V ∈ (E− Ei)∪O;
• L = {L1, . . . ,Lm}, where each Lj is a set of group variables at level j > 1. For
group variable Lji it holds that
1. (V → Lji) ∈ AG implies that V = Ij;
2. P(Lji | Ij) is deterministic.
• I = {I1, . . . , Im} are indicator variables, such that Ij is the only parent of Ij−1
in G, for all 1 6 j 6 m, and P(Ij−1 | Ij) is deterministic;
• XV = {Xv | v ∈ (I∪ E∪O∪ L)}.
Figure 6.4 offers a graphical illustration of the definition. Note that within one MBN
multiple diseases can be modelled as outcome variable. By lemma 1, the outcome
variables O are independent of the level variables L given the value of the I variables.
However, this does not imply that these variables are meaningless. Once the parameters
of the MBN are learned, the level variables can be used to estimate the variance in the
probability distribution of the outcome variables, without knowing the value of the
indicator variables.
6.4.2 Probability distributions for multilevel Bayesian networks
Without taking into account the level variables, the probability of the outcome variables
O conditioned on the explanatory variables E can be obtained by
P(O = o | E = e) = fO|E(o | e;β)
= fO,E(o, e;β)/
∑
o
fO,E(o, e;β),
if O is discrete, and
P(O 6 o | E = e) =
∫o
−∞ fO|E(x | e;β)dx
=
∫o
−∞ fO,E(x, e;β)dx/
∫∞
−∞ fO,E(x, e;β)dx
if O is continuous. The parameter β represents the parameters typically used for a
specific distribution, e.g., β = (µ,σ) in case fO,E(o, e;β) is a Gaussian distribution
with mean µ and variance σ.
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In a multilevel Bayesian network the grouping variable splits the conditional prob-
ability distributions between an outcome variables and its explanatory variables into
multiple (countable) distributions keeping them closely related, i.e., only the distribu-
tion type dependent parameters differ between groups. In case O is discrete we obtain
P(O = o | E = e, I = i) = fO|E(o | e;βi), and likewise, ifO is continuous we obtain
P(O 6 o | E = e, I = i) =
∫o
−∞ fO|E(x | e;βi)dx.
For example, in caseO and E = e are both discrete andO is binary with a Bernoulli
distribution with parameter β = pe,i, we obtain:
P(O = o | E = e, I = i) = fO|E,I(o | e, i;β)
= Bernoulli(pe,i)
=
pe,i if O = o
1− pe,i otherwise
In case O and E are both continuous and O follows a Gaussian distribution, we obtain
the probability density function:
fO|E,I(o | e, i;β) = N(µe,i,σ)
Just as in multilevel linear regression, a linear dependency between E and O can be
obtained if µe,i = βie, also for E being a discrete variable.
In case O is discrete and E is continuous a link function is used in multilevel re-
gression, to keep the linearity in the model, of which the logistic function is the most
popular one. The probability mass function for such a discrete variable with a continu-
ous parent is:
fO|E,I(o | e, i) =
exp
(
βio0 +β
i
o1e
)∑
o
exp
(
βio0 +β
i
o1e
)
For binary outcome variables this reduces to:
fO|E,I(o | e, i) =
[
1+ exp
(
βi0 +β
i
1e
)]−1
6.5 E X P E R I M E N TA L M E T H O D O L O G Y
In the previous section, the basic ingredients of multilevel Bayesian networks were
outlined. In this section, we take the step in making the technique practically useful. At
the end of this section, we demonstrate that the methodology works by using synthetic
data. In the next section, the same is done, but then for a dataset obtained from a public
health registry containing patient data from general practices.
6.5.1 Parameter learning
Because we have incorporated the multilevel regression model as factors in the model,
we can make use of multilevel regression to estimate the outcome variables. This has
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the advantage that we exploit the correlation between different groups (if it exists) and
therefore requires less data per group than a standard Bayesian network learning algo-
rithm needs for parameter learning per group. For multilevel-level logistic regression
models, it is recommended to use a minimum group size of 50 with at least 50 groups to
produce valid estimates [134]. An exact inference algorithm for parameter estimation
in networks with discrete children of continuous parents is proposed in [109]. Com-
pared to multilevel regression models, it is also possible to use a Bayesian approach
for learning the parameters [195] and, therefore, include even more domain knowledge
to the model.
6.5.2 Model validation
Possible criteria to validate the model parameters are the Akaike information criterion
(AIC) [2], the Bayesian information criterion (BIC) [183], and the deviance informa-
tion criterion (DIC) [196]. The AIC and BIC are widely accepted decision criteria, but
computationally expensive when dealing with large amounts of data and MCMC meth-
ods. This problem is overcome using the DIC, which calculates deviance residuals, that
sum up to the deviance statistic, along with the MCMC process. Unfortunately, in dis-
ease mapping, DIC is in favour of overparameterised models, especially when using
large datasets [160].
Alternatively, an approximation method proposed by [128] can be used, which works
very well for large data sets in an MCMC setting. It uses replication of the stochastic
parameters and the outcome variables for a specified part of the data along with the
MCMC simulation based on the remaining part of the data. The replicate outcome vari-
ables can then be compared to the real outcomes, allowing us to assess the predictability
of the model.
Although computationally expensive as well, standard cross validation (e.g., k-fold
cross validation) is a robust method to validate regression and Bayesian models [158],
and receiver operating characteristic (ROC) analysis can be used to validate accuracy
and precision of the model parameters. Recently, a new measure was introduced, the
net reclassification improvement (NRI), offering additional incremental information
compared to the area under the curve (AUC) within an ROC analysis [155], which
provides more insight into risk prediction.
6.5.3 Structure learning
In order to build the structure between variables, we can make use of two approaches.
We can either model the structure manually based on existing medical knowledge or
learn the structure from data. Structure learning of Bayesian networks offers a suit-
able method to learn these dependencies. The constraints imposed by the multilevel
Bayesian network can be captured by blacklisting and whitelisting edges, which can
be incorporated into a wide range of structure learning algorithms (see, e.g., [185]).
For example, the necessary edges between I1 and all variablesOi ∈ O are whitelisted,
whereas edges from a lower level to a higher level are all blacklisted.
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A systematic approach to identify statistically significant edges in a network, has
been developed by Friedman et al. using bootstrap resampling and model averaging
[56]. The empirical probability of an edge, defined as the fraction of occurrences in
the networks learned from bootstrapped samples, are known as edge intensities (or
strengths), and can be interpreted as the degree of confidence that the edge is present
in the true network structure describing the true dependence structure of the original
data. Scutari et al. propose a statistically motivated estimator for the confidence thresh-
old minimizing a specific norm between the cumulative distribution function of the
observed confidence levels and the cumulative distribution function of the confidence
levels of the unknown true network [186]. Classical norms are the rectilinear distance,
denoted as the L1 norm, and the euclidean distance, denoted as the L2 norm [95].
6.5.4 Artificial multimorbidity example with synthetic data
Suppose we have the variables D1, D2, and D3 that model whether the diseases D1,
D2, and D3 are present, a genetic variable G, and two demographic vertices L1 and
L2 that model certain environmental conditions. Furthermore, let the demographics
be variables obtained from higher levels in a hierarchically structured dataset, i.e., L1
and L2 are level-2 and level-3 variables respectively. For example, the variables D1,
D2, andD3 could represent diseases like diabetes, retinopathy, and hypertension. The
variable G could represent gender, or a specific gene, and the grouping variable I1
could represent a division in practices with type as L1, and I2 a division in area with
urbanity as L2.
There are fifty practices (I1 ∈ {1, . . . , 50}) and five areas (I2 ∈ {1, 2, 3, 4, 5}). The
variable type (L1) has 5 possible values and the variable urbanity (L2) is binary. The
deterministic relations between them are:
I2 =

1 if I1 ∈ {1, . . . , 10}
2 if I1 ∈ {11, . . . , 20}
3 if I1 ∈ {21, . . . , 30}
4 if I1 ∈ {31, . . . , 40}
5 if I1 ∈ {41, . . . , 50}
and
U1 =

1 if I1 mod 10 ∈ {0, 1}
2 if I1 mod 10 ∈ {2, 3}
3 if I1 mod 10 ∈ {4, 5}
4 if I1 mod 10 ∈ {6, 7}
5 if I1 mod 10 ∈ {8, 9}
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and
U2 =
0 if I2 ∈ {1, 2}
1 if I2 ∈ {3, 4, 5}
We sampled 10,000 patients uniformly over the fifty practices and determined its re-
spective values for the other higher level variables. The binary variableG is binomially
sampled with a probability of 0.50. The diseases D1, D2 and D3 are sampled as fol-
lows.
D1 =Binomial(0.50+ 0.01G+N(µq,σq))
D2 =Binomial(0.20+N(µs,σs))
D3 =Binomial(0.20+ 0.1D1+ 0.2D2+ 0.2D1D2+N(µqs,σqs))
With q = 1, . . . , 50, and s = 1, . . . , 5, corresponding to the number of practices and
areas. The distributions N(µq,σq) and N(µqs,σqs) are randomly sampled from a
N(0, 0.1) distribution, µs is 0.25, 0.30, 0.35, 0.40, and 0.45, for s = 1, . . . , 5 respec-
tively, and σs = 0.01.
Applying multilevel regression, if we, for example, only allow an influence of the
level-2 and level-3 variables on the intercept and the regression coefficient of the ex-
planatory variable D1, the multilevel regression model becomes:
P(D3qs | d1,d2,g, l1, l2) ∼ Bernoulli(p) (40.1a)
logit p = β0qs +β1qsd1 +β2d2 +β3g (40.1b)
β0qs = β00s +β01sl1 + δ0q (40.2a)
β1qs = β10s +β11sl1 + δ1q (40.2b)
β00s = β000 +β001l2 + γ00s (40.3a)
β01s = β010 +β011l2 + γ01s (40.3b)
β10s = β100 +β101l2 + γ10s (40.3c)
β11s = β110 +β111l2 + γ11s (40.3d)
With δiq ∼ N(0,σiq) and γiqs ∼ N(0,σiqs). Substituting the equations of 40.3
into 40.2, and the equations of 40.2 into 40.1, equation 40.1 becomes:
logit p = (β000 +β001l2 + γ00s + (β011l2 + γ01s +β010)l1 + δ0q)
+ (β100 +β101l2 + γ10s + (β111l2 + γ11s +β110)l1 + δ1q)d1
+ β2d2 +β3g
Since L1 and L2 are discrete variables, and have the same value within a group, we can
rewrite this into:
logit p = (β ′0 +β
′
0s + γ
′
0s +β
′
0qs + γ
′
0qs +β
′
0q + δ0q)
+ (β ′1 +β
′
1s + γ
′
1s +β
′
1qs + γ
′
1qs +β
′
1q + δ1q)d1
+ β2d2 +β3g
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G L1 L2
D1 D2D3
Figure 6.5: Bayesian network representing probabilistic dependencies between certain diseases
(D1,D2,D3), a genetic variableG, and some demographics (L1,L2).
I1
I2
G D1 D3 D2
L2
L1
Figure 6.6: MBN representing multilevel regression of the example in Figure 6.5.
Now, assume that using structure learning (without using the indicator variables) it
is observed that pi(G) = pi(L1) = pi(L2) = ∅, pi(D1) = {G,L1}, pi(D2) = {L2},
and pi(D3) = {D1,D2,L1,L2}. Figure 6.5 then shows the corresponding Bayesian
network and the joint distribution P(V) is given by
P(D3 | D1,D2,L1,L2)P(D1 | L1,G)P(D2 | L2)P(L1)P(L2)P(G)
To predict whether a diseaseD3 is present given that L1, L2 andG are known, we have
by the definition of a Bayesian network and standard probability theory:
P(D3 | L1,L2,G) =
∑
D1,D2
P(D3 | D1,D2,L1,L2)P(D1 | L1,G)P(D2 | L2)
Since the Markov blanket ofD3 is {D1,D2,L1,L2}, any information about the genetic
variation of a person is irrelevant, i.e., since D3 ⊥ PG | D1 we obtain: P(D3 |
D1,D2,L1,L2,G) = P(D3 | D1,D2,L1,L2).
Applying the MBN techniques, Figure 6.6 and 6.7 show the corresponding MBN
representations. One can see that in the multilevel regression network (Figure 6.6) only
D3 is modelled as an outcome variable of interest, as where in the structured model
(Figure 6.7) D1 and D2 are modelled as outcome variables as well (still being an
explanatory variables of D3). As a consequence of Definition 7, the disease variables
in Figure 6.7 do not have edges from I2 and Li directed towards themselves.
The comparison between the multilevel regression technique and the structured mul-
tilevel Bayesian network is outlined in table 6.1, showing the probability of diseaseD3
in the presence of L1, D1 and D2. Parameters of the multilevel regression model are
obtained with the MLWin software, in which the algorithms described at the end of sec-
tion 6.3 are implemented [66]. Parameters of the MBN are learned using the bnlearn
package [185] in the statistical software R.
Using AIC and BIC, the most accurate multilevel logistic regression model allows
random intercepts and random slopes on D1 for each entry of L1. Although the prob-
abilities derived from the MBN are closer to the true probabilities, the area under the
93
M U LT I L E V E L B AY E S I A N N E T W O R K S
Level 2
Level 1
Level 0
I1
I2
G D1 D3 D2
L2
L1
Figure 6.7: Structured MBN representation of the example in Figure 6.5.
L1 = 1 L1 = 2 L1 = 3 L1 = 4 L1 = 5
D1 = 0,D2 = 0 0.150 0.175 0.200 0.225 0.250
D1 = 0,D2 = 1 0.250 0.275 0.300 0.325 0.350
D1 = 1,D2 = 0 0.350 0.375 0.400 0.425 0.450
D1 = 1,D2 = 1 0.650 0.675 0.700 0.725 0.750
(a) True probability distributions in the test set
L1 = 1 L1 = 2 L1 = 3 L1 = 4 L1 = 5
D1 = 0,D2 = 0 0.135 0.137 0.171 0.187 0.198
D1 = 0,D2 = 1 0.279 0.281 0.319 0.335 0.346
D1 = 1,D2 = 0 0.410 0.414 0.479 0.505 0.523
D1 = 1,D2 = 1 0.632 0.635 0.676 0.692 0.702
(b) Multilevel logistic regression (Equation 40)
L1 = 1 L1 = 2 L1 = 3 L1 = 4 L1 = 5
D1 = 0,D2 = 0 0.164 0.148 0.189 0.228 0.218
D1 = 0,D2 = 1 0.271 0.242 0.286 0.304 0.331
D1 = 1,D2 = 0 0.330 0.398 0.442 0.453 0.466
D1 = 1,D2 = 1 0.653 0.680 0.747 0.735 0.749
(c) Structured multilevel Bayesian network (Figure 6.7)
Table 6.1: Probability estimations ofD3 conditioned onD1,D2 and L1.
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curves (AUCs) within an ROC analysis are close together, i.e., 0.725 and 0.712 for the
MBN and multilevel regression respectively. In the multilevel regression all variables
are used for prediction, whereas for the MBN only the variables of the Markov blanket
are used for prediction.
The net reclassification improvement is in favour of the MBN, i.e., the NRI is 0.2144
(p < 0.001). Thus, on average the MBN is significantly better then the multilevel
regression approach in this synthetic example. This due to the fact that an MBN is
able to give an exact solution with respect to a dependency structure between variables
and its observations. Multilevel regression does not have these dependency constraints,
which possibly favours overfitting the model.
6.6 M O D E L L I N G I N T E R - P R AC T I C E VA R I AT I O N I N M U LT I M O R B I D I T Y
Normally, in scientific research, one would investigate diseases separately, resulting in
different predictive values of variables shared by both diseases. As an exaple, multilevel
regression analysis was recently used by Nielen et al. to investigate the influence of
particular family practice variables on hypertension and diabetes mellitus separately,
revealing an inter-practice variance in predictability [140]. However, since interactions
could have an additive effect on prevalence, this yields no insight into the predictive
value in case both diseases are present. In fact, we need an extra regression model on
the combined diagnosis of hypertension and diabetes together to be able to draw such
conclusions.
In this chapter, we will use the research of Nielen et al. as starting point. Firstly,
we compare the parameter estimations of an unstructured MBN with multilevel regres-
sion. Secondly, we compare the predictive power of a structured MBN with multilevel
regression.
6.6.1 Description of the models
To evaluate if the parameter estimations of an MBN are comparable with a multilevel
regression we analysed models for both diabetes mellitus and heart failure. Nielen et
al. analysed hypertension instead of heart failure. However, besides the validation of
parameter estimations, we also want to investigate the predictive power for diseases
that have a different onset during lifetime. Heart failure is known to be associated with
diabetes mellitus and hypertension [78], and its risk management involves almost the
same variables [223]. Since the onset of hypertension and diabetes mellitus is typically
earlier in the patient’s life than the onset of heart failure it is of interest if the finally
structured MBN follows this order.
We used five models for the analysis. The first two models are the multilevel regres-
sion models for predicting either diabetes mellitus (model MLR-DM) or heart failure
(model MLR-HF) using data which is grouped by practice, where the urbanity of the
practice is modelled as as higher level variable. The next two models (MBN-DM and
MBN-HF) are the corresponding unstructured MBNs for the first two models, assum-
ing that no further dependencies between variables exist (cf. Figure 6.3), and that the
urbanity is independent of the disease, given the practice (cf. Property 1). Finally, we
95
M U LT I L E V E L B AY E S I A N N E T W O R K S
consider a structured model (MBN-STR) which contains both diseases as well as struc-
ture between the outcome and explanatory variables, which we call intra-level struc-
ture.
All five models used practice and urbanity as higher level variables. Since the prac-
tices use different types of information systems, one could expect that this might also
be of influence on the predictions. To model this, a second level grouping variable (the
used information system) can be incorporated on top of the first level grouping vari-
able (practice). However, it appeared that there was no significant benefit from doing
so. Therefore, this extra variable was omitted from further analysis.
6.6.2 Research problem and data
The patient data was routinely collected by the Netherlands information network of
general practice (LINH); see Section 3.4 for details. In the analysis here, patients under
25 years were excluded, because of their low probability of multimorbidity. Practices
which recorded during less than six month were also excluded from statistical anal-
ysis. Eventually, we used data of 218,333 patients from 82 Dutch general practices,
meaning an average number of patients around 2650 per practice. Morbidity data were
derived from diagnoses, using the international classification of primary care (ICPC)
and anatomical therapeutic chemical (ATC) codes.
6.6.3 Unstructured MBNs compared to multilevel regression
For both the multilevel regression models MLR-DM and MLR-HF we estimated the pa-
rameters using MLWin [66]. For the models MBN-DM and MBN-HF we used MCMC
simulation, available in the WinBUGS software [195]. All non-group variables were
discretised and modelled using a Bernoulli distribution. Parameter estimates using a
10-fold cross validation are presented in Table 6.2. As expected, the results of the un-
structured MBN models are similar to the results obtained by multilevel regression,
showing that multilevel Bayesian networks are a valid alternative method for multi-
level analysis.
6.6.4 Composition of the structured MBN
The structure of the MBN-STR model was learned using the bnlearn package [185] that
is part of the statistical software R. It provides various methods for structure learning.
We have restricted the search of Bayesian networks to those that satisfy the multilevel
structure by using white- and blacklists. See Figure 6.10 for the resulting Bayesian
network structure. Note that indeed there is only a dependency between consecutive
levels, and that this is solely through the grouping variables. Furthermore, it appeared
that only a subset of the disease variables depends on the practice variable; diabetes
mellitus is amongst them, whereas heart failure is not. So technically, diabetes mellitus
is an outcome variable and heart failure is an explanatory variable within the definition
of an MBN. However, since all variable can be treated as uncertain we can still use the
model to make predictions for heart failure.
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Diabetes mellitus Heart failure
Model MLR-DM MBN-DM MLR-HF MBN-HF
Age 1.029 1.028 1.106 1.106
Gender (ref = male) 0.914 0.915 0.823 0.815
Overweight/obesity 1.725 1.671 1.689 1.600
Diabetes mellitus - - 1.256 1.260
Lipid disorder 6.437 6.392 1.172 1.183
Hypertension 5.675 5.800 2.071 2.067
Peripheral artery disease 0.954 0.949 1.619 1.530
Heart failure 1.132 1.194 - -
Retinopathy 9.253 9.669 1.310 1.104
Angina pectoris 0.679 0.665 2.214 2.184
Stroke / CVA 0.770 0.766 1.388 1.397
Renal disease 1.176 1.200 1.878 1.881
Cardiovascular symptoms 0.848 0.850 2.596 2.636
Urbanity (ref=urban)
urban 1.000 1.000 1.000 1.000
strongly urban 1.261 1.275 1.145 1.158
modestly urban 1.477 1.490 1.181 1.192
little urban 1.436 1.408 1.422 1.456
not urban 1.474 1.259 1.335 1.318
Table 6.2: Parameter estimations of explanatory (parent) variables, represented as odds ratios,
using cross validation in a multilevel analysis for diabetes mellitus and heart failure
(MLR=multilevel regression, MBN=multilevel Bayesian network, DM=diabetes melli-
tus, HF=heart failure).
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Some of the directions of edges is opposite to what the domain experts would ex-
pect, e.g., angina pectoris is pointing towards peripheral artery disease (PAD), but in
reality this is seen as a comorbidity due to atherosclerosis, which itself is not present
in the model. Therefore, we also incorporated some domain knowledge [223, 78] into
the model and allowed a geriatric specialist and two physicians to validate the model.
Removed edges are: angina pectoris→ PAD, angina pectoris→ renal disease, heart
failure → PAD, and practice → cardiovascular symptoms. The edge heart failure →
renal disease is reversed. The final model is showed in Figure 6.8, along with the prior
probability distributions for patients aged over 65 years. However, these results are of
a preliminary nature, and we did not study the validity of the structured model further.
Using bootstrapped samples to validate the strengths of the edges, most edges shown
in the network of Figure 6.8 appear in more than 95% of the networks learned from the
samples. The only edges with a percentage lower than 95% is renal disease → heart
failure (0.73%). Most of the edges not present in the originally learned structure have
an appearance close to 0%.
In this model the prevalence rate of diagnosed diabetes mellitus in practices varies
between 0.008 and 0.135, with mean 0.077 and standard deviation 0.025. The preva-
lence of heart failure varies between 0.001 and 0.059, with mean 0.019 and standard
deviation 0.011. Figure 6.9 shows the same model as in Figure 6.8, but now conditioned
on hypertension and diabetes, i.e., both diseases are present. In this case probabilities
are more or less doubled (or tripled in case of lipid disorder), indicating the population
of elderly patients with both hypertension and diabetes have twice the chance of getting
an additional cardiovascular disease when compared to the general elderly population.
For this population, i.e., diabetics with hypertension, the prevalence of heart failure
varies between 0.001 and 0.230, with mean 0.086 and standard deviation 0.049.
Finally, the conditional probability distribution of a disease variable can be used to
uncover interactions between diseases. If we calculate the probability of angina pec-
toris (ap) in the presence of both hypertension (ht) and lipid disorders (ld), we obtain:
P(ap | ht, ld) ≈ 16%. It turns out that this is much higher than one can expect from
the other probabilities: P(ap | ht,dl) ≈ 7%, P(ap | ht, ld) ≈ 5% and P(ap |
ht, ld) ≈ 1%. We can do this exercise for an arbitrary disease and (a subset of) its par-
ents in the MBN structure. For example, when looking at heart failure (hf), there is an
interaction between hypertension and diabetes mellitus (dm): P(hf | ht,dm) ≈ 9%,
P(hf | ht,dm) ≈ 5%, P(hf | ht,dm) < 1% and P(hf | ht,dm) < 1%; which
suggest that the effect of diabetes on heart failure is only of clinical significance in the
presence of hypertension.
6.6.5 Comparison of the structured MBN with multilevel regression
Besides the estimation of odds, a more practical question is how well the model can
be used for prediction. For this, we compared the predictive performance of the MBN-
STR model to multilevel regression analysis for single diseases, i.e., the models MLR-
DM and MLR-HF.
For the multilevel regression method, we used all the predictors, while for the MBN-
STR model, we can restrict ourselves to the Markov blankets (cf. Section 3.1) of the
diseases and higher level variables where necessary. For diabetes mellitus, the MB
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Level 1
Level 0
practice
totally urban 0.20
strongly urban 0.23
modestly urban 0.14
little urban 0.22
not urban 0.21
urbanity
age
> 65yr
gender yes 0.03
no 0.97
overweight/obesity
yes 0.25
no 0.75
lipid disorder
yes 0.50
no 0.50
hypertension
yes 0.20
no 0.80
diabetes mellitus
yes 0.04
no 0.96
angina pectoris.
yes 0.06
no 0.94
renal disease
yes 0.10
no 0.90
peripheral artery d.
yes 0.08
no 0.92
heart failure
yes 0.05
no 0.95
stroke
yes 0.28
no 0.72
cardiov. symptoms
yes 0.01
no 0.99
retinopathy
Figure 6.8: Structured MBN with prior probability distributions for patients aged > 65 years,
using domain knowledge (expert opinions / evidence from other research) of cardio-
vascular diseases and diabetes mellitus in family practices. The dotted arcs are arcs
from ’age’ and ’gender’ in order to make the model more readable.
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Level 1
Level 0
practice
totally urban 0.18
strongly urban 0.24
modestly urban 0.15
little urban 0.22
not urban 0.21
urbanity
age
> 65yr
gender yes 0.05
no 0.95
overweight/obesity
yes 0.75
no 0.25
lipid disorder
yes 1.00
yes 0.00
hypertension
yes 1.00
yes 0.00
diabetes mellitus
yes 0.09
no 0.91
angina pectoris
yes 0.11
no 0.89
renal disease
yes 0.15
no 0.85
peripheral artery d.
yes 0.14
no 0.86
heart failure
yes 0.08
no 0.92
stroke
yes 0.36
no 0.64
cardiov. symptoms
yes 0.02
no 0.98
retinopathy
Figure 6.9: Structured MBN (cf. Figure 6.8) with posterior probability distributions for patients
with both hypertension and diabetes (aged> 65 years).
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Level 1
Level 0
practice urbanity
overweight
obesity
age
gender
lipid
disorder
hypertension
diabetes
mellitus
peripheral
artery
disease
angina
pectoris
heart failure
retinopathy
stroke
renal
disorder
cardiovascular
symptoms
Figure 6.10: Structure learning without any domain knowledge of cardiovascular diseases and
diabetes mellitus in family practices. The dotted arcs are arcs from ’age’ in order to
make the model more readable.
consists of practice, age, gender, obesity, lipid disorder, hypertension, heart failure,
retinopathy, and renal disorder. However, making predictions in a multilevel model
we treat the indicators, i.e., the practice, as uncertain, and instead we have to use the
urbanity for prediction as well. The MB of heart failure on the other hand consists of
age, gender, lipid disorder, diabetes mellitus, hypertension, peripheral artery disease,
angina pectoris, stroke, renal disorder, and cardiovascular symptoms. For heart failure
no higher level variables are needed for prediction when the diseases that vary along
such variables are known, e.g., obesity, hypertension, and diabetes.
To measure the accuracy of the predictions we performed an ROC analysis (see
Figure 6.11). When comparing the AUC between multilevel regression and the MBN-
STR model, the ones for the MBN-STR model are slightly better with a difference
of approximately 1%. For the MBN-STR they are approximately 0.90 and 0.84 for
diabetes mellitus and heart failure respectively. For the MLR-DM it is 0.89 and for
the MLR-HF it is 0.83. When performing a net reclassification improvement analysis
for the MBN-STR model compared to the multilevel regression models MLR-DM and
MLR-HF, the NRI is significantly positive in both cases, i.e., the NRI is 0.723 (p <
0.001) for diabetes and 0.075 (p < 0.01) for heart failure.
6.7 D I S C U S S I O N
In this chapter, we have presented a new type of multilevel modelling, and applied this
to healthcare data of general practices. As we have discussed, such data often contain
a hierarchical structure, which can be modelled by using different levels of data. Since
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0 0.2 0.4 0.6 0.8 1
0
0.2
0.4
0.6
0.8
1
MBN diabetes mellitus
MLR diabetes mellitus
MBN heart failure
MLR heart failure
Figure 6.11: ROC analysis of a structured multilevel Bayesian network (MBN) and multilevel
regression (MLR) for diabetes mellitus and heart failure.
traditional multilevel regression equations only include one outcome variable each
time, which is unpractical in the context of multiple diseases, we combined Bayesian
networks with multilevel analysis yielding multilevel Bayesian networks. Multilevel
Bayesian networks also allow representing uncertainty of all disease variables con-
cerned into one model.
Furthermore, we can add intra-level structures between variables giving extra insight
into probabilistic dependencies and interactions. Moreover, domain knowledge can be
incorporated, e.g., edges between pathophysiology and its corresponding lab results are
always pointing to the latter, making the model more easy to interpret. Such domain
knowledge can be used to restrict the search space when learning the structure of a
Bayesian network from data.
We have shown that multilevel Bayesian networks have at least the expressive power
of traditional multilevel regression methods. Using synthetic data and a real-world ap-
plication of MBNs with clinical patient data from family practices, we demonstrated
the empirical equivalence of a traditional multilevel regression model to an unstruc-
tured MBN. Furthermore, structured MBNs provide insight into the relationship be-
tween multiple diseases and allow for studying multiple diseases at the same time,
avoiding the redundancy of regression methods (when used to analyse multiple disease
for the same variable set).
Although it was not our main aim to develop a better classifier, the predictive power
of a structured MBN is just as good as multilevel regression equations, despite a re-
duced number of predictors, as defined by the Markov blanket. Both in the synthetic
example and the real-life applications of diabetes mellitus and heart failure, there is a
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small improvement in the AUC and a significantly positive NRI. Bootstrapped samples
showed that the strength of the edges between disease variables in the network repre-
sentation of diabetes mellitus and heart failure is mostly close to 100%, meaning we
can be confident about the found structure.
Using the learned MBN we are able to condition on certain disease variables, e.g.,
when conditioning on hypertension and diabetes, the MBN reveals that chances on
obtaining another cardiovascular disease, such as heart failure, is more or less doubled.
This ‘personalisation’ of the network could be seen as a step forward to personalised
clinical guidelines, as mentioned in the introduction, making the MBN a promising tool
in the new domain of multimorbidity. Further research will focus on the application of
the MBN framework to relevant clinical questions within public health and the related
multimorbidity issues.
Finally, since from the data available it will not be possible to construct a full causal
model, it is important to make use of expert background knowledge. Besides placing
restrictions on existing variables, one might also introduce variables that are missing
from the data, this way adding crucial explanatory power. This is possible in BNs,
and thus MBNs can also use the same expertise to quantify the probabilistic relation-
ships involving these missing variables even though no data exists for them. As an
example, atherosclerosis may be added to the model, and, using the method proposed
in [209], this variable may capture important combinations of observations, e.g., pe-
ripheral artery disease along with a cardiac disease such as angina pectoris. This may
improve the predictive performance of these models further.
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M O D E L L O N G I T U D I NA L C H A N G E I N M U LT I M O R B I D I T Y
A B S T R AC T
Whereas the course of a single disease can be studied well using traditional epidemio-
logical methods, these methods cannot capture the complex joint evolutionary course of
multiple disorders. In this study, multilevel temporal Bayesian networks were adopted
to study the course of multimorbidity in the expectation that this would yield new
clinical insight. Clinical data of patients were extracted from ninety general practice
registries in the Netherlands. One and half million patient years were used for analy-
sis. The simultaneous progression of six chronic cardiovascular conditions was investi-
gated, correcting for both patient and practice-related variables. Cumulative incidence
rates of one or more new morbidities rapidly increase with the number of morbidi-
ties present at baseline, ranging up to 47% and 76% for three and five-year follow-up
respectively. Hypertension and lipid disorders, as health risk factors, increase the cu-
mulative incidence rates for both individual and multiple disorders. Moreover, in their
presence, the observed cumulative incidence rates of combinations of cardiovascular
disorders, i.e., multimorbidity, differ significantly from the expected rates. There are
clear synergies between health risks and chronic diseases when multimorbidity within
a patient progresses over time. The method used here supports a more comprehensive
analysis of such synergies compared to what can be obtained by traditional statistics.
7.1 I N T RO D U C T I O N
The epidemiology of multiple chronic diseases present at the same time is referred to as
comorbidity or multimorbidity. Whereas comorbidity is usually defined in relationship
to a specific index condition, as in the seminal definition of Feinstein [50], the term
‘multimorbidity’ has been introduced to refer to any co-occurrence of two or more
medical, especially chronic, conditions within a person at the same time [206, 208].
In Chapter 3, we showed how multimorbidity can be simply measured by comput-
ing various basic statistics: the number of chronic disorders per patient, corrected for
age, gender, and socio-economical demographics [207, 224, 53, 201], odds that de-
scribe the ratio between observed and expected prevalence rates for specific disease
combinations [177, 68, 19, 215], and disease clusters using principal component anal-
ysis [81, 179, 124, 92].
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Key findings:
• The urbanisation level of a general practice is associated with the cumulative
incidence of chronic cardiovascular conditions, in particular those with a high
prevalence, i.e., obesity, hypertension, dyslipidemia, diabetes mellitus, and is-
chaemic heart disease.
• The overall multimorbidity rate of chronic cardiovascular (related) disorders
rapidly increases when multimorbidity is already present at baseline.
• When multimorbidity progresses over time, certain disease combinations de-
velop more quickly than what can be expected from individual disease pro-
gression. This synergistic effect happens particularly in the presence of hyper-
tension and dyslipidemia.
What this adds to what is known:
• Multimobidity is not only about pairs of diseases, but also about how multiple
diseases in patients interact and how this interaction changes over time. For the
first time this proper perspective on multimorbidity is described and analysed
using the new technique of multi-level temporal Bayesian networks. This new
method not only supports finding multiple associations and how these change
over time, but also which of these represent a direct association or a confounder,
and how factors indirectly influence each other.
Implications:
• Whereas standard multilevel regression methods are very useful to explain a
single disease with respect to a set of patient and practice related observable
variables, multilevel Bayesian networks allow exploring the joint distribution
of multiple diseases and their interactions, which is highly relevant in multi-
morbidity research.
• Clinical guidelines for patients with multimorbidity can be improved when the
advice incorporates all the patient’s specific characteristics. Since the network
in the methodology used here can be personalised for a specific patient, it pro-
vides a valuable tool for the development of such tailored clinical guidelines.
Although systematic reviews [26, 39, 125] have given insight into the rates of cross-
sectional co-occurrence, the progression over time of interactions between chronic car-
diovascular diseases and related disorders is sparsely documented [61]. More insight
into such interactions would help in personalising the therapeutic management of pa-
tients with multimorbidity. As clinical knowledge is mostly organised around single
diseases, that knowledge may not be fully applicable to patients with multimorbid-
ity [17, 11]. The care of patients with multimorbidity can be improved by any method
that tailors the advice to the patient’s specific characteristics [69].
Recent explorations of patient data from primary care registries to quantify associa-
tions between chronic disorders, have shown these to be valuable for obtaining a broad
picture of multimorbidity [11, 77, 225]. In this chapter we explore such registries to as-
sess three aspects of the joint progression of chronic cardiovascular multimorbidity: 1)
its dependency on the practice’s urbanity, 2) the synergistic effects between disorders
when they evolve over time, and 3) the progression of the overall multimorbidity rate.
Patient data in primary care registries are often clustered by practices, introducing
particular biases in the patient’s diagnosis due to practice related effects. For example,
the urbanity of the practice’s area or the physician’s experience. Multilevel regression
analysis is the standard method of choice in these situations [83]. However, it does
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not allow analysing multiple disease outcomes simultaneously. Therefore, we adopted
the method of multilevel Bayesian networks (MBNs) that does offer such support; see
Chapter 6 for details. When used for the analysis of temporal data, the advantage of
an MBN is that the disorders and their interaction are all treated as uncertain. The
representation goes beyond showing how pairs of disorders are associated to each other.
Furthermore, we can extend an MBN to analyse multiple outcomes at multiple time-
points. The latter gives rise to multilevel temporal Bayesian networks, or MTBN for
short.
In summary, we developed a multimorbidity model that yields a much better insight
into interactions, progression over time, and the accumulation of chronic disorders
than existing statistical models are able to provide. Moreover, we show that posterior
probabilities computed from the model at follow-ups can be tailored to any set of con-
ditions present at baseline, which can provide valuable input for personalised clinical
decision-making.
7.2 M E T H O D S
7.2.1 Data collection
The data used for analysis were obtained from the Netherlands Information Network
of General Practice (LINH); see Chapter 3 and Appendix A for further detail on the
data and ICPC codes of the disorders used in the analysis. Here, longitudinal data of
approximately one and half million patient years, covering the decade 2002-2011, from
patients aged over 35 years, were used in our analysis. Patient data is available for the
whole time frame, unless patient moved out of the practice or the practice itself opted
out. Lab results and medication were not always consistent with the diagnoses present
in the LINH database. They were corrected as described in Chapter 3.
We used the definition of a ‘chronic disorder’ given by O’Halloran [144], which in
turn was based on the international classification of primary care (ICPC) codes. Princi-
pally, our focus is on chronic cardiovascular diseases and related disorders, and in our
model we included the following chronic disorders: obesity, hypertension, lipid disor-
der, diabetes mellitus, heart failure, stroke, ischaemic heart disease, retinopathy, and
nephropathy. The first three disorders are seen as health risks. Previous research has
indicated that also some non-cardiovascular comorbidity is associated with cardiovas-
cular disorders [11, 211]. Therefore, the diagnoses of other chronic non-cardiovascular
disorders were modelled as well, but only as a single variable.
7.2.2 Statistical analyses
As the patient data in the LINH dataset were obtained from several general practices,
differences among those general practices may have a confounding effect on the proba-
bility distributions. Taking into account the hierarchical structure into statistical models
demands for a multilevel approach. We used MBNs in our analysis [105]. Bayesian net-
works provide a powerful framework for the representation of knowledge and reason-
ing under uncertainty [149], and they have had a significant impact on the modelling
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and the analysis of medical data [120]. The statistical relationships in such models can
be learned from patient data. In Chapter 6, it was shown that when applying MBNs to a
set of hierarchically structured disease variables, the outcome of multiple diseases can
be very well predicted using a MBN. With a receiver operating characteristic (ROC)
curve it was demonstrated that a single MBN outperformed the use of multilevel re-
gression models for each disease separately.
The use of a network-based approach to human disease, so-called network medicine,
was recently acknowledged to be useful in researching complex disease pathways [10].
In an MBN, the disease variables are also represented as vertices in a network, but the
associations have a direction and probabilistic associations are represented by directed
edges. When there is an edge from vertex i to vertex j, then i is called a parent of
j, and j is called a child of i. Although we cannot assume that these edges represent
true causality, often they do. Temporal edges always point from the past to the future,
and here a causal interpretation is even more natural. Each vertex is associated with
a multinomial probability distribution for each configuration of the parent vertex. The
interactions or moderating effects between parent vertices on their common child are
therefore captured in these local probability distributions.
In the MBN used for this chapter, we modelled the patient’s status in terms of the
predefined disorders at baseline using the first five years of the data in retrospect, with
a registration minimum of three years. The population used here is a fixed cohort of
patients that were alive at baseline. The disease status three and five years after the
baseline was also included in the model, although patients might have been deceased
or moved to another practice at that time. Building the complete MBN required two
major steps:
1. Specifying the qualitative nature of the relationships in the network.
2. Specifying the local probability distributions of the disease variables.
For step 1 all the disorders were represented as binary variables, i.e., the disorder
is present yes or no. Age was discretised into four age groups. The subnetworks con-
stituting the resulted three time slices were then connected in such a way that each
disorder variable had at least one directed edge to the same variable in the next time
slice. By doing this, the MBN is transformed into an MTBN, i.e., a multilevel, tempo-
ral Bayesian network. The urbanity of the practice was operationalised to control for
several potential confounding factors by including it as a higher level variable in the
MTBN.
Although the relationships between the disease variables, expressed by the edges
in the network, can be specified by the user, we instead learned these relationships
from the data. This allows for revealing yet unknown relationships. Both the relation-
ships between disease variables within a time slice and between different time slices
were learned using a score-based searching method in the statistical R package bn-
learn [185]. We assumed that the qualitative nature of associations between disease
variables do not vary over time, i.e., the network structure remains the same for each
time slice. To ensure a multilevel structure and specific medical knowledge, dependen-
cies between disease variables can be secured or avoided through black- and whitelist-
ing. For example, if an association between a demographic variable C and a disease
variable D was found by the structure learning algorithm, the corresponding edge in
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the network clearly should be C → D. Therefore, all possible edges Di → Cj were
blacklisted.
For step 2 we assumed that, although the network structure remains the same for
each time slice, the parameters of the local probability distributions were allowed to
change over time. The latter condition is known as the condition of non-stationarity.
Once the complete structure was determined, the local probability distributions were
estimated using one thousand bootstrapped samples from the dataset, i.e., we computed
P(Dit | parents(D
i
t)) with D
i
t = 1 if disease i is present at time t and D
i
t = 0 oth-
erwise. Note that parents(Dit) is determined by the network structure; it can contain
disease variables of several types, e.g., age, a health risk factor, or another disease, from
both the current time slice and the previous time slice. The variance induced by the ur-
banization level (a practice level variable), age, and gender, in the multilevel model
was explained by using Markov Chain Monte Carlo simulation in WinBUGS [195].
The learned structure and parameters were loaded into the software package SamIam
(© UCLA) for probabilistic inference.
The total number of disorders present simultaneously in patients, i.e., the multimor-
bidity rate, was calculated using variablesMt that kept track of the number of disorders
present in time slice t. The probability distribution of these variables is deterministic,
i.e.:
P(Mt = q | D
1
t ,D
2
t , · · · ,Dnt ) =

1 if
n∑
i=1
Dit = q
0 otherwise
(4)
The value q then represents the number of simultaneously present disorders. See Ap-
pendix A for more detail on the implementation of MTBNs.
Once the local probability distributions were determined we were able to answer the
questions mentioned in the introduction. The urbanity effects were derived by condi-
tioning on a specific value of the corresponding vertex in the network. Secondly, for
each time slice we determined whether cumulative incidence rates of disease combina-
tions significantly deviated by increased occurrence from what might be expected from
individual cumulative incidence rates, assuming statistical independence. Mathemati-
cally this can be expressed for two disorders i and j as:
P(Dit,D
j
t | Rt)  P(Dit | Rt) P(Djt | Rt) (5)
with Rt the a set of health risks Rkt present at time t. Since the size of the studied
patient population favours reaching significance easily, we also examined the clinical
importance of such deviations.
By conditioning on the multimorbidity rate Mt in a specific time slice the model
allowed us to predict the multimorbidity rate in the next time slice, which is mathemat-
ically expressed by:
P(Mt = q |Mt−1 = r) (6)
We are particularly interested in the probabilities for q > r, because if these are large,
the number of simultaneous disorders increases with time. These probabilities can be
biased due to possible disease shifts, i.e., the patient acquires a new disorder but also
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loses one, keeping the multimorbidity rate equal. To evaluate this effect we calculated
how much acquired disorders sustained in the next time slice, mathematically:
P(Dit = 1 | D
i
t−1 = 1) (7)
If these probabilities are close to one, the effects of disease shifts are considered to be
minimal.
7.3 R E S U LT S
The final MTBN consists of three time slices modelling chronic cardiovascular disease
progression. The associations in the MTBN are summarised in Table 7.1. The complete
network structure representing all the parent-child relations, and thus the qualitative na-
ture of the underlying multivariate distributions, is available in Appendix A, together
with the pseudo-code in WinBUGS for parameter estimation. Evidently, age had a sig-
nificant association with all other variables. However, gender did not had a significant
association with CVD, except for ischaemic heart disease.
Data of a total of 182,396 patients were used for analysis. The median and mean
age of the patients at baseline were 53 and 55 years, respectively. At the end of the five
year follow-up, 8.5% of these patients had dropped out of the registry. This happened
because of death or patients moved to a nursery home or practice not present in the
registry. Their disease status until this event was included in our analysis.
For all health risks and chronic disorders that were incorporated into the model, cu-
mulative incidence rates, with their standard errors, were estimated for each time slice.
These were differentiated for age and urbanity, and to examine the model’s validity
further, we also made model predictions for diabetics and non-diabetics. Besides the
individual rates, we also calculated rates of comorbidity patterns. Details on demo-
graphics and probability estimations are available on-line. The effect of urbanity on
disease probabilities, corrected for age and gender is shown in Figure 7.1.
Table 7.2 shows the evaluation of synergies, as defined in Equation (5), in which
cumulative incidence rates of the comorbidity patterns are compared with the rates
of single disorders. As dyslipidemia and hypertension are the major predictors of car-
diovascular morbidities, we computed the conditional probabilities in the absence and
presence of these conditions from the MTBN. Some of the comorbidity patterns de-
viate significantly from the expected values. For example, at five-year follow-up the
probability of ischaemic heart disease and heart failure together is 5.4% when both
dyslipidemia and hypertension are present. However, using Equation (5), the product
of their individual rates is only 2.9%. The true incidence is thus almost twice as high,
which indicates an interaction between the two disorders in relation to hypertension and
dyslipidemia. This phenomenon can be found for several comorbidity patterns through
each time slice. Since probabilities of disease combinations are relatively low, we con-
sider absolute increments, rather than relative increments, where an increment of 0.5%
is considered to be of clinical relevance.
Figure 7.2 shows the multimorbidity rates, as defined in Equation (6). For patients
having one or more health risks, the probability of obtaining a new health risk is rela-
tively low, in comparison to the presence of other cardiovascular disorders. In that case,
the cumulative incidence rate rapidly increases with the number of conditions present
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Chronic Associations known Associations learned from the data
Disease from the literature Direct* Indirect**
diabetes
mellitus
age, dyslipidemia,
hypertension, ischaemic
heart disease, heart
failure, nephropathy,
retinopathy obesity,
stroke [176]†,
practice [140]
age, dyslipidemia,
hypertension, ischaemic
heart disease, heart
failure, nephropathy,
retinopathy,
practice, obesity, stroke
ischaemic heart
disease
age, gender, obesity,
dyslipidemia,
hypertension, diabetes
mellitus, heart failure,
stroke [156]†,
retinopathy [173],
practice [77]
age, gender,
dyslipidemia,
hypertension, diabetes
mellitus, heart failure
practice, obesity, stroke,
nephropathy, retinopathy
heart failure age, obesity,
dyslipidemia,
hypertension, diabetes
mellitus, ischaemic heart
disease, nephropathy,
stroke [129]†
age, hypertension,
diabetes mellitus,
ischaemic heart disease,
stroke, nephropathy
practice, obesity,
dyslipidemia,
retinopathy
stroke age, obesity,
dyslipidemia,
hypertension, diabetes
mellitus, ischaemic heart
disease, heart
failure [156]†,
practice [77]
age, dyslipidemia,
hypertension, heart
failure
practice, obesity,
diabetes mellitus,
ischaemic heart disease,
nephropathy, retinopathy
nephropathy age, gender,
hypertension, diabetes
mellitus, ischaemic heart
disease, heart failure,
stroke [220],
retinopathy [122]
age, hypertension,
diabetes mellitus, heart
failure
practice, obesity,
dyslipidemia, ischaemic
heart disease,
retinopathy
retinopathy age, dyslipidemia,
hypertension, diabetes
mellitus [176]†,
ischaemic heart
disease [173],
nephropathy [122]
age, hypertension,
diabetes mellitus
practice, obesity,
dyslipidemia, ischaemic
heart disease, heart
failure, nephropathy
Table 7.1: Associations between cardiovascular diseases, known from the literature (clinical
guidelines are marked with a †), and learned from the data. * Direct associations cor-
respond with an edge between diseases in the MTBN. ** Indirect associations corre-
spond with diseases that have another disease between them or share a common child
or parent in the MTBN. Italic written associations were not directly clear from the used
literature.
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Baseline Follow-up
0
10
20
30
6.6
20
12
25
12
24.1
7.9
21.6
12
24.7
Hypertension
Baseline Follow-up
0
5
10
15
1.7
7
4.4
9.8
4.3
9.3
2.3
7.8
2.7
8.1
Dyslipidemia
Baseline Follow-up
0
2
4
6
1.1
3.4
1.7
4
1.4
3.8
0.6
3.1
1.4
3.8
Obesity
Baseline Follow-up
0
5
10
15
3.5
9.3
4.7
10.5
4.4
9.8
3.8
9.6
4.3
10.1
Diabetes Mellitus
Baseline Follow-up
0
3
6
9
1.9
5.8
2.5
6.8
2.4
6.2
2
6
2.3
6.3
Ischaemic Heart Disease
Baseline Follow-up
0
2
4
6
0.8
3.3
1.1
3.7
1
3.3
0.8
3.2
1.4
3.5
Stroke
Baseline Follow-up
0
2
4
6
0.6
2.7
0.8
2.8
0.7
2.4
0.6
2.5
0.7
2.7
Heart Failure
Baseline Follow-up
0
2
4
6
0.3
2.2
0.4
2.5
0.4
2.3
0.3
2.2
0.4
2.4
Nephropathy
Figure 7.1: The effect of the urbanization level, varying from very high urban areas (> 2500
addresses per km2, orange) to rural areas (< 500 addresses per km2, yellow), on cu-
mulative disease incidence at base-line and five year follow-up. Numbers are corrected
for age and gender and provided with a 95% confidence interval.
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BaseLine 3 years 5 years
follow-up follow-up
Risk Factors None DL HT DL+HT None DL HT DL+HT None DL HT DL+HT
Comorbidity
DM+IHD 0.2 2.6 1.8 6.2 0.7 5.8 4.4 11.2 1.0 6.8 5.4 14.0
DM+HF <.1 0.5 0.7 1.3 0.4 1.6 2.1 3.9 0.5 2.5 3.0 5.0
DM+NP <.1 0.3 0.4 0.9 0.3 1.1 2.0 3.8 0.5 1.7 3.1 5.0
DM+ST <.1 0.7 0.7 2.6 0.2 1.9 2.1 5.3 0.4 2.4 2.9 6.4
DM+RP <.1 0.1 0.1 0.2 0.1 0.2 0.2 0.3 0.1 0.3 0.3 0.4
IHD+ST <.1 0.6 0.4 1.7 0.2 1.6 1.3 3.8 0.3 2.3 2.0 4.9
IHD+NP <.1 <.1 0.2 0.5 0.1 0.6 1.0 2.0 0.2 1.1 1.7 3.4
IHD+HF <.1 0.8 0.9 1.8 0.4 2.1 2.2 3.9 0.6 2.8 3.2 5.4
ST+HF <.1 0.1 0.3 0.4 0.2 0.5 0.9 1.4 0.3 0.9 1.4 2.2
NP+HF <.1 <.1 0.1 0.2 0.1 0.4 0.9 1.1 0.3 0.6 1.5 2.0
Table 7.2: Estimated probabilities of having comorbid combinations of chronic cardiovascular
diseases at baseline, and after three and five years follow-up, under condition of
the presence or absence of certain health risks. Abbreviations: HT=hypertension;
DL=dyslipidemia; DM=diabetes mellitus; IHD=ischaemic heart disease; HF=heart fail-
ure; ST=stroke; NP=nephropathy; RP=retinopathy. Results are shown in percentages.
The yellow part of the circle represents the expected value based on individual rates,
the surplus is coloured in orange or red (see also Equation (5) of this chapter). Red
circles represent cumulative incidence rates which deviate significantly (p < 0.001)
from the expected values and have a clinical importance as well (absolute increase
> 0.5%). They indicate the clinical significant interactions.
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Chronic Disorder t0 → t1 t1 → t2
Obesity 40 33
Dyslipidemia 78 90
Hypertension 95 97
Diabetes Mellitus 95 91
Ischaemic Heart Disease 94 98
Heart Failure 95 99
Stroke 90 91
Nephropathy 98 99
Retinopathy 99 99
Other 66 90
Table 7.3: Persistence of individual chronic diseases, i.e., the probability (in percentages) of a dis-
order being present at follow-ups under the condition that this disorder was present in
the previous time slice (see also Equation (7) of this chapter). t0=baseline, t1=follow-
up 3 years, and t2=follow-up 5 years.
in the previous time slice. For example, when having two disorders at baseline, the
probability of obtaining one or more cardiovascular disorders after three year follow-
up is approximately 19%+3%=22%, following the edges from vertex two (at baseline)
to vertex three and four plus (at three years follow-up) at the right-hand side of Fig-
ure 7.2. From the remaining 78%, those who attracted no new cardiovascular disorder
within three years, another 32% gets one or more disorders at five years follow-up,
making the total probability 47%.
Table 7.3 shows the persistence probabilities of individual disorders at follow-ups,
as defined in Equation (7). For the majority of the disorders over 90% sustained in the
next time slice. Obesity is the major exception on this.
7.4 D I S C U S S I O N
In this study, the new method of multilevel temporal Bayesian networks was used to
precisely capture the qualitative and quantitative time course of chronic cardiovascular
multimorbidity in general practices. Bayesian network methods have not been used
before in multimorbidity analysis. Although the discovered network dependences are
sometimes similar to the associations described in medical literature, discovered by
standard statistical means, the global picture of how chronic disorders and risk factors
influence each other, as represented by a multilevel Bayesian network, is new.
It gives an overview of direct and indirect associations and it quantifies transition
rates, all in one representation. The results obtained are discussed in more detail below.
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a) # health risk determinants
baseline
0
1
2
3
follow-up 3 years
0
1
2
3
follow-up 5 years
0
1
2
3
86%
12%
2%
86%
11%
3%
94%
6%
100%
81%
17%
2%
84%
14%
2%
93%
7%
100%
b) # chronic cardiovascular diseases
baseline
0
1
2
3
4+
follow-up 3 years
0
1
2
3
4+
follow-up 5 years
0
1
2
3
4+
91%
8%
1%
80%
17%
3%
78%
19%
3%
53%
47%
100%
87%
11%
2%
73%
22%
5%
68%
25%
7%
45%
55%
100%
Figure 7.2: Transition probabilities of a) health risks, and b) chronic cardiovascular diseases (see
also Equation (6) of this chapter). Health risks are obesity, dyslipidemia, and hyper-
tension. Chronic cardiovascular diseases are diabetes mellitus, ischaemic heart dis-
ease, heart failure, stroke, retinopathy, and nephropathy. The left (black) percentages
and lines represent patients who do not acquire a new determinant or chronic disease
within the next time slice, as where the middle (orange) and right (red) percentages and
lines represent patients acquiring respectively one or two new health risks or chronic
diseases within the next time slice.
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7.4.1 Evaluation of the network structure
The associations in summarised in Table 7.1 are compared with current knowledge re-
flected in recent clinical guidelines and the medical literature. A distinction is made
between direct and indirect dependences, something not possible when using standard
statistical methods. For example, represented in the MTBN there is an indirect associ-
ation between dyslipidemia and heart failure via, i.e., conditional on, ischaemic heart
disease and hypertension. This is in line with clinical guidelines on heart failure, which
states that there is no reason to prescribe a statin in the absence of an ischaemic cause
of heart failure [156].
Other disorders share a common parent in the network structure, e.g., both retinopa-
thy and nephropathy share diabetes mellitus and hypertension as a common parent. The
investigation of either of them in the presence of the other, is thus only of beneficial
value if either diabetes mellitus or hypertension is also present.
The analysis shows that gender-induced associations are insignificant or small, and
in case it is small, it is of little clinical significance. The exception on this is ischaemic
heart disease, where it is well established that gender is significant [203].
The comorbid associations between cardiovascular related chronic disorders and
other chronic disorders [211], are also recognised in our model; obesity, hypertension,
dyslipidemia, and diabetes mellitus are associated with non-cardiovascular disorders.
Moreover, the temporal associations show that diabetes mellitus is a direct predictor of
such disorders in follow-ups.
Although the network structure indicates that obesity is a good predictor of hyper-
tension and dyslipidemia, we observe that direct associations between obesity and con-
ditions other than hypertension and dyslipidemia are missing. For example, one would
have expected an edge from obesity to diabetes mellitus, because it is well known that
an elevated body mass index or waist circumferences is associated with diabetes melli-
tus [176]. Hence, the effect of obesity on other conditions is probably underestimated
in the data explored, in particular due to low persistence at follow-ups in the database.
The latter does not mean that most patients actually lose weight, but that registries do
not properly keep track on this matter. However, if we leave obesity out of the model, it
has little effect on the structure and the associated probabilities are minimally affected
(data not shown).
7.4.2 Quantitative analysis
The prevalences of morbidity and comorbidity patterns at three-year follow-up are com-
parable to prevalences obtained from previous studies using LINH data, [215] and
earlier results within the Netherlands [207]. The associations between age, diabetes
and cardiovascular multimorbidity are quantitatively well recognised by the model.
The multilevel approach allowed us to differentiate probabilities for practice related
variables. Where other researchers showed an association between multimorbidity and
socio-economic status [177, 11], we modelled the urbanity of the practice along with
the disease variables. In case of obesity, hypertension, dyslipidemia, diabetes melli-
tus, and ischaemic heart disease, the urbanization level had a significant effect on the
prevalence. In these cases, the cumulative incidences of moderate and high urban areas
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were mostly above average, whereas these incidences of low and very high urban areas
were mostly below average. Rural areas show on average incidences comparable to the
overall average.
The effect of multiple cardiovascular risk factors was already outlined in [87], indi-
cating that the five-year cardiovascular risk can go up to 44% when certain risk fac-
tors, e.g., hypertension, total cholesterol, smoking, high density lipoprotein, gender,
diabetes, and high age, are present. Their results indicate, for example, that a smoking
male patient over 60 years with diabetes, high total cholesterol and low high density
lipoprotein, has a 5-year cardiovascular risk of 22% and 44%, for low and high systolic
blood pressure respectively. We can do more or less the same exercise as described
above: the 5-year cardiovascular risk for a male diabetic living in a rural area, aged
between 65 and 80 years, and having a lipid disorder, is 28% for non-hypertensive
patients and 55% for hypertensive patients.
However, the multiple-risk attributions in their approach could only be derived by
adding the risk factors consecutively in a specific order. In our model there is no restric-
tion on the number of disease variables used as predictor and the number of diseases
variables being predicted. For example, the 5-year cardiovascular risk of two or more
new diseases for is 10% and 23% for the patient described above. It also implies that we
can condition on a specific cardiovascular disease already present. When conditioning
on heart failure the effect on cardiovascular risk is the highest, e.g., a male hyperten-
sive diabetic with dyslipidemia, living in a rural area, aged between 65 and 80 years,
with heart failure already present at baseline, has a 5-year risk of 71% to obtain another
cardiovascular disease, and 27% for two or more diseases.
Although any other cardiovascular risk score also represents a personalisation, the
major difference with an MTBN is that in an MTBN not all disease variables need to
be known. In fact an MTBN captures all predictions for any disease variable within the
model for any subset of the remaining variables. This means that one can also reason
the other way around: given the presence of certain diseases, one can make predictions
about the presence of specific risk factors, e.g., hypertension or lipid disorders are
more likely to be present in the presence of cardiovascular diseases. In Figure 7.3
an example is shown of a personalisation, indicating that multimorbidity at baseline
predicts future multimorbidity better than the demographics do. This is in line with the
idea that the patient’s biological age is of more importance in relationship to morbidity
than chronological age [133], and the relation between frailty and the accumulation of
deficits [172].
In summary, an MTBN can be used to make predictions for multiple diseases in
many ways. To our knowledge this is new in multimorbidity research, and Table 7.2
only reflects a particular personalisation of cardiovascular risk. It reveals multiple in-
teractions between chronic cardiovascular diseases and related disorders, which occur
more frequently at follow-ups in comparison to baseline. We shall not discuss every in-
teraction in detail, but it appears that the presence of hypertension or dyslipidemia are
necessary preconditions for finding clinical significant interactions. For example, the
combination of ischaemic heart disease and heart failure is much higher than expected
after three- and five-year follow-up. Alternatively, although cumulative incidences in-
crease over time, they behave as expected, e.g., in the case of ischaemic heart disease in
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A
urbanity age group
hypertension
dyslipidemia
diabetes m.
5yr risk CVD
21% rural 23% > 65yr
10% true
5% true
4% true
> 1 : 10%
> 2 :< 1% B
urbanity age group
hypertension
dyslipidemia
diabetes m.
5yr risk CVD
18% rural 60% > 65yr
100% true
100% true
100% true
> 1 : 61%
> 2 : 20%
C
urbanity age group
hypertension
dyslipidemia
diabetes m.
5yr risk CVD
100% rural 100% > 65yr
27% true
10% true
11% true
> 1 : 35%
> 2 : 10% D
urbanity age group
hypertension
dyslipidemia
diabetes m.
5yr risk CVD
100% rural 100% > 65yr
100% true
100% true
100% true
> 1 : 65%
> 2 : 23%
Figure 7.3: personalisation of a subset of the disease model. Straight lines represent the atemporal
associations at baseline, and dashed lines represent the temporal associations between
baseline conditions and the five year cardiovascular risk. Subfigure (A) shows the 5-
year risk on a cardiovascular (related) disease (ischaemic heart disease, heart failure,
stroke, retinopathy, or nephropathy) of the general Dutch population aged over 35
years. This probability is 10%, and within this population we have the following prior
probabilities of risk factors: 21% lives in a rural area, 23% is older than 65 years, 10%
has hypertension, 5% has dyslipidemia, and 4% has diabetes mellitus. The subfigures
(B), (C) and (D) show how probabilities change when specific information of the
patient is incorporated. (B) represents patients with hypertension, dyslipidemia and
diabetes at baseline, but without knowledge about the patient’s demographics. The 5-
year risk has increased to 61%, and it is estimated that 18% lives in a rural area and
60% is over 65 years. (C) represents patients older than 65 years, living in a rural area,
but without knowledge about the patient’s disease status. The 5-year risk on CVD
has increased to 45% and it is estimated that cumulative incidences of risk factors are
doubled or more. (D) is the combination of (B) and (C), showing that the 5-year risk
has gained only a little with respect to (B).
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combination with stroke. This fits with the fact that only an indirect association exists
in the model.
Another new aspect of our model are the temporal associations. They cause the
incidence of chronic disorders to rise quickly over time. In particular, the probability
of acquiring at least one new chronic cardiovascular disorder increases with the number
of chronic cardiovascular disorders already present, regardless of age (Figure 7.2). At
three years follow-up this is respectively 9%, 20%, 22% and 47%, for zero to three
disorders present at baseline. At five years follow-up this has increased to respectively
21%, 42%, 47% and 76%. In reality, these numbers can be even higher due to disease
shifts. Since the probability of sustaining a chronic disorder is at least 90%, for the
ones we used in our model, we believe this effect is minimal.
Cross-sectional research of other registries show that the prevalence of multimor-
bidity can be up to 90% [207, 224, 53, 11]. Moreover, 80% of the elderly patients
with heart failure face at least four chronic comorbidities [211]. These numbers are
comparable with the prevalences of cardiovascular comorbidity at follow-ups retrieved
in our model. However, the prevalence of cardiovascular multimorbidity, in particular
for diabetes mellitus, ischaemic heart disease and stroke, is much lower at baseline in
our model. This indicates the importance of the temporal dimension; estimates cannot
be directly extrapolated to follow-ups, e.g., by using the prevalences of a higher age
group.
7.4.3 Strength, limitations and implications
The major strength of the results is that the obtained MTBN allows analysing several
aspects of multimorbidity in a single model. Our research encompassed an analysis
of data obtained from public health registries, and because of the size of the data set
used, significant results could be established. Although the data used here contained
more patients and more disease variables as mostly present in controlled studies, it also
contains more noise and typically involved more preprocessing. Controlled studies are
relatively small in size and often exclude patients with multimorbidity. There are some
exceptions on this, e.g., recently a cohort study of nearly 15,000 elderly people had a
focus on the epidemiology of chronic diseases using a variety of biomarkers and non-
invasive measurements [80]. But the majority of its research has a single-disease focus.
We recommend to apply Bayesian networks here as well to discover the coherence
between the multiple biomarkers and disorders present in such studies.
Several aspects of the results could have been analysed by alternative methods. For
instance, multi-state models could have been used to analyse the transition rates in
the multimorbidity number, a separate multilevel regression model for each disease to
investigate the urbanity effects, and a chi-squared test to see if the joint prevalence of
two conditions is higher than would be expected. However, investigating more complex
interactions, like in Table 7.2, would require logistic regression with added interaction
terms [86]. Logistic regression demands building a separate model for each disorder; in
this way, the insight into the qualitative nature of the interactions between the disorders
would be lost.
With an MTBN we also avoid the redundancy that is obtained when using multiple
separate regression models for each disease. For example, if we regress disease D on
119
M U LT I L E V E L T E M P O R A L B AY E S I A N N E T W O R K S
diseaseD ′ in one model and in another modelD ′ onD, we obtain two parameters for
the same association. This could produce certain ambiguity because the two models
do not necessarily have to provide the same odds ratio for that pair. In summary, the
MTBN used here allows analysing all the results presented in this chapter without
losing any of the epidemiological coherence between all the disease variables. To our
knowledge, this is new in multimorbidity research, and there is no single alternative
that analyses multimorbidity the way we did.
There are some aspects of registries that introduce a certain bias. Patients that did not
visit their physician within the used time frame are not included in the data. Although
we explored a decade of patient data within a time frame of ten years and patients
of age 35 and above, making the proportion of missing patients likely to be very low,
prevalences are probably slightly overestimated. On the other hand, in a public health
registries data are missing and there are also incorrectly coded diagnoses, implying
that prevalences might also be underestimated. Clinical guidelines often recommend
specific additional investigations making it that certain disorders are discovered more
likely than others. For example, retinopathy in a diabetic may only be discovered be-
cause of the recommendation mentioned in the guideline of visiting an ophthalmolo-
gist.
In our results, there is a considerable prevalence change between the baseline and
follow-ups. Partly this is due to the fact that the population has aged five year. On the
other hand, the absence of a diagnosis is interpreted as the absence of the corresponding
disease, however, certain pathophysiology could already be present at baseline without
knowing it. This delay in diagnosis also makes longitudinal associations between dis-
orders less detectable.
7.5 C O N C L U S I O N S
Several attempts have been made in the literature to capture prevalences of multimor-
bidity. Lately, electronic databases of general practices are used more and more to
quantify these numbers on a larger scale, but there is no clear method that fully de-
scribes how multiple disease evolve over time. Traditional statistical techniques are
very useful to evaluate a single-disease framework by which most medical care, re-
search, and education is configured. However, a multiple-disease orientation requires a
more complementary strategy.
In that respect, the MTBN used here is a valuable step forwards in multimorbidity
research. It combines the advantages of a temporal Bayesian network together with
a multilevel analysis, and it was able to discover complex multimorbidity patterns of
chronic diseases within healthcare data. First, the model was shown to be valid by
comparing known disease interactions for diabetes mellitus with those present in the
network structure. Second, several new disease interactions, qualitative and quantita-
tive, for three and five years follow-up were discovered, showing that cumulative inci-
dence rates are accelerated in the presence of multimorbidity. Especially, the presence
of conditions such as hypertension, dyslipidemia, and diabetes mellitus accelerates car-
diovascular risk significantly.
Here we only discussed the most significant results that can be obtained from an
analysis of the MTBN model. The model itself can be used to extract many other
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relevant conclusions. We conclude that Bayesian network models make the analysis
and visualization of the interactions between chronic disorders and their evolutionary
course more comprehensive than traditional statistical techniques. They can be used to
answer a variety of clinical and epidemiological questions without losing the context
of these dependences out of sight. This is of great importance in the management of
multimorbidity and the aim to adopt personalised clinical guidelines. The next step in
multimorbidity research might be to address mortality rates, differentiated for cardio-
vascular and non-cardiovascular chronic diseases, in the same way as was done here
for multimorbidity rates.
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Q UA L I TAT I V E C H A I N G R A P H S A N D T H E I R A P P L I C AT I O N
A B S T R AC T
For many problem domains, such as medicine, chain graphs are more attractive than
Bayesian networks as they support representing interactions between variables that
have no natural direction. In particular, interactions between variables that result from
certain feedback mechanisms can be represented by chain graphs. Using qualitative
abstractions of probabilistic interactions is also of interest, as these allow focusing on
patterns in the interactions rather than looking at the numerical detail. Such patterns are
often known by experts and sufficient for making decisions. So far, qualitative abstrac-
tions of probabilistic interactions have only been developed for Bayesian networks in
the form of qualitative probabilistic networks. In this chapter, such qualitative abstrac-
tions are developed for chain graphs with the practical aim of using qualitative knowl-
edge as constraints on the hyperspace of probability distributions. The usefulness of
qualitative chain graphs is explored for modelling and reasoning about the interactions
between diseases.
8.1 I N T RO D U C T I O N
Probabilistic graphical models (PGMs) have been shown to be convenient and intuitive
formalisms to capture the probabilistic independence information in many application
fields. In a PGM, random variables are modelled as vertices connected by edges in a
graph. These connections reflect the probabilistic dependences and independences be-
tween variables and one can associate a probability distribution to the graph that is faith-
ful in some way to the dependences and independences. Popular PGMs include mod-
els based on undirected graphs (UGs), i.e., Markov networks, and based on directed
acyclic graphs (DAGs), i.e., Bayesian networks [149]. However, both undirected and
directed graphs have certain undesirable limitations when representing independence
information for an actual problem domain. Hybrid graphs, containing both directed and
undirected edges, such as chain graphs, offer an elegant generalisation of both Markov
and Bayesian networks [108].
A chain graph (CG) uses potentials rather than straight probabilities to represent the
probability distribution of variables and is, therefore, often seen as a blackbox model.
Nevertheless, chain graphs have been shown to model equilibrium systems [107], which
occur in many areas including biology, physics, chemistry, and economics. In fact, it
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was shown that particular sets of conditional independence statements, which cannot
be modelled by a Bayesian network, can indeed be modelled with a chain graph; the
ideal gas law and the price and demand model in economics are examples [34].
On the other hand, Bayesian networks have the advantage that both structure and
parameters can be assessed from either expert knowledge, data, or both, which renders
Bayesian networks whitebox rather than blackbox models. For the more expressive
chain graphs, it is much more difficult to exploit human knowledge in assessing their
parameters, and, as a consequence, these models do not share all the advantages of
Bayesian networks as whitebox models. One of the aims of the research described in
this chapter is to come up with ways to move chain graphs closer to whitebox models,
in particular by the use of qualitative probabilistic abstractions.
Probabilistic information is available in different forms, ranging from numerical,
quantitative probabilistic values (possibly with a confidence interval) to qualitative in-
formation. Qualitative abstractions of Bayesian networks, called qualitative probabilis-
tic networks (QPNs) [221], offer a useful method for exploiting qualitative constraints
in assessing probabilistic information. Qualitative information in QPNs may consist of
qualitative influences and synergies, and independence information. While it is well
known that QPN theory has its limitation when it comes to qualitative reasoning – the
main reason why QPN theory is not used in actual systems – qualitative knowledge
may be quite useful when looked at as offering constraints that should be taken into ac-
count when estimating a probability distribution. Some algorithms have been proposed
in the past to derive bounds [114] and qualitative influences [24] in the presence of both
quantitative and qualitative knowledge, with applications in e.g. computer vision [35].
Furthermore, it has been proposed to derive marginal probability distributions in the
presence of such hybrid knowledge [46]. If exact probabilistic information is not re-
quired, then such distributions, also called second-order distributions1, provide insight
into the domain and could, e.g., be used to make decisions.
In the next section, we will first argue why chain graphs provide a good starting point
for modelling feedback mechanisms. Here we explore three realistic examples drawn
from the medical field. The needed theoretical basis underlying the work presented in
this chapter is provided in Section 8.3. In Section 8.4, we extend the known QPN the-
ory towards chain graphs, which we call qualitative chain graphs (QCGs). In particular,
we will formally discuss qualitative relationships, compare these to the relationships in
QPNs, and prove their most important properties. In Section 8.5, we show that sign
propagation, a qualitative variant of belief propagation, can be amended to qualitative
chain graphs. In Section 8.6, we also demonstrate their usefulness in semi-qualitative
reasoning and present experimental results supporting this claim. Although examples
were drawn from the field of medicine, which offers a rich source of qualitative mod-
elling, the results will be of value to many other domains. The work is rounded off by
conclusions and plans for future research in Section 8.7.
1 In this context, a second-order distribution yields a distribution over all possible probability distributions that
obey a set of qualitative constraints.
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Figure 8.1: Single disease modelling – a graphical representation of physiological processes in-
volved in blood glucose regulation.
8.2 M OT I VAT I O N F RO M T H E M E D I C A L F I E L D
Many regulatory mechanisms within the human body, described by its physiology, can
be seen as causal feedback systems, in which some kind of equilibrium setpoint – called
homoeostasis – is maintained. Diseases can be conceived as a derangement of one or
more regulatory mechanisms and treatments typically interact with these systems in
non-trivial ways. In non-healthy people the equilibrium setpoint typically differs from
the healthy people, but therapeutic interventions can reset the equilibrium setpoint to a
state that is closer to that of the healthy people.
Example 1 concerns a simplified model of the blood glucose level regulation, show-
ing how different agents, natural and pharmacological, have their role in maintaining
the blood sugar homoeostasis. The representation here is often found in medical text-
books. A plus-sign typically represents stimulation of a process, and a minus-sign typ-
ically represents inhibition.
Example 1. Blood sugar levels are regulated by negative feedback systems in order
to keep the body in homoeostasis. High blood glucose levels stimulate the secretion of
insulin by the pancreas, inducing glucose uptake in peripheral tissue. High blood glu-
cose levels inhibit the secretion of glucagon by the pancreas, thereby also inhibiting
glycogenolysis and gluconeogenesis, which both elevate blood sugar levels. Figure 8.1
shows a graphical representation of the blood glucose regulation, as typically used in
medical textbooks. Glycated hemoglobin (HbA1c) is a marker of average blood glu-
cose levels over the previous months, and thus provides a valid measurement of the
blood glucose equilibrium. In diabetics, elevated glucose levels are caused by either
an impaired insulin production (type I), or an insulin resistance of peripheral cells
(type II). Possible solutions to re-establish a healthy equilibrium are insulin therapy or
oral medication.
The disturbance of the equilibrium of one physiological process might also alter
the equilibrium setpoints of other regulatory systems, which might in turn induce new
pathophysiology that deteriorates the patient’s prognosis even further. In the interest of
the physician, it is important to know the qualitative dynamics of such interactions, e.g.,
whether it is likely that a therapy for a specific disease gives rise to symptoms related
to another (patho)physiological process. Example 2 shows the possible interactions
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Figure 8.2: Multiple disease modelling – Interactions between multiple physiological regulation
mechanisms: blood pressure regulation, blood glucose regulation, β-blocker therapy,
insulin therapy; and some pathophysiological findings, e.g., hypertension, impaired
vision, and a high blood glucose biomarker (Hb1Ac).
when two different therapies are administered: a blood glucose lowering therapy and
an antihypertensive therapy.
Example 2. A simplified abstract model of blood pressure and blood glucose regula-
tion is shown in Figure 8.2. The blood pressure is regulated, among other physiologic
processes, by a feedback loop with sympathetic stimulation. The same applies to blood
sugar and insulin. Both high blood pressure and a high blood glucose level contribute
to retinopathy, leading to impaired vision. Beta-blockers may stimulate the onset of
diabetes mellitus [67].
Another medical problem domain where associations without natural direction ap-
pear is the co-occurrence of two or more chronic diseases at the same time; this prob-
lem, described in detail in Chapter 3, is referred to as the problem of multimorbidity.
Several attempts give a probabilistic classification of the different associations between
diseases that occur when multiple diseases are present within one patient. An overview
can be found in Chapter 4, which discusses multimorbidity in terms of association and
direct causation.
Often, the associations between diseases occur because the diseases share the same
pathophysiology, or the physiology is somehow related. When modelling such pro-
cesses, Bayesian networks cannot adequately model the feedback mechanisms, and
more expressive models are required. It is natural to model these associations by mix-
tures of undirected edges (lines) and directed edges (arcs), which is for example done
in [204], even though the models presented in that paper are not given a (formal) proba-
bilistic meaning. Example 3 shows a simplified feedback mechanism between diabetes
mellitus and a lipid disorder. The variables of this model can be easily measured by a
physician in general practice. Since we have patient data available coming from sev-
eral general practices, this last example will be used as a running example throughout
this chapter. This patient data is then used as input for the experimental results in Sec-
tion 8.6.
Example 3. Figure 8.3 shows an abstraction of the interaction between two diseases,
i.e., diabetes mellitus and a lipid disorder, along with its typical blood measurements,
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Figure 8.3: Running example – Schematic representation of the interaction between diabetes mel-
litus and lipid disorders, showing that between the diseases feedback exists within
their pathophysiology.
two risk factors, i.e., obesity and familial hypercholesterolaemia, and a possible ther-
apy for diabetes. It is assumed that there is feedback between the pathophysiology of
both diseases, which is almost always in some kind of equilibrium. The relation be-
tween these pathophysiologies can be determined by the fact that the symptoms of each
pathophysiology are linked to each other, i.e., elevated glucose levels are associated
with elevated cholesterol levels, and given the current status of obesity and diabetes
mellitus, the status of a lipid disorder is independent of the therapy for diabetes.
8.3 P R E L I M I N A R I E S
In this section, we introduce the necessary technical preliminaries used in the remain-
der of this chapter. In particular, we introduce chain graphs and their properties, in
particular factorisation criteria and probabilistic independence. After this, we briefly
introduce QPNs and their properties for qualitative reasoning.
8.3.1 Notation
In the following, we will denote random variables by, sometimes indexed, capital letters
A,B and C and we write V ,W,X, Y and Z for sets of random variables. For clarity of
exposition, we will assume that each random variableA is a binary variable, which can
take the values a (A = true) and a¯ (A = false). Further, for notational convenience,
we will sometimes write the singleton set {A} as A, and, if X and Y are sets of random
variables, then we will write XY instead of X ∪ Y. Also, we write X − Y for X \ Y.
For example X − AB is an abbreviation of X \ {A,B}. In probabilistic expressions,
we adhere to the standard convention that {A1, . . . ,An} should be understood as the
conjunction A1 ∧ · · ·∧An, which we also sometimes use. A conditional probability
distribution P(X | Y) is defined as P(X, Y)/P(Y), for positive P(Y), and X is marginally
independent of Y if P(X | Y) = P(X). Finally, if we write an unbounded set of random
variables X in a probability expression, then the expression is implicitly universally
quantified over all configurations of X, for example, P(a | X) = P(a) expresses that
for all X (either x or x¯ if it is a single variable) the probability of a given X is the
probability of a alone.
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Figure 8.4: A chain graphG ′ used to illustrate some of the graphical concepts.
8.3.2 Chain graphs
I N T RO D U C T I O N A chain graph (CG) is a probabilistic graphical model that con-
sists of labelled vertices, representing random variables, connected by directed and
undirected edges. These models were originally introduced by Lauritzen and Wermuth
[108]. Frydenberg [57] proposed a Markov property for these models, which is now
known in the literature as the Lauritzen-Wermuth-Frydenberg (LWF) interpretation of
chain graphs. Alternative Markov properties have been proposed for chain graphs, in
particular by Andersson et al. [5] (AMP chain graphs). The LWF interpretation has an
intuitive equilibrium interpretation and it factorises according to the graph, whereas
AMP chain graphs only partially factorise. The complete factorisation is useful in this
context as this allows the qualitative representation of some of its factors, so we concern
ourselves with LWF chain graphs only. The results of this chapter do not generalise to
the other chain graph interpretations. The concepts introduced here are in accordance
with existing literature on probabilistic graphical models [32] and chain graphs [197].
They are illustrated by an example chain graph G ′ as shown in Figure 8.4.
G R A P H I C A L C O N C E P T S Let G = (V ,E) be a hybrid graph, where V denotes
the set of vertices and E the set of edges, where an edge is either directed, also called
an arc , or undirected, also called a line. Let indexed letters, e.g., V1 and V2, indicate
vertices of a chain graph. We denote an arc connecting two vertices by ‘→’ and a line
by ‘−’. Suppose two vertices V1 and V2 are in E. If V1 → V2 then V1 is a parent of
V2. If V1 − V2 then V1 is a neighbour of V2. The set of parents and neighbours of a
vertex Vi are denoted by pa(Vi) and ne(Vi), respectively. The set pa(Vi) ∪ ne(Vi)
is the boundary of Vi, denoted by bd(Vi). For example, in G ′, it holds that bd(D) =
{C,E}. We will denote cl(Vi) as the closure of Vi defined by bd(Vi) ∪ {Vi}. These
concepts are also assumed to be defined over sets of variables, e.g., if W ⊆ V , then
bd(W) =
⋃
Vi∈W bd(Vi).
One of the key concepts in chain graphs is a route, which is a sequence of vertices
V1, . . . ,Vn+1, such that Vi − Vi+1 ∈ E, Vi → Vi+1 ∈ E, or Vi ← Vi+1 ∈ E.
This concept is distinct from a path, which is a route where no vertex appears more
than once. For example, in G ′, the sequence A → B− C → H ← C is a route, but
not a path. By a section of a route ρ, we mean a maximal undirected subroute σ ⊆ ρ:
Vi− . . .−Vj with 1 6 i 6 j 6 n+ 1. Note that a section can consist of a single vertex,
e.g., in the route B−C→ I← E, the sections are {B−C, I,E}. A section Vi− . . .−Vj
is called a head-to-head section on a route ρ if Vi−1 → Vi and Vj ← Vj+1 are on the
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route ρ. For example, in a routeA→ B−C−D← E, the section B−C−D is called
a head-to-head section. A cycle is a route (with n > 1) where the first and last vertex
are the same. A descending route is a route, where there are no Vi ← Vi+1 ∈ E. A
vertex Vi is an ancestor of Vj if there exists a descending route from Vi to Vj. The set
an(Vi) denotes the set of ancestors of Vi. A directed route is a route which includes
at least one arc, and where all arcs have the same direction. We will call a vertex Vi a
predecessor of Vj if there exists a directed route from Vi to Vj. Notice the difference
between ancestors and predecessor: if a vertex is a predecessor of another vertex, it is
also an ancestor of that vertex, but not vice versa. For example, C has five ancestors in
G ′ (A, B, C,D, and E), but only two predecessors (A and E). C is an ancestor of itself
because of, for example, the route C−B−C.
A chain graph is a hybrid graph with the restriction that no directed cycles, i.e., a
directed route which is a cycle, exist. Removing all the arcs from the graph leaves us
with vertices connected by lines, called chain components; the set of all chain compo-
nents is denoted here by C. For example, G ′ contains five chain components: {A}, {E},
{B,C,D}, {H}, and {I}. A chain component with its parents plays an important role in
the factorisation as shown below. For this reason, we introduce a final graphical con-
cept which is the family of a vertex Vi, denoted by fa(Vi), as the set C∪ pa(C) where
C ∈ C and Vi ∈ C.
G L O B A L M A R K OV P RO P E RT Y There exists a simple separation criterion for
reading off independence statements from a chain graph, which was introduced by Stu-
dený and Bouckaert [197]. Having a route ρ and a set of vertices Z ⊂ V , we say that ρ
is hit by Z if a vertex of ρ belongs to Z. If ρ is not hit by Z, it will be called free with
respect to Z. A route is called superactive if for every section σ of ρ, the section σ is
hit by Z iff σ is a head-to-head section w.r.t. ρ. A set of vertices X (in the graph G) is
c-separated from a set of vertices Y by the set of vertices Z, denoted by X ⊥ Y | Z, if
there are no superactive routes between X and Y. Equivalently, we can say that X and
Y are c-separated given Z if for every route ρ in G between X and Y, there exists a
section σ of ρ such that:
• either σ is a head-to-head section w.r.t. ρ, and σ is free w.r.t. Z;
• or σ is not a head-to-head section w.r.t. ρ, and σ is hit by Z.
If X is not c-separated from Y given Z, then this is denoted by X 6⊥ Y | Z. Consider
again the graphG ′. If Z = {H}, then the routeA→ B−C−D← E is not superactive
as the head-to-head section B−C−D is free w.r.t. Z. However, the route A → B−
C→ H← C−D← E is superactive as the only head-to-head section (H) is hit by Z,
and all the other sections are free w.r.t. Z. This implies that A 6⊥ E | H.
F AC T O R I S AT I O N Associated to a chain graph G = (V ,E) is a joint probability
distribution over the set of vertices V that is faithful to the chain graph G, i.e., it con-
tains all the independences implied by the global Markov property. Such distributions
can be factorised by an outer factorisation:
P(V) =
∏
C∈C
P(C | pa(C)) (8)
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with V =
⋃
C∈C C, and where each P(C | pa(C)) is defined by a clique-wise factori-
sation:
P(C | pa(C)) = Z−1(pa(C))
∏
M∈MC
ϕM(M) (9)
given that MC are the complete (fully connected) subsets in the closure graph of C,
i.e., the subgraph GC∪pa(C) where each arc is replaced by a line and each pair of
vertices of pa(C) is also connected by a line, also referred as to moralisation. The
functions ϕ are non-negative real functions, called potentials; they generalise joint
probability distributions in the sense that they do not need to be normalised. Finally,
the normalising factor Z is defined as:
Z(pa(C)) =
∑
C
∏
M∈MC
ϕM(M) (10)
Conversely, (discrete) distributions that factorise in this way are almost always (in a
measure-theoretic sense) faithful to the graph G [153].
As a Bayesian network is a special case of a chain graph model where each chain
component consists of a single vertex, the chain graph Markov property simplifies in
that case to
P(V) =
∏
Vi∈V
P(Vi | pa(Vi))
which is the well-known factorisation theorem of Bayesian networks [32]. In this case,
the chain components are formed by single random variables. Therefore, for each of
those random variables the distribution is defined as the conditional probability func-
tion of this variable, given the value of its parents.
I N T E R P R E TAT I O N Undirected edges in chain graphs can be interpreted as an equi-
librium (steady-state) in a feedback model [107]. For example, consider again the graph
in Figure 8.3, where there is a feedback relationship between lipid disorder and diabetes
mellitus. In practice, this feedback system is in a steady state, although the setpoint of
the feedback system may be changed, for example by the amount of insulin given in
the therapy. Therefore, only the relationships between variables within a steady-state
are relevant, rather than the underlying dynamic process that leads to the equilibrium.
Moreover, the underlying dynamics are very difficult to measure in vivo, hence, the
parameters of such dynamical models, e.g., ordinary differential equations, are diffi-
cult to elicit. Therefore, we argue that chain graphs offer an attractive abstraction of
the underlying dynamic mechanism for feedback systems in disease models, as there
is plenty of data derived from patients in a state of near-equilibrium, i.e., homoeosta-
sis. The corresponding chain graph and factorisation of Figure 8.3 in its steady state is
shown in Figure 8.5.
8.3.3 QPNs
Qualitative probabilistic networks (QPNs) were introduced by [221], as a qualitative
abstraction of Bayesian networks. Conditional probability distributions are replaced by
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(i)
F Ob Th
LD DM
Ch Gl
(ii)
F
Ob
Th
LD DM
Ch Gl
(iii)
P(F,Ob,Th,LD,DM,Ch,Gl) =
P(Ch | LD) ·P(Gl | DM)·
ϕ1(F,Ob,LD) ·ϕ2(Ob,LD,DM)·
ϕ3(F,Ob,Th) ·ϕ4(Ob,Th,DM)·
P(Ob) ·P(Th) ·P(F)
Figure 8.5: Chain graph representation (i), the closure graph of chain components (ii), and the
factorisation (iii) of the example in Figure 3.
qualitative knowledge in the form of signs, which describe the relationships among
variables by the concepts of probabilistic influences and synergies. Here we briefly
recall the theory in accordance with the definitions in [221, 164, 117].
A qualitative influence expresses how the value of one variable influences the proba-
bility of observing values of another variable. Let Z denote the set of variables pa(B)−
A. We say that A has a positive qualitative influence on B, written as S+(A,B), if
P(b | a,Z) > P(b | a¯,Z)
A negative influence, written as S−(A,B), and a zero influence, written as S0(A,B),
are defined analogously, by replacing > with 6 and = respectively. Finally, it always
holds that an influence is ambiguous, written as S?(A,B), in particular if none of the
other cases hold. Note that all types are influences are mutually consistent, e.g., if both
S−(A,B) and S+(A,B) holds, then this implies S0(A,B).
Influences adhere to a set of convenient properties [221]. The property of symme-
try guarantees that if an influence, say S+(A,B), exists, the influence S+(B,A) also
exists. Qualitative influences are transitive, i.e., the qualitative influences along a di-
rected path (as defined in Section 8.3.2) between two variables, specifying at most one
incoming arc for each variable, combine into a single influence using the ⊗ operator
from Table 8.1. The property of composition further asserts that multiple qualitative
influences between two variables along parallel paths combine into a single influence
between these variables using the ⊕ operator from Table 8.1.
In addition to influences, a qualitative probabilistic network includes synergies mod-
elling interactions between influences. An additive synergy expresses how the interac-
tion between two variables influences the probability of observing the values of a third
variable. Now, let Z denote the set consisting of the variables pa(B) −A1A2. We say
there is a positive additive synergy of A1 and A2 on B, written as Y+({A1,A2},B), if
P (b | a1,a2,Z) + P (b | a¯1, a¯2,Z) > P (b | a¯1,a2,Z) + P (b | a1, a¯2,Z)
A product synergy is used to provide intercausal reasoning, i.e., it expresses how
upon observation of a common child of two vertices, observing the value of one parent
vertex influences the probability of observing a value of the other parent. We say there
is a positive product synergy of A1 and A2 with regard to the value b of variable B,
written as X+({A1,A2},b), if
P (b | a1,a2,Z) · P (b | a¯1, a¯2,Z) > P (b | a¯1,a2,Z) · P (b | a1, a¯2,Z)
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+ - 0 ?
+ + - 0 ?
- - + 0 ?
0 0 0 0 0
? ? ? 0 ?
(a) Sign product (⊗)
+ - 0 ?
+ + ? + ?
- ? - - ?
0 + - 0 ?
? ? ? ? ?
(b) Sign sum (⊕)
Table 8.1: Operations on signs.
Negative, zero, and ambiguous additive and product synergies are defined analogously.
It has been shown that the sign of the product synergy implies the sign of the influence
between causes given the observation of the child [76, 222], for a given Z. Therefore,
the product synergy expresses intercausal reasoning to some extent [47].
8.4 Q UA L I TAT I V E C H A I N G R A P H S
In this section, we will analyse influences and synergies in the context of chain graph
models. The resulting representation will be referred to as qualitative chain graphs
(QCGs).
8.4.1 Influences in chain graphs
The properties of signs in qualitative probabilistic networks rely on the fact that signs
hold in any context, i.e., intuitively, a variable A positively influences another variable
B if in any possible context the probability of b is higher for a compared to a¯. While
such a context is relatively clear in case of directed arcs, it is more subtle for proba-
bilistic chain graphs, in which influences can also exist through lines. From a technical
point of view, multiple definitions of influences are possible, e.g., the context of the
influence may be defined based on e.g., the parents, the neighbours, or possibly the par-
ents of a chain component. Besides technical considerations, a proper definition is also
particularly relevant for knowledge elicitation, as the domain expert has to be able to
understand influences without reference to the technical details. We believe that such
a natural semantics can be defined by means of defining influences in terms of inter-
ventions [107] on particular variables in the chain graph. For most domain experts, the
effect of one variable after the intervention on another variable is an easy to understand
concept and is captured in the following formal definition.
Definition 8. The influence of A on B in a context c ∈ V −AB, where A and B are
two vertices, is the probability P(b || a, c) − P(b || a¯, c) where P(B || A,C) is the
probability of B after an intervention on A and C.
In other words, the influence of A on B, in a particular context, can be defined as
the difference in probability of B from a situation where A is manipulated to A = true
to a situation where A is manipulated to A = false. For example, obesity increases
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the chance of a lipid disorder (see Example 3); conversely, it is not thought that lipid
disorder influences the weight of the patient, even though lipid disorder has a predictive
value for ‘Obesity’.
It is well-known that without any information about causality, the distribution after
an intervention cannot be established. However, similarly to directed graphs [150], a
causal interpretation can be given to chain graphs. Given this causal chain graph in-
terpretation, where chain components are interpreted as equilibria, influences between
random variables can be restated in terms of conditional probabilities. This forms the
basis of the qualitative chain graph theory that will be developed in the remainder of
this chapter. In the following lemma, we will first relate the marginal probability of a
random variable after an intervention to a conditional probability. This causal interpre-
tation of chain graphs will be assumed throughout the rest of the chapter.
Lemma 2. If a chain graphG = (V ,E) is generated by a causal feedback model where
lines represent equilibria [107], and P(B || V −B) denotes the probability distribution
of B after an intervention on all other variables, then:
P(B || V −B) = P(B | fa(B) −B)
Proof. This is a direct corollary of Equation (18) in [107], which states that:
P(V −A || A) =
∏
C∈C
P(C−A | pa(C),C∩A)
Now let A = V − B. Given some chain component C ∈ C, suppose that B 6∈ C, then
P(C− (V −B) | pa(C),C∩ (V −B)) = 1, because C− (V −B) = ∅. Let C ′ ∈ C be
the chain component with B ∈ C ′. It then follows that:
P(B || V −B) = P(B | pa(C ′),C ′ ∩ (V −B)) = P(B | pa(C ′),C ′ −B)
Finally, note that pa(C ′)∪ (C ′ −B) = fa(B) −B.
From this property it is straightforward to show that one can generalise the defini-
tion of qualitative influences. In order to do so, a convenient tool is the local Markov
property of chain graphs, which states that a vertex is independent of its ancestors that
are not in its closure given its boundary. This implies the following lemma.
Lemma 3. Given a chain graph G = (V ,E) and vertices A,B ∈ V such that A ∈
bd(B), then the following three families of conditional probability distributions are
equivalent:
1. P(B | an(B) −B)
2. P(B | fa(B) −B)
3. P(B | bd(B))
Proof. Observe that:
bd(B) ⊆ fa(B) −B ⊆ an(B) −B
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so in each case, B is conditioned on bd(B). Furthermore, it holds that the remaining
conditioning variables are related to the set of ancestors of B as follows:
fa(B) −B− bd(B) ⊆ an(B) − cl(B)
an(B) −B− bd(B) = an(B) − cl(B)
Since the local Markov property of chain graph states [57]:
Vi ⊥ an(Vi) − cl(Vi) | bd(Vi)
the equalities follow.
Then, using these two lemmas, we obtain an expression of influences in chain graphs
in terms of conditional probabilities.
Proposition 2. Given a chain graph G = (V ,E) and vertices A,B ∈ V such that
A ∈ bd(B), and a context c. Let Z = bd(B) −A and z the variable Z instantiated
according to c, i.e., c ≡ z∧ x, where X = V − ZAB, then the influence of A on B in
context c – as formalised in terms of interventions in Definition 8 – equals:
P(b | a, z) − P(b | a¯, z)
Proof. By Definition 8, the influence in context c is:
P(b || a, c) − P(b || a¯, c)
By Lemma 2, this is equivalent to:
P(b | a, fa(B) −AB) − P(b | a¯, fa(B) −AB)
Finally, by Lemma 3, this is equivalent to:
P(b | a, z) − P(b | a¯, z)
Note that it follows that the influence ofA on B is a zero influence ifA 6∈ bd(B) and
A ∈ an(B). Also note that the qualitative influences generalise the QPN definitions,
since bd(B) = pa(B) for any B ∈ V if every chain component consists of a single
vertex.
8.4.2 Qualitative influences
Given the properties of influences in chain graphs, we are now in the position to de-
fine the usual notions of qualitative probabilistic networks for chain graphs. First, we
will define qualitative influences, starting with positive qualitative influences, which is
defined as a positive influence in all possible contexts.
Definition 9. Given a chain graph G = (V ,E) with A,B ∈ V , such that A ∈ bd(B),
then vertex A positively influences a vertex B, written as S+(A,B), if
P(b | a, bd(B) −A) > P(b | a¯, bd(B) −A)
for all configurations of bd(B) −A.
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Generally, if δ ∈ {+,−, 0, ?} then Sδ(A,B) denotes the qualitative influence be-
tween A and B. The negative (-), zero (0), and ambiguous (?) influences are defined
in line with QPNs, i.e., for the negative and zero influence we replace > by 6 and =,
respectively. Finally, S?(A,B) always holds if A ∈ bd(B).
Qualitative influences in QPNs adhere to the properties of symmetry, transitivity, and
composition [221, 76], which form the basis for qualitative inference in QPNs. Sym-
metric means that if there is some influence from a vertex A to a vertex B, then there
is an influence from B to A with the same sign if the arc is reversed.2 Therefore, only
a single sign is needed for every arc in a QPN. In the following, we will prove that this
symmetry is preserved for qualitative chain graphs, i.e., also for neighbouring vertices
the signs are symmetric. First we prove a lemma that rephrases qualitative influences
in terms of relationships between potential functions. We will focus in this lemma and
theorem on positive influences, however, the same reasoning holds for negative and
zero influences.
Lemma 4. Given a chain graph G containing vertices A and B, with A ∈ bd(B) and
B an element of a component C, it holds that:
P(b | a, fa(B) −AB) > P(b | a¯, fa(B) −AB)
if and only if∏
M∈MAB
ϕM(a,b)ϕM(a¯, b¯) >
∏
M∈MAB
ϕM(a, b¯)ϕM(a¯,b)
where MAB = {M ∈ MC | {A,B} ⊆ M} and ϕM(A,B) is shorthand for ϕ(M−
AB,A,B).
Proof. In the following, we will writeϕM(a,X) forϕM(X) ifA 6∈M for any X ⊆ V .
This allows us to consider all cliques conditioned on a certain variable (e.g.A) without
making a distinction between those that contain A and those that do not contain A. By
basic probability theory, we have:
P(B | A, fa(B) −AB) =
P(C, pa(C))
P((C, pa(C)) −B)
=
P(C | pa(C))P(pa(C))∑
B
P(C | pa(C))P(pa(C))
Using Equation (9), that factorises conditional probabilities of a component into poten-
tials, the left-hand side therefore equals to:
Z−1(pa(C))
( ∏
MC
ϕM(a,b)
)
P(pa(C))∑
B
Z−1(pa(C))
( ∏
MC
ϕM(a,B)
)
P(pa(C))
>
Z−1(pa(C))
∏
MC
(
ϕM(a¯,b)
)
P(pa(C))∑
B
Z−1(pa(C))
( ∏
MC
ϕM(a¯,B)
)
P(pa(C))
2 Note that parents are added during arc reversals in Bayesian networks. See [221] for details.
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Given that B ∈ C, we have B 6∈ pa(C), so the term Z−1(pa(C))P(pa(C)) only
depends onA. By replacing this term by f(A) and multiplying each side by the denom-
inators, we obtain:∏
MC
ϕM(a,b)f(a)
∑
B
∏
MC
ϕM(a¯,B)f(a¯) >∏
MC
ϕM(a¯,b)f(a¯)
∑
B
∏
MC
ϕM(a,B)f(a)
Writing out the possible values for the summation over B, i.e., b and b¯, we obtain:∏
MC
ϕM(a,b)ϕM(a¯,b)f(a)f(a¯) +
∏
MC
ϕM(a,b)ϕM(a¯, b¯)f(a)f(a¯) >∏
MC
ϕM(a¯,b)ϕM(a,b)f(a)f(a¯) +
∏
MC
ϕM(a¯,b)ϕM(a, b¯)f(a)f(a¯)
Removing the factors that are the same on both sides of the equation we get:∏
MC
ϕM(a,b)ϕM(a¯, b¯) >
∏
MC
ϕM(a, b¯)ϕM(a¯,b)
For all potentials not depending on both A and B, e.g., ϕM(A,B) = ϕM(B), its
corresponding factors are also the same on both sides of the equation, leaving us with:∏
M∈MAB
ϕM(a,b)ϕM(a¯, b¯) >
∏
M∈MAB
ϕM(a, b¯)ϕM(a¯,b)
Example 4. Continuing Example 3, to evaluate a (say, positive) influence of Ob on LD
only involves ϕ1 and ϕ2 (cf. Figure 8.5(iii)). Therefore, a positive influence of Ob on
LD is equivalent to:
ϕ1(F, ob, ld) ϕ1(F, ob, ld) ϕ2(ob, ld,DM) ϕ2(ob, ld,DM) >
ϕ1(F, ob, ld) ϕ1(F, ob, ld) ϕ2(ob, ld,DM) ϕ2(ob, ld,DM)
for all values of F and DM.
In other words, determining the nature of a qualitative influence between two ver-
tices implies that one only has to consider those potentials for cliques containing the
two variables that describe the influence. In general, we have the following result that
we were aiming for, proving the symmetry property of qualitative influences.
Theorem 2. It holds that qualitative signs of chain graphs are symmetric, i.e., given
a chain graph G = (V ,E), suppose (A,B) ∈ E (i.e. A− B or A → B), then P(b |
a,X) − P(b | a¯,X) > 0 if and only if P(a | b,X, Y) − P(a | b¯,X, Y) > 0, where
X = bd(B) −A and Y = bd(A) −B.
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Proof. Suppose P(b | a,X) > P(b | a¯,X). Assume P(b | a,X) − P(b | a¯,X) > 0.
Since Y ⊆ an(B) − cl(B), by the local Markov property, we have B ⊥ Y | AX, so it
follows that P(b | a,X, Y) − P(b | a¯,X, Y) > 0. Let Z = X∪ Y. Then, by Bayes’ rule,
we have:
P(b | a,Z) > P(b | a¯,Z) ⇔ P(a | b,Z)P(b,Z)
P(a,Z)
> P(a¯ | b,Z)P(b,Z)
P(a¯,Z)
So then this is equivalent to:
P(a | b,Z)∑
B P(a | B,Z) | P(B,Z)
> P(a¯ | b,Z)∑
B P(a¯ | B,Z)P(B,Z)
⇔ P(a | b,Z)
∑
B
P(a¯ | B,Z)P(B,Z)
> P(a¯ | b,Z)
∑
B
P(a | B,Z) | P(B,Z)
⇔ P(a | b,Z)P(a¯ | b¯,Z) > P(a¯ | b,Z)P(a | b¯,Z)
⇔ P(a | b,Z)(1− P(a | b¯,Z)) > P(a | b¯,Z)(1− P(a | b,Z))
⇔ P(a | b,Z) > P(a | b¯,Z)
Note that this does not prove S+(A,B) iff S+(B,A) in a strict sense, as an influence
of B on A is only defined if B is in the boundary of A. Instead it should be seen as the
influence after the reversal of the arc where the A obtains the boundary of B, which is
similar to arc reversal in Bayesian networks and QPNs [188, 221].
As mentioned, besides symmetry, there are two other important properties. First, for
a single route from vertices A to B in a chain graph G, the influences along a path are
transitive, and the influence ofA on B is the sign-product (Table 8.1a) of all influences
along the path. For multiple paths between two vertices A and B, the influences of
these routes are composite, i.e., the influence of A on B is the sign-sum (Table 8.1b) of
all influences of each paths. These properties are combined in the following theorem.
Theorem 3. Let Sδ(A,B,G) be the qualitative influence in the distribution of chain
graph G, and let red(B,G) be the probability distribution of chain graph G with
B marginalised out. It holds that Sδ1(A,B,G) ∧ Sδ2(B,C,G) ∧ Sδ3(A,C,G) ⇒
S(δ1⊗δ2)⊕δ3(A,C, red(B,G)).
Proof. Let X = bd(B) −A and Y = bd(C) −AB. Observe that:
P(C | A,X, Y) =
∑
B
P(C,B | A,X, Y)
=
∑
B
P(C | A,B,X, Y)P(B | A,X, Y)
Choose an arbitrary X and Y, and let ∆AB = P(b | a,XY) − P(b | a¯,XY), ∆BCa =
P(c | a,b,XY) − P(c | a, b¯,XY), ∆ACb = P(c | a,b,XY) − P(c | a¯,b,XY), and
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Figure 8.6: Qualitative representation with influences of the chain graph from Figure 8.3.
∆ACb¯ = P(c | a, b¯,XY) − P(c | a¯, b¯,XY). Furthermore, define x = P(c | a,b,XY)
and y = P(b | a,XY). Then:
P(c | a,XY) − P(c | a¯,XY) = xy+ (x−∆BCa)(1− y)
−(x−∆ACb)(y−∆AB)
−(x−∆ACb¯ −∆BCa)(1− y+∆AB)
= ∆ACb¯((1− y) +∆AB) +∆ACb(y−∆AB)
+∆AB∆BCa
Note that 1− y+∆AB = P(b¯ | a¯,XY) > 0 and y−∆AB = P(b | a¯,XY) > 0, so it
follows that:
sign(P(c | a,XY) − P(c | a¯,XY)) = sign(∆ACb¯ +∆ACb +∆AB∆BCa)
The properties can then be verified. Note that both ∆ACb¯ and ∆ACb have the sign δ3;
∆AB has the sign δ1; ∆BCa has the sign δ2. The sign-product operator behaves as a
product and the sign-sum operator behaves as a sum. Note that in case δ3 = 0, we have
transitivity only.
Example 5. Consider Figure 8.6, which is a qualitative version of the model in Fig-
ure 8.3. Since S+(Ob,DM) and S+(DM,Gl), we derive, for example, S+(Ob,Gl).
Similarly, we can derive S−(Th,Gl), i.e., therapy lowers the chance on a high blood
glucose.
8.4.3 Additive synergies
As mentioned in the preliminaries, an additive synergy expresses information about
the joint influence of two vertices A1 and A2 on a neighbour of these vertices. The
intuitive idea is that there is a positive synergy if the joint influence is larger than
their separate influence on this neighbour. Following Definition 9, we define a synergy
within a certain context as follows.
Definition 10. Given a chain graphG = (V ,E) and three verticesA1,A2 and B, with
A1,A2 ∈ bd(B). Let c be any context c ∈ V −A1B. Let k be the influence of A1
on B in context c∧ a2 and l be the influence of A1 on B in context c∧ a¯2. Then the
synergy between A1 and A2 on B in context c is k− l.
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Figure 8.7: The model presented in Figure 8.6 with an additional additive synergy on DM.
From Proposition 2, where we show that the influence of A1 on B in context c∧
A2 is equal to P(b | a1,A2, z) − P(b | a¯1,A2, z) where z is a configuration of
bd(B) −A1A2, it follows that the synergy of A1 and A2 on B in context c is positive
if P(b | a1,a2, z) − P(b | a¯1,a2, z) > P(b | a1, a¯2, z) − P(b | a¯1, a¯2, z). Therefore,
again, a probabilistic definition for additive synergies in QCGs naturally follows, which
is defined as a synergy in any possible context.
Definition 11. We say that vertices A1 and A2 express a positive additive synergy on
a vertex B, written as Y+({A1,A2},B), iff A1,A2 ∈ bd(B), Z = bd(B) −A1A2,
and
P(b | a1,a2,Z) − P(b | a¯1,a2,Z) > P(b | a1, a¯2,Z) − P(b | a¯1, a¯2,Z)
Again, the negative and zero synergies are defined similarly by replacing > with 6
or = respectively. Ambiguous synergies always hold.
Example 6. Continuing Example 5, consider Figure 8.7. In this model, we express a
positive additive synergy between the variables obesity and therapy on diabetes melli-
tus, i.e., Y+({Ob,Th},DM). This implies that e.g. the positive influence of therapy on
diabetes is positively influenced by weight loss. Conversely, the positive influence of
weight-loss on diabetes is positively influenced by treatment.
It can be verified that additive synergies in chain graphs are similar to additive syner-
gies in QPNs. For example, it is obvious that additive synergies are symmetric, i.e., if
Yδ({A1,A2},B) then Yδ({A2,A1},B). Other properties of synergies have been well
studied for QPNs, in particular in context of variable elimination [221]. We do not fur-
ther study additive synergies in this context as in this chapter we mainly focus on the
use of these kind of synergies for imposing constraints on the probability distribution.
It seems reasonable to conjecture that similar results to the QPN case will apply.
8.4.4 Intercausal reasoning and product synergies
In QPNs, a product synergy expresses how the value of one cause influences the prob-
ability of the value of another cause when observing the common child. A negative
product synergy of A1 and A2 given b expresses that if a1 is the case, then this ren-
ders a2 less likely. While in a QPN a cause is simply the parent of a vertex, it is less
clear what it means in the undirected case. First, we will define product synergies in
general and then study its properties.
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Definition 12. We say that vertices A1 and A2 express a negative product synergy
with regard to the value w for the set of verticesW, denoted by X−({A1,A2},w), iff
P(w | a1,a2,Z)P(w | a¯1, a¯2,Z) 6 P(w | a1, a¯2,Z)P(w | a¯1,a2,Z)
where Z = bd(W) −A1A2.
Again, the other signs are defined analogously.
As said, the purpose of product synergies is to define intercausal relationships be-
tween vertices. First, we will relate intercausal reasoning to product synergies in chain
graphs using the following theorem.
Theorem 4. Given a chain graph G = (V ,E) and two vertices A1,A2 ∈ V and a
set of vertices W ⊆ V . Let Z = bd(W) −A1A2, X = bd(A2) and suppose that
A1 ⊥ A2 | ZX and W ⊥ X | A1A2Z. If we observe w, then we have a negative
influence of A1 on A2, i.e.,
P(a2 | a1,w,Z,X) 6 P(a2 | a¯1,w,Z,X)
if and only if
P(w | a1,a2,Z)P(w | a¯1, a¯2,Z) 6 P(w | a¯1,a2,Z)P(w | a1, a¯2,Z)
The same equality holds if we replace 6 by > or =.
Proof. By Bayes’ theorem we have:
P(A2 | A1,w,Z,X) =
P(w | A1,A2,Z,X)P(A2 | A1,Z,X)
P(w | A1,Z,X)
Since A1 ⊥ A2 | ZX, the term P(A2 | A1,Z,X) = P(A2 | Z,X). Similarly, P(w |
A1,A2,Z,X) = P(w | A1,A2,Z) and P(w | A1,Z,X) = P(w | A1,Z). Now by
marginalising over A2 in the denominator:
P(A2 | A1,w,Z,X) =
P(w | A1,A2,Z)P(A2 | Z,X)∑
A2
P(w,A2 | A1,Z)
=
P(w | A1,A2,Z)P(A2 | Z,X)∑
A2
P(w | A1,A2,Z)P(A2 | Z,X)
Now we find:
P(a2 | a1,w,Z) 6 P(a2 | a¯1,w,Z)
⇔ P(w | a1,a2,Z)P(a2 | Z,X)∑
A2
P(w | a1,A2,Z)P(A2 | Z,X)
6 P(w | a¯1,a2,Z)P(a2 | Z,X)∑
A2
P(w | a¯1,A2,Z)P(A2 | Z,X)
⇔ P(w | a1,a2,Z)P(a2 | Z,X)
∑
A2
P(w | a¯1,A2,Z,X)P(A2 | Z) 6
P(w | a¯1,a2,Z)P(a2 | Z,X)
∑
A2
P(w | a1,A2,Z)P(A2 | Z,X)
⇔ P(w | a1,a2,Z)P(w | a¯1,a2,Z)P(a2 | Z,X) +
P(w | a1,a2,Z)P(w | a¯1, a¯2,Z)P(a¯2 | Z,X)
6 P(w | a¯1,a2,Z)P(w | a1,a2,Z)P(a2 | Z,X) +
P(w | a¯1,a2,Z)P(w | a1, a¯2,Z)P(a¯2 | Z,X)
⇔ P(w | a1,a2,Z)P(w | a¯1, a¯2,Z) 6 P(w | a¯1,a2,Z)P(w | a1, a¯2,Z)
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It is clear that in case we have a QPN, product synergies characterise intercausal
reasoning if A1,A2 ∈ pa(W) and A1 and A2 are unconditionally independent. This
particular case was discussed in [76] and in subsequent papers. In contrast, in chain
graphs, the following holds, which states that in case the main condition of Theorem 4
holds – i.e., that A1 and A2 are independent given the boundary of the conditioning
vertex and the boundary of A2 – then these vertices must be predecessors of the condi-
tioning vertices.
Proposition 3. Given a chain graph G = (V ,E) and three vertices A1,A2,B ∈ V .
Let Z = bd(B) −A1A2 and X = bd(A2) and assume A1 6⊥ B and A2 6⊥ B | X,
and B 6∈ X. If A1 ⊥ A2 | ZX, then A1 and A2 are predecessors of B.
Proof. Suppose not: suppose A1 is the vertex which is not a predecessor of B (the
argument is similar for A2). Then we have a descending superactive route ρ from B to
A1 w.r.t ZX. Similarly, for A2, there exists a superactive route σ from A2 to B w.r.t.
ZX. Since ρ = B− · · ·A1 or ρ = B→ · · ·A1, B cannot be a head-to-head section, so,
given that B 6∈ ZX, the union of ρ and σ (from A2 to A1) is also superactive w.r.t. ZX.
This contradicts the assumption A1 ⊥ A2 | ZX.
In case we condition on a vertex in a chain component, it follows from the definition
of c-separation, that we create a superactive route between parents of a chain compo-
nent. This could be seen as intercausal reasoning between these parents. For example,
if we have a graph A1 → C− B← A2, there will be an influence of A1 on A2 if we
condition on B. A natural question is whether there are any relationships between these
intercausal influences. In the following theorem we show that they can be composed
by the sign-sum operator.
Theorem 5. Given a chain graph G = (V ,E) andW1 ⊆ V andW2 ⊆ V two disjoint
sets of some chain component, such that A1 and A2 are predecessors of bothW1 and
W2. If Xδ1({A1,A2},w1) and Xδ2({A1,A2},w2), then Xδ1⊕δ2({A1,A2},w1 ∧
w2)
Proof. Let Z = bd(W1 ∪W2) − A1,A2, Z1 = bd(W1) − A1,A2 and Z2 =
bd(W2) −A1,A2. Observe that:
P(w1 ∧w2 | A1,A2,Z) = P(w1 | w2,A1,A2,Z)P(w2 | A1,A2,Z)
Since Z1 ⊆ Z and Z2 ⊆ Z, and W1 ⊥ (Z \Z1) | Z1,A1,A2 and W2 ⊥ (Z \Z2) |
Z2,A1,A2, we find:
P(w1 ∧w2 | A1,A2,Z) = P(w1 | A1,A2,Z1)P(w2 | A1,A2,Z2)
Now, suppose for example that δ1, δ2 are negative, then given X−({A1,A2},wi), for
i ∈ {1, 2}, Theorem 4 states:
P(wi | a1,a2,Zi)P(wi | a¯1, a¯2,Z) 6 P(wi | a1, a¯2,Zi)P(wi | a¯1,a2,Zi)
141
Q UA L I TAT I V E C H A I N G R A P H S A N D T H E I R A P P L I C AT I O N
Then:
P(w1 | a1,a2,Z1)P(w1 | a¯1, a¯2,Z1)P(w2 | a1,a2,Z2)P(w2 | a¯1, a¯2,Z2)
6 P(w1 | a1, a¯2,Z1)P(w1 | a¯1,a2,Z1)P(w2 | a1, a¯2,Z2)P(w2 | a¯1,a2,Z2)
⇔ P(w1 ∧w2 | a1,a2,Z)P(w1 ∧w2 | a¯1, a¯2,Z)
6 P(w1 ∧w2 | a1, a¯2,Z)P(w1 ∧w2 | a¯1,a2,Z)
⇔ X−({A1,A2},w1 ∧w2)
For other pairs of δ1, δ2, the result can be verified similarly.
In practice, this means that if we specify the product synergies Xδ({A1,A2},bi) and
Xδ
′
({A1,A2}, b¯i) for every Bi in a chain component, where A1 and A2 are parents,
then for each subset of variables in this chain component, there is a product synergy
with a default sign determined by the sign-sum operator. To strengthen this sign, e.g.,
if the result is an ambiguous sign, intercausal reasoning using subsets in the chain
component can be specified.
It would therefore be natural to define all product synergies for pairs of parents of a
chain component. However, for QCGs, such intercausal reasoning does not completely
coincide with product synergies as we will show in the next proposition.
Proposition 4. Given a chain graph G = (V ,E) and three vertices A1,A2,B ∈ V
such thatA1 andA2 are two parents of a chain component C. Given any vertex B ∈ C,
if Z = bd(B) −A1A2, X = bd(A2) and A1 6⊥ A2 | BZX, then A1 and A2 are the
(direct) parents of B.
Proof. Suppose without loss of generalisation that A1 is not a parent of B (though
recall that A1 and A2 are predecessors). Then there is someD ∈ Z such that there is a
directed route from ρ = A1 → · · ·D−B. Now take some route σ from B toA2. Then
the union of ρ and σ is not superactive with respect to Z, so A1 ⊥ A2 | BZX.
In other words, Theorem 4 can only be applied if there are intercausal relationships
between direct parents of a vertex. One might think that this is only because the con-
dition A1 6⊥ A2 | ZX in this theorem is too strong. While this may be partially true,
consider the graphA1 → C−B−D← A2. Obviously, P(B | A1,A2,C,D) = P(B |
C,D). Therefore the product synergy of A1 and A2 given b is necessarily zero, even
though A1 6⊥ A2 | B. Therefore, it is impossible that product synergies can com-
pletely characterise intercausal reasoning in chain graphs. Previously, it was already
shown that product synergies do not characterise intercausal reasoning in case there
are uninstantiated ancestors [47]. This paper generalises this negative result by observ-
ing that product synergies also do not characterise intercausal reasoning within chain
components in general.
Example 7. Continuing Example 6, consider Figure 8.8. We expect a negative product
synergy X−({F,Ob}, ld): for patients who have a lipid disorder, the observation that
the patient is obese renders it less likely that the lipid disorder is caused by a familial
hypercholesterolaemia. The same effect could be expected for diabetes since diabetes
can be caused by a lipid disorder, therefore, we expect a negative intercausal influ-
ence given diabetes as well. However, this property cannot be expressed by a product
synergy.
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Figure 8.8: Example model with a negative product synergy on DM. Graphically, we only specify
one, although the product synergies is dependent on the number of variables in the
chain component.
8.5 S I G N P RO PAG AT I O N
Several papers [45, 214, 165, 110] have studied qualitative inference in QPNs using a
qualitative version of belief propagation, which is called sign propagation. Similar to
belief propagation, the idea is that vertices in the graph maintain a (qualitative) belief
and send their beliefs to their neighbours. Upon receiving beliefs from neighbours,
beliefs are updated and further distributed. It can be shown that the complexity of sign
propagation is linear in the number of vertices in the graph, making it an attractive
method for purely qualitative inference.
To generalise sign propagation in chain graphs, we need to introduce some additional
concepts, in particular the concept of a trail in a CG. However, trails may be confusing
as the QPN literature contains at least two notions of trails (cf. [45]3 and [164]4), which
are both distinct from trails in CG [197]. Here we refer to the CG trails, which is a
route such that no arc appears twice in this route and each section in the route consists
of distinct vertices. A trail can be active, which means that none of its sections are
blocked by the evidence. This is relevant in this context, because of the following
property.
Lemma 5 (Lemma 4.1, [197]). Let G = (V ,E) be a chain graph with vertices X, Y,
and Z. Then X ⊥ Y | Z iff every trail in G from a vertex of X to a vertex of Y is
c-separated by Z.
This shows that it is sufficient to only consider the active trails rather than all routes
in the graph. Active trails are also interesting because they directly relate to evidential
trails, which are used to propagate signs in QPNs. This shows that the remainder of
this section generalises the definitions for QPNs.
Proposition 5. Given a QPN with and some route ρ in the graph. If ρ is an evidential
trail, which was defined as an active path from e to n [45], then it is an active CG trail.
Proof. Let ρ be an evidential trail. The claim is that (i) no directed edge appears twice
in ρ and (ii) that each section in the route consists of distinct vertices. Note that each
3 In [45], trails correspond to routes. In context of Bayesian networks, this can be used to define the concept of
d-separation [60].
4 In [164], trails are connected subgraphs between vertices.
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section in a QPN consists of a single vertex. Therefore, the condition that vertices
appear only once implies (i) and (ii).
Note that the QPN evidential trail is not a correct definition in the context of chain
graphs, because some vertices may appear multiple times in a CG trail. This cannot be
ignored as they may make e and n dependent.
Example 8. Consider the following QCG where D and I are observed.
A
B C D
E
H I
−
+ +
+ −
+
+
Consider the routes between A and H. There are two active trails, i.e., t1 = A →
B− C → H and t2 = A → B− C −D ← E → I ← C → H. Of course, there
are other superactive routes, e.g., A → B− C− B− C → H. In this case t2 is not
an evidential trail, but cannot be ignored: suppose for example that B is also observed,
then t2 is the only evidential trail between A and H. Through intercausal reasoning
between A and E, and C and E, it may be the case that A has an effect on H.
In case there is a single evidential trail between two vertices, we can use the transi-
tivity and symmetry property to compute the qualitative signs.
Lemma 6. Given an active trail ρ in a QCG G from A to B with observed vertices
O. Remove all the head-to-head sections X → . . . ← Y in ρ and replace them by a
line with an influence according to the product synergy in G and the observations O.
If there are no other active trails besides ρ, then the sign product of the intermediate
influences is the influence between A and B.
Proof. (sketch) After removing the head-to-head sections, we have a path between A
and B. If there are diverging vertices, these can be reversed using Theorem 2. After
this, Theorem 3 can be applied repeatedly to marginalise out the intermediate vertices
in this graph. Note that the boundary of the vertex changes during arc reversals and
marginalisation; the influence however holds for any context.
This provides a way to perform sign propagation in singly-connected chain graphs,
i.e., chain graphs where the underlying undirected graph is a tree. This is because of
the following property of chain graphs.
Proposition 6. Given a singly-connected chain graph G = (V ,E), and given a pair of
vertices A,B ∈ V and observations O ⊆ V , if A 6⊥ B | O, there exists a single active
trail between A and B given O.
Proof. It is sufficient to show that there is at most one trail between the vertices A and
B: if A 6⊥ B | O, then this trail must exist and be active. Suppose there are two trails,
then clearly, because the chain graph is singly-connected, one of the trails must contain
the same vertex at least twice. Let ρ be this trail, which contains a subtrail σ from X
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to X. It cannot be that σ is completely undirected (i.e., they are in the same section),
because then ρ is not a trail. But then there must be Y in σ with a route from X to Y
that contains a directed edge and a route from Y to X that contains the same edge. This
also contradicts the assumption that ρ is a trail.
For two vetices with multiple evidential trails, sign propagation is difficult. The orig-
inal algorithm by Druzdzel and Henrion [45] propagates the signs over all trails and
then combines signs by a sign-sum operator. For a long time, it was assumed that this
algorithm was correct. More recently, van Kouwen et al. [214] showed that this may
not always give the correct result in multiply-connected networks. One issue is that
direct influences dominate influences through intercausal mechanisms [44]. Another
issue is that the direction of arcs in a trail matter when propagating signs. Finally, if
there are multiple observations, the result may depend on the order of observations
or may be unnecessarily ambiguous [165]. To overcome these problems, solutions
have been suggested that solve these issues, resulting in a complex inference algo-
rithm [214, 165, 110]. It should be noted that while these solutions overcome the prob-
lems that have been recognised in the original algorithm, as far as we are aware, a
general correctness and completeness proof of recent algorithms for sign propagation
in QPN is an open problem.
8.6 E X P E R I M E N TA L R E S U LT S
Since chain graphs have been shown to model equilibrium systems, as mentioned in the
introduction, the theoretical foundation of the previous sections can be used to explore
the qualitative dynamics in such systems. Here we continue with the running example
that assumes that there is a kind of equilibrium between diabetes mellitus and lipid
disorders, and that its state can be influenced by other (patho)physiological conditions.
These influences can now be expressed in terms of qualitative influences and synergies,
and the resulting QCG can be used to perform probabilistic inference.
While probabilistic inference with a QCG can be done using sign propagation, based
on message-passing between neighbouring vertices as presented in the previous section,
such inference has serious limitations in case of trade-offs, i.e., when there are two op-
posite influences. Consider again Figure 8.6 and suppose we need to make a decision
for an obese patient. In case the patient loses weight and therapy is started, it is clear
that this will reduce the blood sugar (by S+(Ob,DM) and S−(Th,DM)). Often, how-
ever, weight reduction is unsuccessful. In that case, the effect of therapy is unclear;
obesity will make diabetes more likely and the therapy makes it less likely; so by the
sign-sum operator the whole effect is ambiguous.
An alternative approach is to look upon the qualitative signs as constraints on the
joint probability distribution, as proposed in [46], where a canonical representation
consisting of (in)equalities expressing constraints on the hyperspace of possible joint
probability distributions is used. In this approach, some of the conditional probabilities
or (clique) potentials may be elicited from experts or learned from data, where for
others, only qualitative information is available.
In this section, we take a similar approach, where we sample the unknown potentials
from the factorisation of a given chain graph (cf. Equations (8) and (9)). Without any
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further constraints on the hyperspace, the possibility that a positive influence exists
between two variables is just as high that a negative influence exists. In fact, when
sampling uniformly using a sufficient sample size, the second-order distribution of the
value P(b | a,X) − P(b | a¯,X) resembles a normal distribution with zero mean. The
same holds for synergies.
Instead of sampling the full joint probability distributions and then establishing
whether the distribution is consistent with the qualitative influences, the potentials can
be sampled more efficiently using Lemma 4, as this shows that influences impose local
constraints on the potentials. An influence can thus be introduced into the hyperspace
efficiently by omitting those samples that violate the constraints. Likewise, synergies
can be stated in terms of constraints on the local potentials using the following propo-
sition.
Proposition 7. Given a chain graph G containing vertices A1, A2, and B, with
A1,A2 ∈ bd(B) and B an element of a component C, it holds that a positive addi-
tive synergy Y+({A1,A2},B) exists if and only if
φC(a1,a2,b) +φC(a¯1, a¯2,b) > φC(a1, a¯2,b) +φC(a¯1,a2,b)
and, likewise, a positive product synergy X+({A1,A2},b) exists if and only if
φC(a1,a2,b) ·φC(a¯1, a¯2,b) > φC(a1, a¯2,b) ·φC(a¯1,a2,b)
with
φC(A1,A2,B) =
∏
M∈MB
ϕ(A1,A2,B)∑
B
∏
M∈MB
ϕ(A1,A2,B)
Proof. Similar to Lemma 4, note that:
P(B | A1,A2, fa(B)−A1A2B) =
Z−1(pa(C))
( ∏
MC
ϕM(A1,A2,B)
)
P(pa(C))∑
B
Z−1(pa(C))
( ∏
MC
ϕM(A1,A2,B)
)
P(pa(C))
Here, pa(C) and Z−1(pa(C)) do not depend on B, so this simplifies to:
P(B | A1,A2, fa(B) −A1A2B) =
∏
MC
ϕM(A1,A2,B)∑
B
∏
MC
ϕM(A1,A2,B)
Finally, we can put those potentials that do not depend on B in front of the summation
and obtain:
P(B | A1,A2, fa(B) −A1A2B) =
∏
M∈MB
ϕM(A1,A2,B)∑
B
∏
M∈MB
ϕM(A1,A2,B)
Call this expression ϕC(A1,A2,B). Then, the claims readily follow from the defini-
tions of the synergies.
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Procedure 1 sample-distribution( potentials: ϕknown,ϕunknown;
qualitative constraints: C)
satisfied = FALSE
while NOT satisfied do
for ϕM ∈ ϕunknown do
φM ← sample potential randomly > 0
end for
satisfied = TRUE
for Ci ∈ C do
satisfied← satisfied∧ check-constraint(ϕknown ∪ {ϕM},Ci)
end for
end while
φknown ← φknown ∪ {ϕM}
return ϕknown
Procedure 2 check-constraint(potentials: ϕ;
constraint: Sδ(A,B) or Yδ({A1,A2},B) or Xδ({A1,A2},B))
satisfied = FALSE
if type = influence then
determine all ϕM ∈ ϕ for whichM ∈MAB
satisfied← check {ϕM} with Lemma 4
end if
if type = synergy then
determine all ϕM ∈ ϕ for whichM ∈MB
satisfied← check {ϕM} with Proposition 7
end if
return satisfied
Given these properties, distributions can be sampled (cf. Procedure 1) that satisfy the
qualitative constraints (cf. Procedure 2). Then, using these samples, second-order distri-
butions of arbitrary marginal distributions can be derived in a straightforward manner.
While typically the marginals range over the whole [0, 1] interval, the qualitative con-
straints alter the shape (e.g., the mean and variance) of the distribution, which can then
be used to draw conclusions from the model.
Using patient data electronic health records of general practices in the Netherlands –
the LINH data (see Chapter 3 for details) – we were able to produce realistic qualitative
and quantitative information for our running example. Table 8.2 shows the contingency
table for familial hypercholesterolaemia, obesity, antidiabetic therapy, high total choles-
terol, and high blood glucose levels measured by HbA1c. The prevalences are 0.28%,
1.4%, 7.8%, 4.1%, and 5.0% respectively. This is in line with numbers known for the
Dutch population, except for obesity. Research on chronic disease prevalences in the
Netherlands [79] showed that the prevalence of obesity is a tenfold of the one found
here. The difference might be explained by the fact that in most cases obesity is only
diagnosed when the patient specifically asks for a treatment. In our experiment we will
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ch,gl ch,gl ch,gl ch,gl S(Ch,Gl) S(Gl,Ch)
f,ob, th 160849 764 2481 1487 0.645 0.370
f,ob, th 7182 3585 176 2845 0.419 0.609
f,ob, th 1876 32 126 86 0.666 0.389
f,ob, th 99 146 13 139 0.372 0.319
f,ob, th 381 4 26 23 0.788 0.459
f,ob, th 4 19 3 15 0.013 0.007
f,ob, th 24 1 3 3 0.639 0.460
f,ob, th 1 1 1 1 0.000 0.000
Table 8.2: Contingency table for familial hypercholesterolaemia (f), obesity (ob), antidiabetic ther-
apy (th), high total cholesterol (ch), and high blood glucose levels (gl) measured by
HbA1c. Patient counts are derived from electronic health records of 82 general prac-
tices in the Netherlands. The two most right columns show the evaluation of a possible
influence between high total cholesterol and high blood glucose levels in the context
(Z) of that specific row, i.e., S(X,Y) = P(x | y,Z)−P(x | y¯,Z).
use the prevalence known from the literature. Table 8.2 also contains the evaluation
of a possible influence between high total cholesterol and high blood glucose levels,
showing that P(gl | ch, F,Ob,Th) − P(gl | ch, F,Ob,Th) > 0 for any context (instanti-
ation) of F, Ob and Th. This implies a positive influence between total cholesterol and
blood glucose levels, i.e., S+(Ch,Gl). It should be noted that the zero-influences of the
last row are probably a coincidence due to the small numbers observed there.
Now, consider the quantitative and qualitative information available in Figure 8.9a,
representing the information derived from both the patient data and the literature. We
assume that high total cholesterol strongly correlates with lipid disorder (in fact, this is
one of the most important measures used to diagnose this disorder). The second-order
distribution of high cholesterol (Ch) within the general population, based on 10, 000
samples, is shown in Figure 8.9b.
Interventions on Th and Ob yield the second-order distribution in Figure 8.9d, 8.9d,
8.9e, and 8.9f. In case Ob = true the second-order distributions shift to the right, and
in case of Ob = false the second-order distributions shift to the left. The opposite
holds for Th, suggesting with high confidence that diabetic therapy is also beneficial
to reduce cholesterol levels. Note that this has been derived without any quantitative
information about the chain component containing LD and DM.
Table 8.3 compares the second-order distribution of high total cholesterol levels for
the different interventions on obesity and anti-diabetic therapy. One can see that anti-
diabetic therapy has a small benefit to reduce cholesterol levels for both obese and
non-obese patients. However, the differences between obese and non-obese people are
much larger, suggesting that an additional reduction of weight in combination with
diabetic therapy is even more beneficial to reduce cholesterol levels.
These conclusions cannot be derived from the data directly. Since the data used
here is derived from general practices, untreated diabetics are sparse, which makes the
negative influence from Th toDM impossible to detect. In fact, in the data, the presence
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F Ob Th
LD DM
Ch Gl
P(F) = 0.003
P(Ob) = 0.014
P(Th) = 0.078
P(Ch | LD) = 0.90
P(Ch | LD) = 0.10
+ + + −
+ +
+
(a) (b)
(c) (d)
(e) (f)
Figure 8.9: Qualitative and quantitative information (a) of Figure 8.5(i), and second-order proba-
bility distributions of Ch in general (b), and in the presence of specific interventions,
i.e., Ob,Th (c), Ob,Th (d), Ob,Th (e), and Ob,Th (f).
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Probabilities being compared Percentage
P1 P2 P1 < P2
Effect of therapy P(Ch | Ob,Th)e P(Ch | Ob,Th)c 62.72
P(Ch | Ob,Th)f P(Ch | Ob,Th)d 64.24
Effect of obesity P(Ch | Ob,Th)d P(Ch | Ob,Th)c 85.22
P(Ch | Ob,Th)f P(Ch | Ob,Th)e 84.59
Combined effect P(Ch | Ob,Th)f P(Ch | Ob,Th)c 87.81
Table 8.3: Comparison of second-order distribution of high total cholesterol for different interven-
tions on obesity and antidiabetic therapy. The superscripts c, d, e, and f, refer to the
second-order distributions in Figure 8.9.
of antidiabetic therapy makes higher blood glucose levels more likely. However, from
the literature it is known that diabetic therapy reduces glucose levels. We argue that it is
better to incorporate this as qualitative information into the model rather than learning
it from the data, thereby avoiding the biased relation between Th and DM.
8.7 C O N C L U S I O N S
The work described in this chapter started off with the wish to exploit qualitative in-
formation in modelling dynamic systems in a state of equilibrium. This brought us
to the development of an extension of qualitative probabilistic networks (QPNs) to-
wards qualitative chain graphs (QCGs). We were able to obtain generalised definitions
of qualitative influences and additive synergies. Product synergies still express inter-
causal reasoning in QCGs, although some of the intercausal reasoning in chain graphs
cannot be captured by product synergies. Furthermore, we studied sign propagation for
singly-connected chain graphs; similar ideas can be explored for multiply-connected
networks. From the point of view of sign propagation, the key difference between
QPNs and QCGs are the trails over which signs are propagated. This makes it clear
that it matters whether qualitative relationships between variables in a probabilistic
network are defined with respect to a line or an arc as this changes the dependences
between variables. Elicitation of qualitative relationship should, therefore, go hand in
hand with graph structure elicitation.
The value of QPNs for modelling biomedical problems has been recognised be-
fore [138, 117]. Although qualitative reasoning with QCGs has similar limitations as
with QPNs, we showed that by exploiting qualitative constraints on the chain graph
potentials we are able to estimate arbitrary influences and synergies in the chain graph,
i.e., by means of the second-order distribution of the marginal probabilities. For exam-
ple, we can provide the second-order distribution of P(b | a,X) − P(b | a¯,X), and
decide up to a certain significance level how likely it is that an influence S+(A,B)
exists. Therefore, we believe that this result may have a real practical bearing on areas
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such medicine: without knowing the exact joint probability distribution, we are still
able to draw qualitative conclusions on the dynamics that exist within a model.
One apparent limitation of this work is that we restrict the theory to dealing with
binary variables. The qualitative properties of QPNs are based on the concept of first-
order dominance [221], which does capture ordinal relationships between probability
distributions, in particular that a positive influence makes the higher values of that vari-
able more likely, i.e., P(c > c0 | a1, x) > P(c > c0 | a2, x) for all a1 > a2, c0, and
context x. It is not difficult to see that all our results generalise to arbitrary discrete dis-
tributions, because we can always encode a discrete distribution using binary variables.
In a naive way, a random variable A with n values may be represented by binary vari-
ables for each ai > aj, which is true if ai holds and false if aj holds. Subsequently,
factors can be added to the network to make sure that exactly one ai is true. For con-
tinuous random variables, the situation is more difficult. Most of the proofs are similar
by just taking A = true as shorthand for a1 and A = false as shorthand for a2, such
that a1 > a2. However, for proofs that depend on the factorisation, such as Lemma 4,
it is required that the distribution is faithful to the graph. While there exists research
for the discrete and Gaussian case [153, 154], other distributions have not been studied
thoroughly.
From a theoretical point of view there are some clear directions for further research.
For QCGs, sign propagation can be investigated for general chain graphs. Another in-
teresting line of research is to investigate qualitative abstractions of other probabilistic
graphical models, such as acyclic directed mixed graphs, which have directed and bi-
directed edges. The latter can be used to represent hidden common causes (see [169]
for its Markov properties). To improve inference in the sampling algorithm, the sam-
pling of potentials may be improved by exploiting Monte Carlo methods which take
into account bounds on the hyperspace (e.g. based on [191]).
With respect to the medical problems we have used for illustrative purposes, we aim
to apply this formalism in a study on diabetes and cardiovascular comorbidities involv-
ing multiple feedback systems. Since most physiological systems cannot be measured
directly, and relevant parameters are, therefore, mostly absent in large epidemiological
datasets that are available, we believe that the methods presented here form a good
foundation for developing multiple disease models.
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The goal of the research underlying this thesis was to develop new techniques to anal-
yse interactions between different entities of all kinds based on data. The techniques
we developed used ideas from the area of probabilistic graphical models; healthcare
was the field used to validate the novel techniques. Sometimes, important special fea-
tures of healthcare data guided the development of the techniques. The entities and
their interactions on which most of the research focused were diseases, and, in par-
ticular the presence of multiple diseases in patients, also called multimorbidity. The
value of having available probabilistic models of multiple diseases is that these can
act as a foundation for clinical guidelines of multimorbidity that can be tailored to the
requirements of individual patients.
Firstly, we will summarise and discuss the individual scientific achievements of the
Chapters 3 through 8, and place their contribution in a broader context. Secondly, we
provide some directions for future research, both for probabilistic graphical models
and multimorbidity.
9.1 M A I N C O N T R I B U T I O N S
9.1.1 Bayesian networks as means to capture interactions
At the beginning of the research we asked ourselves the question how interactions be-
tween entities, in particular when they are stochastic in nature, can be best described. In
most of the empirical scientific literature, the interaction between two variables is de-
scribed by the odds ratio, whereas interactions involving more variables are described
using regression equations. Furthermore, different complementary measures are used
to obtain the full picture of the presence of interactions. Usually it is hard to fit these
together to obtain a single, comprehensive view. Often an interaction between two vari-
ables can be clarified in terms of a third variable; more complex interactions also exist.
These interactions can be seen as conditional dependences and independences involv-
ing multiple variables, which can be expressed quite naturally by Bayesian networks.
A further advantage offered by Bayesian networks is that dependences and indepen-
dences can be hand crafted, learned from data – Bayesian-network structure learning
–, or one can combine manual modelling and learning. Throughout this thesis, we have
explored the usefulness of Bayesian networks in modelling disease interactions.
Bayesian-network learning was explored in several chapters: in Chapter 4 to better
understand the mutual interaction between chronic diseases, in Chapter 5 to obtain in-
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sight into the behaviour of different Bayesian-network structure-learning algorithms
on large datasets, and in Chapters 6 and 7, to detect static and temporal interactions
between disorders. A large dataset with patient data from general practices in the
Netherlands was used for that purpose. In comparison to other research in this area
that focuses on pairwise associations only, more detailed insights in the interaction,
temporal and atemporal, of chronic diseases were obtained. The main achievement of
this research is that Bayesian-network structure learning methods can significantly con-
tribute to unravelling the intricate interactions that are hidden in clinical data. Also of
interest is that available domain knowledge can be exploited in the learning process to
guide model construction, also known as supervised structure learning.
9.1.2 Bayesian networks for multilevel analysis
Large datasets often come from multiple sources, thereby introducing a certain bias in
the data. In these cases, multilevel regression is often used for analysis. We introduced
a new Bayesian-network framework in Chapter 6 that combines probabilistic graphical
modelling with multilevel analysis, called multilevel Bayesian networks (MBNs). Us-
ing both synthetic and real-world data we showed that the results obtained by MBNs
match those of multilevel regression equations in predictive power with the additional
advantages offered by Bayesian networks. In Chapter 7 we extended the new frame-
work with a temporal dimension, to be able to analyse longitudinal observational data,
giving rise to multilevel temporal Bayesian networks (MTBNs). They were used to
model longitudinal change in multimorbidity and showed their usefulness in determin-
ing the temporal effects of interactions.
The hierarchical models described in the Chapters 6 and 7 are generalisable to any
observational longitudinal dataset containing a hierarchical structure. In that respect,
they are suitable for application in population studies of any kind. Returning to the
Arctic example from the introduction; the Polar bear population is divided into four
major regions, i.e., divergent ice, convergent ice, seasonal ice, and archipelago regions.
In turn, these major regions are divided into nineteen minor regional subpopulations.
In the work of Amstrup [4] a Bayesian network model was developed for each major
region. One can notice that the data consists of variables acting on a regional level, e.g.,
subpopulation counts, and variables acting on a global level, e.g., worldwide green-
house gas concentrations. Together with the temporal aspects – yearly and seasonally
counts – of the data, the models used in [4] could be merged into an MTBN, tighten-
ing the regional effects together by global effects, which would make predictions more
accurate.
9.1.3 Chain graphs as means to model feedback systems
In Chapter 8 we took a different approach to model interactions: we adopted a qual-
itative viewpoint to understand interactions present in data. Qualitative abstractions
of Bayesian networks are known as qualitative probabilistic networks (QPNs); inter-
actions between variables are expressed by signs. In many real-life systems, interac-
tions often participate in feedback loops. Unfortunately, feedback loops cannot be han-
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dled by a Bayesian network. However, hybrid probabilistic graphical models, known as
chain graphs, can be used to model feedback loops. In the thesis, we adopted QPN the-
ory to develop the new concept of qualitative chain graphs (QCGs) and demonstrated
their usefulness in the context of medicine.
Although qualitative reasoning with QCGs has similar limitations as for QPNs, we
showed that by exploiting qualitative constraints on the chain graph potentials, we are
able to estimate arbitrary influences and synergies. Therefore, we believe that this re-
sult may have a real practical bearing on areas such as medicine: without knowing the
exact joint probability distribution, we are still able to draw qualitative conclusions on
the dynamics that exist in a system. However, the application of QCGs is not restricted
solely to the medical field. Many natural processes, such as in chemistry or economics,
are characterised by feedback loops that maintain an equilibrium. QCGs may be appli-
cable to these domains as well.
9.1.4 Multimorbidity and disease interactions
In Chapters 3 and 4 we especially explored the question whether the many different,
and often informal and imprecise concepts used in multimorbidity research as found
in the clinical and epidemiological literature can be translated into the formal frame-
work of Bayesian networks. The probabilistic represenations of multimorbidity allows
making a distinction between: (1) aetiological models of multimorbidity, and (2) mod-
els for reasoning about the clinical impact of multimorbidity. The latter models can be
further divided into diagnostic, prognostic, and therapeutic interaction models. The ad-
vantage of expressing multimorbidity concepts into probabilistic form is that we are in
this way able to model dependences between multiple disease variables. Such models
are crucial to adequately manage the illness of patients with multimorbidity.
Speaking of aetiological models, in real-life, some people have to deal with cancer
multiple times in their lifetime. This is either due to metastatis, common risk factors,
such as smoking, or just bad luck. For such patients, we explored the possible interac-
tions between pairwise observed cancers, using a novel measure called critical factors
in Chapter 5. It is defined as the minimal set of risk factors in a disease network, that
is needed to explain an indirect interaction, and the results for the oncological data
demonstrate that the measure is a useful concept. Moreover, being defined as a prop-
erty of a Bayesian network, the use of critical factors is not solely limited to the field
of oncology.
We used multilevel Bayesian networks, both static and dynamic, for the analysis of
disease interaction and clinically meaningful results were obtained in this way (Chap-
ters 6 and 7). The developed methodology is not restricted to the particular set of dis-
eases studied in this thesis. In fact, since the method takes the epidemiologic bias intro-
duced by obtaining patient data from multiple sources into account, the effect of any
combination of diseases on any set of other diseases can be evaluated. Therefore, we
recommend the usage of multilevel temporal Bayesian networks to further explore mul-
timorbidity statistics in a broader sense. For example, analysis of the musculoskeletal
disorders revealed multiple interactions with chronic diseases of many other organic
systems. It would be valuable to describe which of the interactions are the most respon-
sible for this phenomenon.
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ti+1
Figure 9.1: Schema of a multimorbidity–mortality model.
9.2 F U T U R E R E S E A R C H
9.2.1 Probabilistic graphical models
Although there has been a lot of research in Bayesian network structure learning, very
few of the papers on this subject deal with the problem of learning from very large
real-world datasets, that is, including both many records and many variables. Little
is known, therefore, about which algorithms perform best under these circumstances.
Our experience with the the LINH dataset was that search-and-score-based algorithms
with the AIC as scoring method gave the best results. In preliminary experiments, we
were unable to significantly improve the results using hybrid search-and-score-based
with constraint-based algorithms, i.e., by restricting the search space using results from
a constraint based algorithm. Therefore, we believe that there is a need for further
improvement of structure-learning algorithms to deal with large real-world medical
datasets.
Multilevel Bayesian networks (MBNs) as proposed in Chapters 6 and 7 offer room
for more research with regard to methods for parameter estimation. In this thesis we
used MCMC methods, but there might be more efficient ways to estimate parameters.
In Chapter 8 we developed the initial foundations of qualitative chain graphs (QCGs)
as a means to model feedback systems in a qualitative fashion. There are many direc-
tions for further research here, such as further investigation of sign propagation in
QCGs, or improving the inference that was based on second order distributions. Fur-
thermore, one could develop qualitative abstractions of other probabilistic graphical
models, such as maximal ancestral graphs, which have undirected, directed and bidi-
rected edges. It would also be interesting to use the formalism to study multiple feed-
back systems involved in multiple chronic diseases.
9.2.2 Multimorbidity and mortality
In the medical research described in the thesis, we have not investigated the relationship
between multimorbidity and mortality, although this is clearly a relevant research topic.
The MTBN formalism developed in Chapter 7 can be easily extended with a vertex in
each timeslice representing the mortality rate for that particular timeslice. Figure 9.1
shows a schematic picture of an MBN that includes mortality rates.
In preliminary research, we have applied this schema to data from the LINH database,
as it contains information about mortality and residential movements. Although not
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Urbanisation Follow-up Follow-up
level 3 years 5 years
very high 0.48 (0.2) 1.9 (0.4)
high 0.50 (0.2) 2.2 (0.5)
moderate 0.50 (0.2) 2.1 (0.5)
low 0.42 (0.2) 1.8 (0.4)
rural 0.49 (0.2) 2.1 (0.5)
(a) Urbanity
Age Group Follow-up Follow-up
3 years 5 years
35-50 years 0.34 (0.2) 1.7 (0.4)
50-65 years 0.48 (0.2) 2.0 (0.4)
65-80 years 0.72 (0.3) 2.6 (0.5)
80+ years 0.74 (0.3) 3.0 (0.5)
Overall 0.48 (0.2) 2.0 (0.4)
(b) Age
Table 9.1: Demographic differentiations of mortality rates (in % with standard errors).
entirely accurate in its completeness – something which can be checked against the na-
tional registry of births and deaths – the numbers can shed light on the relation between
multimorbidity and mortality. Tables 9.1 and 9.2 show that there is enough differenti-
ation in the dataset concerning mortality rates with respect demographics and clusters
of chronic diseases.
If we divide the LINH data into several timeslices for the clusters distinguished in
Table 9.2, and apply structure learning – guided by the high-level structure of Figure 9.1
– we obtain a preliminary view on how multimorbidity is related to mortality. Figure 9.2
shows that in particular cardiovascular, endocrine, and musculoskeletal disorders are
associated with disorders of all kinds in the next time slice. This is in line with the
results described in Chapter 3. In contrast, the disease clusters associated with mortality
are the respiratory, psychiatric, oncologic, and cardiovascular disease clusters.
These results suggest that multimorbidity affects both quality of life and mortality.
However, not necessarily the same diseases are involved in these two processes. After
all, prolonging the length of life by medical care is not the same as prolonging the
quality of life by medical care, and the relation between multimorbidity, mortality, and
quality of life requires further investigation.
9.3 F I N A L N OT E
In this thesis, we have provided new methods for probabilistic graphical models that
can be used in the analysis of disease interactions. This was done by extending and
combining particular concepts – both quantitative and qualitative – from existing prob-
abilistic graphical models. We applied them to the medical area of multimorbidity, but
the ideas are certainly generalisable to other areas of scientific research. As an exam-
ple we briefly discussed a simplified model coming from the environmental modelling
field, i.e., a model of the Arctic summer sea-ice decline.
Besides, we provided some preliminary ideas on how to use network models in
building clinical guidelines, keeping in mind that a patient can face multiple diseases
at the same time. However, their actual use in practice has still to be explored. We are
convinced that network models can be very useful to link together the statistics, on
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which individual clinical guidelines are based, with the clinical reasoning. This would
create a sound foundation for the development of clinical guidelines that are more
suitable for the multimorbidity patient.
urbanity
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Figure 9.2: Preliminary multimorbidity–mortality model for disease clusters.
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A P P E N D I X
A D D I T I O N A L M AT E R I A L S A N D R E S U LT S O N
M U LT I L E V E L T E M P O R A L B AY E S I A N N E T W O R K S
Here we provide extra figures and tables belonging to the analysis that was made in
Chapter 7. Figure A.1 shows the global structure of the MTBN used. A distinction is
made between cardiovascular health risk determinants, chronic diseases in relation to
practice, and patient characteristics. Besides incidence rates per time slice, the proba-
bility distribution of the MTBN allows us to detect interactions between disorders in
the context of health risks as well.
Model 3 shows the pseudocode for parameter learning of the MTBN in WinBUGS.
The number of patients is denoted by N, the number of practices by K. The hyper
parameter γ is mostly set to zero initially, but one can also choose other values. The
vectors of mean Γ is also typically set to zero. The variance σ is mostly drawn from
a gamma distribution with parameters 0.001 and 0.001, and likewise the co-variance
matrix Σ is initialised. Here, the local probability distributions are estimated using a lo-
gistic link function for each variable (the variables Di∗t are just intermediate variables
to accomplish this). For readability, the health risk factors were modelled in the pseu-
docode as they were diseases as well (i.e., for some Dit it holds that D
i
t = R
k
t ). The
data to be provided along with the model contains the raw data on urbanity (Ur), age
Age, gender Gen, and diseases (Dit). In the model P and Q stand for any parent of a
disease Dit not being a higher level variable (urbanity), i.e., P,Q ∈ parents(Dit) \
{Ur}. Note that age and gender can also be a parent ofDit. The double sums in the logit
equation model the interaction terms between parents on a disease.
The results from the model in Chapter 7 are aggregated into more comprehensive
figures in the chapter itself. Here we show the numbers that were used to build these
figures. Table A.1 shows which diseases were used in the final model. Table A.2 shows
the baseline characteristics with respect to the urbanization level of the practice loca-
tion, and the age and gender of the patient. Figure A.2 shows the final MTBN obtained
by structure learning. All variables depend on age and gender; for clarity these depen-
dencies have been omitted. Table A.3 and A.4 show prevalences differentiated for age
and urbanity. The baseline and 5-year follow-up results differentiated for urbanity are
also visualised in Figure 7.1 of the Chapter 7. Table A.5 and A.6 of this supplementary
show prevalences of comorbid patterns, and they are aggregated into Table 7.2 of 7.
Finally, Figure A.3 of this supplementary shows detailed information for diabetics.
161
A P P E N D I X
health risk
determinants
(Rkt3 )
chronic
diseases (Dit3 )
multimorbidity
rate (Mt3 )
Multimorbidity
5 years
health risk
determinants
(Rkt2 )
chronic
diseases (Dit2 )
multimorbidity
rate (Mt2 )
Multimorbidity
3 Years
health risk
determinants
(Rkt1 )
chronic
diseases (Dit1 )
multimorbidity
rate (Mt1 )
Multimorbidity
Base Line
practice char-
acteristics
e.g., urbanity,
type, size
patient char-
acteristics
e.g., age, gender,
genetics (Cj)
Level 2
Level 1
Figure A.1: High level structure of the multimorbidity model. Solid arcs represent associations
between diseases within one time slice. Dashed arcs represent associations between
diseases for different time slices. A double arc represents a deterministic relation. 4)
The dotted line separates the practice variables from the patient variables.
Model 3 pseudocode WinBUGS
model;
{
for (n in 1:N)
{
# For all values of i and t:
Dit[n] ∼ dbern(D
i∗
t [n])
# Variables without practice variation:
logit(Di∗t [n])← γit0 +
∑
P∈parents
γitpP[n]+∑∑
P,Q∈parents
γitpqP[n]Q[n]
# Variables with practice variation:
logit(Di∗t [n])← γit0[Ur[n]] +
∑
P∈parents
γitp[Ur[n]]P[n]+∑∑
P,Q∈parents
γitpq[Ur[n]]P[n]Q[n]
}
# Priors non-practice related parameters
γit0 ∼ dnorm(γ,σ)
γitp ∼ dnorm(γ,σ)
γitpq ∼ dnorm(γ,σ)
# Priors practice related parameters
γit0[1 : K] ∼ dmnorm(Γ ,Σ)
γitp[1 : K] ∼ dmnorm(Γ ,Σ)
γitpq[1 : K] ∼ dmnorm(Γ ,Σ)
}
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A P P E N D I X
Disease ICPC codes Description
Obesity T82, T83 Obesity and overweight
Dyslipidemia T93 Lipid disorders
Hypertension K86, K87 Complicated and un-complicated
hypertension
Diabetes Mellitus T89, T90 Insulin and non-insulin dependent
diabetes mellitus
Ischemic Heart Disease K74, K75, K76 Angina pectoris, coronary
atherosclerosis, myocardial infarct
Heart Failure K77 Heart failure
Stroke K89, K90 Transient cerebral ischaemia and
cerebrovascular accident
Nephropathy U88, U99 Glomerulonefritis/nephrosis,
renal failure
Retinopathy F83 Retinopathy
Other Diseases
– Malignant A79, B72, B73, D74, D75, D76, D77, L71, N74, R84, R85,
S77, T71, U75, U76, U77, W72, X75, X76, X77, Y77, Y78
– Non-Malignant A70, B90, D85, D86, D94, F84, F92, F93, F94, H84, H85,
H85, K73, L83, L84, L85, L86, L88, L89, L90, L91, L95,
N85, N86, N87, P15, P70, P72, P74, P76, P79, P85, T06,
R91, R95, R96, S87, S88
Table A.1: ICPC codes used to identify the diseases that were used in the model.
Urbanization Age Group Gender
level 35-49 yr 50-64 yr 65-79 yr 80+ yr Male Female Total
very high 16580 10631 5957 2369 17446 18091 35537
high 16925 13297 7195 2425 18888 20956 39844
moderate 13675 9738 4709 1167 14231 15058 29289
low 16787 14147 7438 1735 19686 20421 40107
rural 15869 13047 6766 1937 18799 18820 37619
Total 79836 60860 32067 9633 89050 93346 182396
Table A.2: Age and gender of the study population at baseline by urbanization level of the practice
location. Urbanization varies from ‘very low’ (less than 500 addresses per km2), also
denoted as ‘rural’, to ‘very high’ (more than 2500 addresses per km2).
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Figure A.3: Prevalences of ischemic heart disease, heart failure, stroke, and nephropathy for di-
abetics and non-diabetics, at baseline, and 3 and 5 years follow-up. There are four
age-groups, 35-50 years, 50-65 years, 65-80 years, and above 80 years, which are
respectively represented by circles, triangles, diamonds, and squares. Straight lines
represent prevalences for diabetics and the dotted lines represent prevalences for non-
diabetics.
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S U M M A RY
The epidemiology of multiple chronic diseases present at the same time is referred to
as comorbidity or multimorbidity. With the ageing of people multimorbidity becomes
the rule rather than the exception, especially for the elderly. The human body is a com-
plex adaptive system and very often we only see a few symptoms as a tip of the iceberg.
Current statistical methodologies are not entirely suitable to analyse this phenomena as
they often consider only one (primary) disease. In this thesis we have explored the use-
fulness of probabilistic network models in the field of multimorbidity. First we asked
ourselves the question how interactions between diseases, frequently present with mul-
timorbidity, can be best described. These interactions are often stochastic by nature and
it turns out that many of the interactions can be expressed very well by using proba-
bilistic networks, e.g., Bayesian networks. An important achievement of our research
is that learning the structure of a network from data can significantly contribute to un-
ravelling the intricate interactions that are hidden in clinical data. Another problem
we faced in this research is the fact that much of the clinical data comes from multi-
ple sources, e.g., from multiple general practices that use different kinds of electronic
health care systems. This introduces a certain bias, and to be able to deal with such data
we introduced a new concept called multilevel Bayesian networks. These networks can
deal with any big dataset that is hierarchically structured. We applied them by inves-
tigating the simultaneous progression of chronic cardiovascular conditions, correcting
for both patient and practice-related variables. Because of the network structure the
progression is easier to understand. For example, it turned out that in the presence of
hypertension, the observed cumulative incidence rates of combinations of cardiovascu-
lar disorders, i.e., multimorbidity, differ significantly from the expected rates. Another
aspect is that in many real-life systems, interactions often participate in feedback loops.
Here we adopted a qualitative viewpoint to model and understand such feedback loops.
Although qualitative reasoning has its limitations, we showed that without knowing
exact probabilities, we are still able to draw qualitative conclusions of the dynamics
that exist in a system. The ideas in this thesis are certainly generalizable to other areas
of scientific research. As an example we briefly discussed a simplified model of the
Arctic summer sea-ice decline and its regional effects on the polar bear populations.
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S A M E N VAT T I N G
De epidemiologie van meerdere chronische aandoeningen tegelijkertijd bij een patiënt
wordt meestal aangeduid als comorbiditeit of multimorbiditeit. Met het toenemen van
de gemiddelde leeftijd van de mens is multimorbiditeit meer regel dan uitzondering,
vooral bij ouderen. Het menselijk lichaam is een complex adaptief systeem en vaak
zien we alleen maar enkele symptomen als topje van de ijsberg. De huidige statis-
tische methoden zijn meestal niet toereikend genoeg om dit fenomeen te bestuderen
omdat ze vaak uitgaan van één (hoofd)aandoening. In dit proefschrift hebben we on-
derzocht of bepaalde kansmodellen met een netwerkstructuur ons meer inzicht kun-
nen verschaffen in multimorbiditeit. In eerste plaats vroegen we ons af hoe de inter-
acties tussen aandoeningen, die men vaak tegenkomt bij multimorbiditeit, modelmatig
het best beschreven kunnen worden. Omdat de interacties vaak stochastisch van aard
zijn blijkt dat ze goed beschreven kunnen worden met behulp van een probabilistische
netwerk zoals een Bayesiaanse netwerk. Een belangrijk resultaat van het onderzoek
is dat het leren van de netwerkstructuur ons op het spoor brengt van de juiste intrin-
sieke interacties die er bestaan tussen bepaalde aandoeningen. Een ander probleem is
dat veel van de patiëntgegevens betreffende multimorbiditeit vaak uit meerdere bron-
nen komt, zoals de elektronische patiëntgegevens van huisartsenpraktijken die ook nog
eens verschillende systemen gebruiken. Als we dit feit negeren introduceren we een
systematische fout in de analyses en resultaten. Om hiervoor te kunnen corrigeren intro-
duceerden we een nieuw concept: een multilevel Bayesiaans netwerk. Deze netwerken
kunnen goed omgaan met grote datasets die hiërarchisch georganiseerd zijn. Dit con-
cept hebben we toegepast om de simultane progressie van chronische cardiovasculaire
aandoeningen, daarbij corrigerend voor patiënt en huisartspraktijk gerelateerde vari-
abelen, te analyseren. Door de samenhang van de aandoeningen in een netwerk is de
progressie van multimorbiditeit beter te begrijpen. Het blijkt bijvoorbeeld dat bij de
aanwezigheid van een hoge bloeddruk, de cumulatieve incidentie van combinaties van
cardiovasculaire aandoeningen, en dus multimorbiditeit, veel sneller stijgt met de tijd
dan verwacht mag worden op basis van de individuele incidentie. Een ander aspect van
interacties is dat deze vaak participeren in een fysiologisch regulatiemechanisme. Om-
dat er dan vaak sprake is van feedback, vereist dit soort interacties een andere aanpak.
Hier gebruiken we een kwalitatieve benadering en het gaat ons dan in het bijzonder om
de aard van de interacties, dat wil zeggen, is deze positief of negatief, en is er sprake
van synergie. Hoewel een kwalitatieve benadering zijn beperkingen heeft, laten we zien
dat de hier gebruikte methodologie bruikbaar is om klinische conclusies te trekken, ook
in geval van multimorbiditeit. De ideeën in dit proefschrift kunnen makkelijk vertaald
worden naar andere domeinen. Als voorbeeld geven we de jaarlijkse afname van het
ijsoppervlak op de Noordpool en de regionale effecten daarvan op ijsbeerpopulaties.
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